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Aldosterone contributes to end organ damage in heart failure and renal 
disease. Spironolactone, a mineralocorticoid receptor inhibitor, slows disease 
progression but side effects including hyperkalemia limit its use. Damage to 
the endothelial glycocalyx (a luminal biopolymer layer) has been implicated in 
pathogenesis of endothelial dysfunction and albuminuria, but to date no one 
has investigated if the glomerular endothelial glycocalyx is affected by 
aldosterone or if the beneficial actions of spironolactone in diabetic 
nephropathy are mediated through glycocalyx preservation. 
Results 
In vitro human glomerular endothelial cells exposed to 0.1nM aldosterone 
and 145mMol NaCl exhibited reduced cell surface glycocalyx components 
(heparan sulphate and syndecan 4) and disrupted shear sensing consistent 
with glycocalyx damage. In vivo 0.6µg/g/day of aldosterone (subcutaneous 
minipump) and 1% NaCl drinking water caused albuminuria in two mouse 
strains. We subsequently developed an intravital multiphoton imaging 
technique to confirm that aldosterone caused; glomerular endothelial 
glycocalyx damage and increased the glomerular albumin sieving coefficient. 
Targeting matrix metalloproteinases 2 and 9 with a specific inhibitor 
preserved the glycocalyx, blocked the rise in the glomerular albumin sieving 
coefficient and prevented albuminuria. In addition we have demonstrated that 
the mineralocorticoid receptor inhibitor, spironolactone, when started early in 
the diabetic disease course, can reverse the development of proteinuria, 
reduce the glomerular albumin permeability to control levels, and preserve 
the glomerular endothelial glycocalyx. 
Conclusion 
Damage to the glomerular endothelial glycocalyx occurred in both animal 
models.  Spironolactone or MMP2/9 inhibition prevented albuminuria, 
preserved the glomerular endothelial glycocalyx and reduced glomerular 
albumin leakage. Together these data suggest that preservation of the 
glomerular endothelial glycocalyx may represent a novel strategy for limiting 
the pathological effects of salt and aldosterone excess and diabetes. 
Glycocalyx targeted therapy will be free from the inherent risk of 
hyperkalemia associated with mineralocorticoid receptor blockade and so 
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The Renin Angiotensin Aldosterone System (RAAS) 
1.1.1.1 The evolution of the renin angiotensin aldosterone system 
Multicellular organisms are believed to have evolved in brackish water pools, 
where the concentration of electrolytes in the water was similar to that 
maintained in the extracellular fluid today.1 As organisms developed, they 
evolved the ability to leave these pools and colonise areas where the 
surrounding electrolyte concentrations were less conducive to life. Thus 
control of the extracellular electrolyte concentration and volume became key 
to survival.1 The evolution of the renin angiotensin aldosterone system 
(RAAS) appears to have occurred as bony fish begin to evolve approximately 
500 million years ago.1 The RAAS has been preserved by evolution since 
and remains one of the key systems responsible for regulating the 
extracellular environment in vertebrates today. Once stimulated the RAAS 
has many physiological targets, but the final effect is largely mediated 
through the kidneys.  
 
1.1.1.2 Renin 
Renin has a molecular weight of 37 326 Da (human).2 It is a globular protein 
consisting of two domains.2 In between these two domains is a deep cleft, 
which forms the binding site, facilitating the molecules proteolytic action.2 
Renin is synthesised as an inactive preprohormone within a number of 
tissues but the conversion of prorenin to active renin occurs almost 
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exclusively within kidney.2 Active renin is released in response to reduced 
perfusion pressure within the kidneys detected by baroreceptors within the 
juxtaglomerular apparatus, reduced sodium concentrations within the distal 
tubule lumen (sensed by the macular densa), sympathetic nervous system 
activation or prostacyclin / ACTH.2 Once released active renin has a 
circulating half-life of less than 80 minutes.2 Active renin has only one known 
function, to cleave angiotensin I from the terminal end of angiotensinogen, a 
peptide synthesised in the liver.2 The specificity of renin’s enzymatic activity 
made it a potential drug target. As hoped new (third generation) renin 
inhibitors resulted in minimal ‘off target’ side effects however their 
introduction has been limited by predictable ‘on target’ side effects including 
hyperkalaemia at a level comparable to ACEi use, acute kidney injury and 
hypotension.3 In particular the results of the ALTITUDE study (a study 
conducted in patients with type 2 diabetes looking at cardio-renal disease 
endpoints) has resulted in concern regarding these compounds’ safety 
particularly when used in patients with impaired renal function or diabetes.4 
 
1.1.1.3 Angiotensin I and II 
Angiotensin I is a physiologically inactive molecule, the removal of a histidyl-
leucine complex is needed to generate the active form (angiotensin II).2 This 
is achieved by the enzyme angiotensin-converting enzyme (ACE). This 
enzyme is located within vascular endothelial cells. The vascular beds of the 
lungs are the major site of production.2 In contrast to renin, ACE has a 
number of molecular targets other than angiotensin I. Bradykinin is 
metabolised by this enzyme and so predictably ACE inhibitors, widely used in 
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clinical practice, cause cough in 20% of patients.2 Active angiotensin II has a 
circulating plasma half-life of 1-2 minutes but directly affects a number of 
physiological processes.2 Angiotensin II is also produced locally in a number 
of tissues resulting in local paracrine and possibly intracrine signalling in 
cardiac and renal tissue.5 Angiotensin II is a potent vasoconstrictor resulting 
in rapid increases in systemic blood pressure and selective vasoconstriction 
of the efferent arteriole of the glomeruli increasing glomerular perfusion 
pressure.2 Actions on the brain result in the sensation of thirst, increasing 
fluid intake, a reduction in the sensitivity of the baro-reflex and increased 
vasopressin (anti-dieuretic hormone) and adrenocorticotrophic hormone 
release.2 Angiotensin II also acts on the adrenal cortex to increase the 




Aldosterone is produced in response to angiotensin II or elevations in 
extracellular potassium levels. Under physiological conditions aldosterone 
synthesis has a circadian rhythm that parallels cortisol in humans and 
corticosterone in rodents.7,8 Aldosterone is produced in the zona glomerulosa 
of the adrenal cortex.6 Fluctuations in circulating aldosterone levels are 
largely the result of variations in denovo synthesis.6 Steroidogenesis starts 
with the “early regulatory step” of translocation of cholesterol to the inner 
mitochondrial membrane.9 Translocation is facilitated by steroidogenic acute 
regulatory protein (St AR Protein) and alterations in this step can happen 
within minutes.9 The “late regulatory step” in aldosterone production is 
mediated largely through modulation of expression levels of CYP11β-
hydroxylase, a key enzyme in aldosterone production.9 The direct regulation 
of this enzyme by circulating factors outside of the RAAS may help explain 
variations in serum aldosterone levels. Leptin, a hormone produced by 
adipose tissue, regulates hunger and energy balance.6 Recently it has been 
suggested that it may also increases circulating aldosterone levels.10 Leptin 
acts, via its own binding site on CYP11β-hydroxylase, modulating a calcium-
dependent regulatory mechanism to increase aldosterone production.11 In 
addition the adipokine compliment C1q TNF-related protein 1 (CTRP1) is 
also increased in obesity and increases aldosterone secretion by up-
regulating CYP11β-hydroxylase.12,13 These findings may help to explain why 
certain clinical groups have high circulating aldosterone levels even in the 
absence of ‘traditional’ RAAS stimuli and a diminished response to 
angiotensin blockade or ACE inhibitors. The discovery of leptin and CTRP1 
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as direct stimuli for aldosterone production also opens the possibility that 
there may be other circulating factors capable of stimulating aldosterone 
release.  
 
1.1.2.1 Extra-adrenal aldosterone 
The role of extra-adrenal aldosterone production remains debated. There is 
some evidence that cardiac myoctes,14,15 pulmonary vascular endothelial 
cells,16 systemic vascular endothelial cells17 and cells within the central 
nervous system (CNS)15 may be able to produce aldosterone in quantities 
capable of eliciting a local effect. However recent work has failed to 
demonstrate significant aldosterone synthesis within the vascular 
endothelium and so its effect within these specialized cells is thought to be 
limited.18 Adipocytes surrounding blood vessels may produce a basal level of 
aldosterone and respond to stimulation with angiotensin II with further 
increased production.19 Blocking the effect of locally produced aldosterone 
within mesenteric arteries from diabetic db/db mice was shown to increase 
the degree of the vasodilation seen in response to acetylcholine. The authors 
concluded that in the context of diabetes, adipocyte derived aldosterone may 
act in an autocrine and paracrine manner to regulate adipocyte differentiation 
and vascular function respectively.19 A consensus view on the importance of 
extra-adrenal aldosterone production clinically has yet to be reached and it 
remains an area of on-going research. 
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1.1.2.2 Aldosterone acts on multiple tissues  
The classical role of aldosterone is to conserve sodium.20 This action is 
achieved within the distal tubules and collecting ducts of the kidney via 
stimulation of epithelial cytosolic mineralocorticoid receptors (MR). Binding of 
aldosterone to MR dislodges chaperone proteins from the receptor to form an 
aldosterone-MR complex. This complex trans-locates, from the cytosol to the 
nucleus, where it alters target gene transcription. The increased serum and 
glucocorticoid-induced kinase 1 (SGK-1) leads to altered expression of 
amiloride-sensitive epithelial sodium channels (ENaC). These channels 
migrate to the cell membrane and facilitate the conservation of sodium.20 The 
above pathway has been well studied, but in recent years it has become 
apparent that MR expression in other tissues is common. MR are widely 
expressed in epithelial tissues including the bowel and salivary glands,21 but 
also in non-epithelial tissues such as vascular smooth muscle,22-25 skeletal 
muscle,26 cells of the immune system,27 vascular endothelial cells,22,28-32 
cardiac myocytes33 and adipocytes.34  
 
1.1.2.3 Aldosterone is not the only MR agonist 
Aldosterone and the much more prevalent glucocorticoids, such as cortisol, 
have an equal affinity for the MR binding zone.35 Specificity is achieved in a 
tissue-specific manor though the expression of 11–beta-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2) (figure 1.1).35 This enzyme metabolises 
cortisol to its metabolically inactive substrate, cortisone. 11β-HSD1 in 
contrast can catalyse this reaction in either direction but generally favours the 
generation of active cortisol from inactive cortisone. It is the balance in 
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activity of these 2 enzymes that dictates the level of MR stimulation by 
circulating glucocorticoids. In mice, deficiency of 11β-HSD2 in the vascular 
endothelium increased inflammatory markers within the endothelium and 
accelerated atherogenesis in ApoE -/- mice.36 The MR antagonist eplerenone 
reversed this effect.36 Knock out of 11β-HSD2 in rats renders animals 
polydipsic, polyuric and proteinuric with histological changes within the 
kidneys that are consistent with chronic kidney disease.37 In human umbilical 
vein endothelial cells (HUVEC) cortisol has been noted to reduce endothelial 
nitric oxide synthase (eNOS) production.38 This effect was markedly 
increased following pre-treatment of cells with siRNA targeting 11β-HSD2, an 
effect that could be attenuated with spironolactone. These results suggest 
that knock down of 11β-HSD2 allowed cortisol to remain active in the cytosol, 
modulating eNOS via MR.38 Down regulation of 11β-HSD2 has also been 
linked with salt sensitive hypertension in human linkage studies and animal 
models.35,39,40 Unilateral nephrectomy, in animal models, reduced 11β-HSD2 
expression within the remaining kidney and predisposed animals to a salt-
responsive hypertension.35,41,42 In humans, a number of studies have 
demonstrated a prolonged plasma half-life for cortisol in patients with chronic 
kidney disease (CKD). A study of 95 adult renal patients also demonstrated a 
direct correlation between the expression of 11β-HSD2 and creatinine 
clearance.43 In humans we know that liquorice ingestion (which inhibits 11β-
HSD2) or functional polymorphisms in 11β-HSD2 can predispose individuals 
to a salt sensitive form of hypertension, but the full effect of reduced 
functioning renal mass (with its potential to reduce renal 11β-HSD2) has yet 
to be studied.44-45 
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Figure 1-1 Aldosterone signalling complexity 
Aldosterone release from the adrenal gland may be influenced directly, as well as by 
traditional stimuli. Aldosterone may be produced locally and may activate multiple 
receptors. Additionally MR is not specific to aldosterone and relies on the presence 
of 11β-HSD2 to confer mineralocorticoid specificity. 
 
1.1.2.4 Context dependant aldosterone signalling  
Hyperkalaemia and angiotensin II (released in response to hypovolaemia) 
are two of the most potent stimuli for aldosterone production and release. 
However the biological response to these two stimuli appears to be different. 
The aldosterone-related response to hypovolaemia is to increase sodium 
chloride reabsorption without altering potassium secretion. In contrast, when 
aldosterone is released in response to hyperkalemia aldosterone increases 
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potassium secretion without increasing sodium chloride reabsorbtion.46 
These contrasting responses have been attributed to altered phosphorylation 
of the ligand-binding domain S843 on MR.46 This finding was discovered in 
renal intercalated cells and appears to allow a level of ‘context dependence’ 
to MR signalling in the distal tubules because phosphorylation at this site 
increases the dissociation constant more than 100 fold. The specificity of this 
system is a result of the limited expression of the phosphorylated form of the 
receptor (it is only expressed in the renal intercalated cells).46 Angiotensin II 
signalling reduces MRS843-P whilst potassium loading increased MRS843-P.46 By 
switching intercalated cells MR receptors on and off chloride absorption can 
be regulated, which in turn affects potassium handling in the distal tubules.46 
To date, 16 phosphorylation sites have been identified on the MR receptor.46 
Whether phosphorylation at other sites could provide an endothelial-specific 
target has yet to be established but it could represent a valuable therapeutic 
target. 
 
1.1.2.5 Aldosterone acts on multiple receptors 
Aldosterone does not act solely via modulation of nuclear transcription of 
target genes. ‘Non-classical’ mechanisms have also been demonstrated and 
are illustrated in figure 1.1.47 The first detectable response to aldosterone 
occurs within minutes of exposure. This response is due to direct interaction 
with enzymes within the cytosol and extra nuclear compartments and result 
in the activation of protein kinases.48 Activated kinases subsequently 
phosphorylate membrane channels and secondary enzymatic targets to 
modulate sodium and potassium channel activity or availability and pro-
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inflammatory pathways.49,47 Aldosterone also stimulates receptors located at 
the vascular endothelial cell surface. Atomic force microscopy with a single 
aldosterone molecule attached to the vibrating cantilever tip has been used 
to measure the unbinding forces between plasma membrane associated 
molecules and aldosterone and suggests the presence of a cell surface MR 
receptor.50 The isolation of MRs in the cell membrane fractions from Wistar 
rats and human embryonic kidney cells (HEK 293) adds further weight to the 
argument that cell surface MR exists and may be functional.51,52 In rats, the 
function of surface receptors has been studied using pegylated aldosterone. 
Pegylated aldosterone is incapable of crossing cell membranes but still 
activates ERK 1/2 phosphorylation by binding to receptors on neonatal 
cardiac myocyte H9c2 cells surface. In Sprague Dawley rats, activation of 
these surface receptors did not increase infarct size (in contrast to non-
pegylated aldosterone). Spironolactone did not prevent ERK 1/2 
phosphorylation but the G-protein associated oestrogen receptor (GPER or 
GPR 30) inhibitor G36 did prevent phosphorylation suggesting that 
aldosterone may activate GPER on the cell surface.53 Despite being labelled 
as an oestrogen receptor, GPER is sensitive to aldosterone at very low 
doses.47 This field remains controversial however due to a lack of evidence 
of competitive aldosterone binding, thus not all conditions to define GPER as 
an aldosterone receptor have been met.54 Although the status of GPER as 
an aldosterone receptor remains uncertain, a number of groups have found 
that GPER seems to be involved in aldosterone signalling. Rat aortic 
endothelial cells have been used to study the effects of GPER stimulation by 
aldosterone because in contrast to the majority of the systemic vasculature 
rat aortic endothelial cells do not express MR but do consistently express 
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GPER.55 In this preparation GPER stimulation mediated pro-apoptotic and 
anti-proliferative effects as well as vasodilatation.55 The vasodilator effect 
seen is in contrast to the action of aldosterone via MR, where generally 
vasoconstriction is considered the predominant effect as a result of reactive 
oxygen species (ROS) production and impaired nitric oxide (NO) 
production.56 Recent work studying GPER on a breast cancer-derived 
endothelial cell line suggested that aldosterone does not bind to GPER, 
however it does induce a direct interaction between MR and GPER and 
between GPER and epidermal growth factor receptor (EGFR). In this study, 
the presence and activation of both MR and GPER was required for 
proliferation and migration of breast cancer cells to occur.57 Whilst these 
findings need to be validated in other cell lines, they open the possibility that 
the net effect of aldosterone exposure on different tissues may be dependent 
on the variable expression of both MR and GPER. 
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1.1.3 The clinical relevance of aldosterone excess 
Adenomas in the adrenal cortex or bilateral adrenal hypertrophy can both 
cause primary hyperaldosteronism, which predictably results in hypertension 
and hypokalaemia.6 However, primary hyperaldosteronism remains 
associated with an increased risk of cardiovascular events and proteinuria 
even when matched to hypertensive controls.58,59,60 Secondary 
hyperaldosteronism occurs in a number of common conditions including 
idiopathic hypertension,61 obesity,62,63 advanced renal failure,64 obstructive 
sleep apnoea61 and sleep disorder including shift work.61 These patient 
groups also have an increased risk of developing proteinuria and 
cardiovascular disease.65,66 In addition polymorphisms that result in a gain in 
function of CYP11β-hydroxylase, the rate limiting enzyme in aldosterone 
synthesis have been linked with increased risks of developing FSGS, IgA 
nephropathy and proliferative glomerulonephropathies.67 
 
1.1.3.1 Aldosterone escape 
Pharmacological blockade of the RAAS has become a common therapeutic 
strategy in the treatment of heart failure and chronic kidney disease. The 
commonly used therapeutic agents include ACE inhibitors (ACEi) and 
angiotensin receptor blockers (ARB). In trials where these therapies have 
been studied closely, however, it has become evident that in a subset of 
patients aldosterone levels ‘bounce back’ after an initial decline.68 This 
phenomenon is known as aldosterone escape or breakthrough. The 
incidence of aldosterone escape varies depending on the definition used, but 
the estimates range from 10% at 6 months up to 53% at one year after the 
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initiation of ACEi or ARB therapy.68 Aldosterone breakthrough does not 
appear to affect patients’ blood pressure, but does appear to prevent the 
beneficial left ventricular remodelling normally associated with ACEi or ARB 
initiation.69 In patients with IgA nephropathy, aldosterone escape is 
associated with an increased level of urinary albumin loss.70 When 
aldosterone escape occurs in diabetic patients it is associated with an 
enhanced decline in glomerular filtration rate.71 The high frequency of 
aldosterone escape, and its potential to result in additional end-organ 
pathology, has driven the on going search for alternative methods of RAAS 
blockade. 
 
1.1.4 Serum aldosterone levels and clinical kidney disease  
As mentioned previously the high levels of serum aldosterone seen in 
primary hyperaldosteronism can cause albuminuria. Longitudinal studies 
have, however, also shown that in patients consuming a western diet 
aldosterone levels above the population median value (but within the 
accepted ‘normal’ range) are associated with an increased risk of developing 
chronic kidney disease. This finding remains significant even when 
adjustments are made for other known risk factors including blood 
pressure.72 The mechanistic link between serum aldosterone levels and CKD 
progression are, however, not yet known. 
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1.1.5 Serum aldosterone and clinical cardiovascular disease 
Elevated aldosterone levels, even within the ‘normal range’, are strong 
predictors of cardiovascular disease risk.73 This effect remains even when 
adjusted for baseline atheroma.74 These data were gathered in largely 
Caucasian populations, but the effect applied to both genders. A recent 
longitudinal study in the USA also confirmed that this effect applies to African 
Americans, nearly 5000 participants were followed for a median of 7 years. 
Baseline aldosterone levels were assessed and then incident data for 
coronary heart disease, stroke and heart failure were collected. Using Cox 
models, adjustments were made for established risk factors before 
calculating hazard ratios. Every 1 standard deviation increase in baseline 
serum log-aldosterone was associated with a 26% increase in cardiovascular 
events. This study was sufficiently powered to also confirm that serum 
aldosterone levels were positively associated with the individual outcomes 
(stroke, coronary heart disease or heart failure).75 
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1.1.6 Mineralocorticoid receptor antagonists 
The benefit of MR inhibition in humans, beyond BP control, was established 
following two landmark studies. The first study was performed by Pitt et al 
and was designed to review the effects of spironolactone administration on 
the morbidity and mortality of patients with heart failure.76 The second study, 
again by Pitt et al, looked specifically at patients with left ventricular 
dysfunction after a myocardial infarction.77 Both studies reported significantly 
improved clinical outcomes in patients receiving spironolactone.  
 
1.1.6.1 Spironolactone 
The MR antagonist spironolactone was originally developed as a potassium-
sparing diuretic for the treatment of oedema. Its usefulness in primary 
hyperaldosteronism was subsequently discovered. More recently, as the 
benefits of MR blockade in heart disease have become more widely 
recognised,76-78 the use of spironolactone in the UK has greatly increased.79 
Spironolactone is readily absorbed with a bioavailability of 80-90%.80 It has a 
half-life of only 1.4h due to metabolism within the liver, however the major 
metabolite (7 α-thiomethylspironolactone) is also pharmacologically active 
and accounts for 80% of the effects of the parent compound. Because of 
these effects, spironolactone can be administered once daily but it takes 
several days to reach steady state and several weeks to reach its maximal 
hypotensive effect.80 Spironolactone has a relative binding efficacy for MR of 
0.11 (Aldosterone = 1) but it is not selective for MR blockade.80 The non-
specific binding of spironolactone accounts for the sexual side effects 
including gynaecomastia, mastodynia, impotence and menstrual 
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irregularities. These effects occur as a result of spironolactone’s effect on 
progesterone receptors and androgen receptors. Spironolactone’s use is also 
limited by the predictable retention of potassium that results from aldosterone 
blockade. This becomes an issue in patients with impaired potassium 
regulation. For this reason spironolactone has to be used with extreme 
caution in patients with CKD. The BARAK-D trial should give us valuable 
information regarding the safety of spironolactone in patients with CKD and 
its results are eagerly awaited.81 
 
1.1.6.2 Eplerenone 
Eplerenone, a second-generation MR antagonist, became available for 
clinical use in 2002. Compared to spironolactone, eplerenone is a much 
more selective antagonist for MR.82 However the relative affinity of 
eplerenone for MR is lower (0.005) and with a plasma half life of only 4-6h 
(and no active metabolites), twice daily dosing is needed. Eplerenone has a 
much more limited side effect profile due to its reduced affinity for 
progesterone receptors (140 fold lower) and androgen receptors (1200 fold 
lower) relative to spironolactone.82 The third generation of MR antagonists 
are currently under development. These dihydropyridine –derived non-
steroidal MR antagonists should be able to combine the potency of 
spironolactone with improved specificity for MR receptors. Eplerenone and 
these newer agents will still predictably increase serum potassium levels in 
patients with CKD, limiting their use clinically. 
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1.1.7 The RAAS summary  
The RAAS system evolved from evolutionary pressure to maintain the 
extracellular fluid compartment composition and circulating pressure. The 
system is well adapted to optimise the conservation of sodium and 
compensate for acute circulating volume loss. However exposure to the 
western diet, and an aging population have highlighted the negative role that 
RAAS stimulation also has. Elevated levels of aldosterone cause, or 
contribute to, cardiovascular and renal disease, even when adjustments are 
made for hypertension. RAAS blockade is an important therapeutic 
intervention in blood pressure control, but also seems to have direct effects 
on tissue inflammation and fibrosis. In the heart RAAS blockade appears to 
result in beneficial left ventricular remodelling. In the kidney RAAS blockade 
(typically as ACEi or ARBs) has become a mainstay in the treatment of many 
forms of proteinuric renal disease. Why RAAS blockade has these beneficial 
effects is currently an area of intense research. Once these processes are 
more fully understood new therapeutic targets may become evident. More 
specific targets, ‘down stream’ of the MR may allow us to prevent the 
pathological effects of MR stimulation, whilst not inhibiting the renal tubular 




1.1.8 The influence of salt  
Clinical studies looking at the effect of salt intake on health have had mixed 
results.83 However the majority of studies have suggested that salt restriction 
may be beneficial. As a result the World Health Organisation (WHO) has 
published guidance suggesting that sodium intake should be limited to <2g 
per day in adults.84 A meta-analysis of randomised controlled trials in adults 
and children showed that salt restriction reduced systolic and diastolic blood 
pressure.85 However when sodium intake is restricted to less than 3g/day  
 
 
Figure 1-2 Sodium excretion (as a surogate of sodium intake) and 
all cause mortality 
Most recent studies have concluded that j-shaped curve exists between sodium 
intake and mortality. The lowest level of mortality was associated with moderate 




RAAS stimulation occurs, resulting in increased circulating levels of renin, 
angiotensin II and aldosterone.87 Studying all cause mortality in 101,945 
subjects from 17 countries prospectively highlighted a J shaped mortality 
curve for salt intake (figure 1.2).87 Within subgroup analysis the highest risk 
was associated with high sodium intake (derived from the urinary sodium 
excretion) in hypertensive and elderly subjects. The authors of the study 
suggest that sodium-related increases in blood pressure may have increased 
the mortality odds ratio in this group. However, an underlying alteration that 
independently caused BP elevation and increased mortality (e.g. endothelial 
dysfunction) could also explain such results. The most recent consensus 
view is that sodium intake in between 3g and 5g per day may be optimal for 
the mass population.88 At this level RAAS stimulation is minimised and blood 
pressure increases (relative to low intake groups consuming less than 2g per 
day) are small.89 If studies of sufficient power to look at subgroups are 
published in the future we may find that patients treated with RAAS blockade 
may benefit from lower salt intake levels. 
 
1.1.8.1 Sodium intake and chronic kidney disease 
Salt restriction has been recommended in the management of chronic kidney 
disease by a number of groups.90,91 However large studies, reliant on spot 
urine samples, have failed to find an association between derived sodium 
intake and CKD progression.92 In contrast, smaller studies using multiple 24-
hour urine collections to assess sodium excretion have demonstrated 
increased CKD progression rates in patients consuming the highest level of 
salt (highest quartile of sodium excretion compared to those in the lowest 
quartile, hazard ratio 1.54 for CKD progression).93 The contrasting findings 
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are likely to be due to the methodological variations between the studies and 
the heterogeneity of the groups studied in the larger trials, but they suggest 
the need for further high quality studies in this group. 
 
1.1.8.2 The mechanism of salt and aldosterone interaction 
When sodium intake is increased the negative impacts of RAAS stimulation 
are increased despite the suppression of circulating RAAS components by 
negative feedback.94,95 An explanation for this paradox has been sought by a 
number of groups. One avenue of research has stemmed from the 
observation that salt may interact with MR signalling via Rac-1. Rac-1 is a 
member of the Rho GTPase family and is capable of altering MR signalling in 
vitro and in vivo. A number of studies have now demonstrated that salt can 
paradoxically lead to the activation of MR via Rac-1.96-98 The net result of this 
interaction appears to be increased MR stimulation. This mechanism may be 
particularly important when auto-regulation of aldosterone falters such as in 
primary hyperaldosteronism, CKD and obesity. In CKD the tight regulation of 
the circulating volume and plasma aldosterone levels fail, resulting in 
paradoxical high aldosterone levels despite an adequate circulating volume, 
blood pressure and sodium.99 This will lead to high levels of circulating 
aldosterone in the presence of relatively elevated sodium chloride, and may 
explain the amplified level of MR activation seen in these patients despite 
only moderate elevations in aldosterone. In addition autonomous aldosterone 
secretion, in response to leptin or other adipokines, may also result in a ‘high 
aldosterone - high salt’ milieu and excessive stimulation of MR. Salt may also 
act remotely from aldosterone, but with a synergistic effect. The entry of 
sodium into a cell can also result in increased cytosolic calcium 
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concentrations via activation on the Na+/Ca+ exchangers and voltage gated 
calcium channels, thereby inducing diverse effects through calcium 
dependant signalling pathways.100 Increasing the intracellular sodium 
concentration in HUVECs by blocking Na+/K+ATPase with ouabain for 3 
hours altered the expression of 737 genes, suggesting again that alterations 
in sodium handling can have diverse effect on endothelial cells.101 Within 
endothelial cells increasing cell media sodium concentrations from 
137mmol/L to 142mmol/l resulted in a 25% reduction in NO production, 
through an unknown signalling pathway.102 Sodium entry into the cell will be 
accompanied by chloride ions and water, inducing cellular swelling.100 Small 
rises in sodium concentrations above 140mmol/L have also been shown to 
result in dramatic increases in endothelial cell stiffness, possibly by altering 
actin expression.103 The stiffness of endothelial cells is important, affecting 
the cellular response to biochemical and physical stimuli.103 High salt 
conditions also increase oxidative stress and result in endothelial 
dysfunction.104 Oxidative stress also plays a key role in aldosterone related 
tissue damage, and the two conditions together are likely to have an additive 
effect.105-107  
 
1.1.8.3 The influence of salt summary 
In summary, salt and the RAAS interact at a number of levels. Salt intake 
increases our circulating volume and increases blood pressure, which 
normally results in RAAS suppression. However, in the presence of 
aldosterone (which may be produced autonomously or via mechanisms 
outside the control of RAAS) sodium at high physiological levels appears to 
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alter multiple signalling pathways. MR signalling is altered though Rac-1 
mediated changes in both ligand dependant and independent manors, whilst 
salt induced oxidative stress may directly contribute to the negative effects of 
MR activation. Clinically, advising against sodium consumption above 5g per 
day is universally agreed, whether we should universally advise consumption 




The kidneys and the glomerular filtration barrier 
1.1.8.4 The kidneys  
The kidneys lie within the retro-peritoneum on the posterior abdominal wall 
bilaterally. In humans they are adjacent to the vertebral column at the level 
between the twelfth thoracic and third lumbar vertebrae. They function to 
remove the waste products of protein metabolism, excess water and salt 
from the plasma and act as an important endocrine organ. Measuring 
approximately 10cm in length and 5cm in width they are perfused via the 
renal arteries, which directly branch from the abdominal aorta. The renal 
arteries and veins attach to each kidney at the hilum. At rest the kidneys 
receive 1.2-1.3 litres of blood per minute, which equates to approximately 
25% of cardiac output.108 Blood enters the human glomerulus with an 
estimated pressure of 55-60mmHg.108 Within the Bowman’s capsule the 
hydrostatic pressure is estimated to be 10-15mmHg thus the net hydrostatic 
pressure across the glomerular filtration barrier (GFB) is approximately 
45mmHg.108 The net pressure for ultrafiltration, accounting for estimated 
oncotic pressures of 28mmHg at the afferent end of the glomerular capillary 
bed, and 35mmHg at the efferent end capillary bed, are 17 and 8 mmHg 
respectively.109 Although hydrostatic pressure is needed to drive ultrafiltration 
excessive hydrostatic pressure could damage the intricate machinery of the 
GFB. The glomerular perfusion pressure therefore has to be maintained 
within very tight limits. Vertebrates have evolved systems to regulate 
glomerular perfusion during periods of circulating volume expansion or loss. 
This regulation occurs at two levels. Firstly systemic blood pressure is 
regulated through effects on cardiac output and vascular resistance.108 
	 45	
Secondly the vascular beds of the kidney dynamically alter their resistance to 
maintain a remarkably constant perfusion pressure – a process known as 
glomerular auto-regulation.6,110 Both these mechanisms are modulated by 
the RAAS.110 
	
1.1.8.5 The Nephron 
The nephron is the functional excretory unit of the kidney, consisting of a 
glomerulus and its associated tubules (figure 1.3).111 There are 
approximately 1.3 million nephrons within each human kidney.6 This figure is 
fixed from birth, and as a result the kidneys have limited capacity to 
compensate for injuries that result in nephron loss. 
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1.1.9 The glomerulus 
A typical human glomerulus measures approximately 200µm in diameter.6 
Glomeruli form via the invagination of a ‘tuft’ of capillaries into the blind 
ending of a tubule called the Bowman’s capsule.6 Blood enters the capillary 
tuft of the glomerulus via the afferent arteriole and leaves via the efferent 
arteriole.6,111  
 
Figure 1-3 The nephron forms the functional excretory unit of the 
kidney 
A. The diagram of a sectioned kidney illustrating the position of glomeruli within the 
kidney. B The anatomy on tubules (PT = proximal tubule, LOH = loop of Henle, DT 
= distal tubule, CD = collecting duct). C. A detailed view of the glomerulus 
highlighting the proximity of the DT to the glomerulus and the AA (afferent arteriole), 
EA (efferent arteriole). Within the glomerulus mesangial cells (MC) forma central 
core surrounded by the endothelial cells (EC) and podocytes (Pod). The glomerular 
basement membrane (GBM) (grey) forms a continual layer between the EC and 
Pod. Primary filtrate is collected in the Bowman’s space (BS), line by the parietal 
epithelial cells (PEC) before draining into the PT. Figure adapted from Scott et al.111 
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The GFB separates the blood, within the capillary lumen, and the glomerular 
filtrate. This barrier consists of a number of specialised layers illustrated in 
figures 1.3 and 1.4 and outlined below. 
§ The glomerular endothelial glycocalyx 
§ Glomerular endothelial cells (GEnC) 
§ Glomerular basement membrane (GBM) 
§ Podocytes 
 
Figure 1-4 The glomerular filtration barrier 
In the representative diagram (A) as the filtrate passes the layers of the filter. 
albumin is largely excluded, as indicated by the estimated local albumin 
concentration on the right. GBM= glomerular basement membrane. B. Electron 
microscopy demonstrates the functional arrangement of cells within the glomerulus. 
GEnC= glomerular endothelial cells, PFP = podocyte foot process F = 
fennestration. Figure adapted from Salmon et al.112 
 
Functionally the GFB permits the relatively free filtration of molecules <4nm 
in diameter with a neutral charge, whilst impeding the filtration of larger 
negatively charged molecules. The GFB has a remarkably high permeability 
to water, allowing the passage of filtrate volumes in excess of 60* plasma 
















1.1.9.1 Endothelial glycocalyx 
Lying on the luminal surface of the specialised GEnC is an anionic 
biopolymer layer called the glycocalyx. This complex structure consists of 
components anchored to the cell surface such as proteoglycans and 
sialoproteins, interwoven with elements adsorbed from the circulation 
including albumin.113 The anionic charge is largely due to the expression of 
the glycosaminoglycans heparan sulphate and chondroitin sulphate.113 The 
integrity of the overall structure seems to be dependent on both fixed and 
adsorbed components. Many of the specialist functions performed by the 
endothelium are dependent on a ‘healthy’ glycocalyx.113 This complex 
structure is discussed in detail below. 
 
1.1.9.2 Glomerular endothelial cells  
These specialised cells line the capillaries of the glomerulus forming a 
continuous cellular layer.114 These unique cells are highly permeable to water 
whilst remaining relatively impermeable to macromolecules. The presence of 
fenestrae, covering approximately 20% of the cell surface area, is thought to 
have evolved to facilitate the flow of the primary filtrate across the GFB.114	
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Typically fenestrae measure 70-100nm in diameter with a typical depth of 
70nm.114 These ‘pores’ are thought to facilitate the movement of fluid across 
the capillary wall. The glycocalyx covers the fenestrae and the endothelial 
cell surface and contributes to endothelial cell function helping to regulate 
shear stress reactivity, permeability, coagulation, immune cell transit and 
signalling.112,113 The glycocalyx is discussed in detail in section 1.13. 
 
Figure 1-5 Glomerular endothelial cell fenestrae in rat  
Rat kidney was fixed using gluteraldehyde before dehydration using an extended 
methanol freeze-substitution technique. Helium ion scanning electron micrographs 
of the rat kidney were then taken. A. Two adjacent GEnC imaged from their luminal 
aspect. The arrows indicate the tight junction between the two cells. The presence 
of fenestrae facilitates the high level of water permeability needed for effective 




1.1.9.3 Glomerular basement membrane  
The GBM is a hydrated gel meshwork containing 90% water by volume.116 
The GBM is potentially (although measurements of glycocalyx thickness vary 
widely) the thickest component of the GFB measuring approximately 250-
400nm in healthy humans.116,117 The GBM results from the fusion of the 
basal laminae of GEnC and podocytes. The GBM is largely composed of 
laminin, type 4 collagen, nidogen, and heparan sulphate.118 The GBM is 
thought to provide structural support for the glomerular capillaries and 
contains receptors on the surface for endothelial cells, podocytes and 
mesangial cells.117 Genetic mutations in key components of the GBM are 
known to cause human kidney disease (see below) with prominent 
albuminuria, suggesting that the GBM may also have a direct role in perm-
selectivity of the GFB.117 It is not thought that the GBM contributes 
significantly to charge specific glomerular perm-selectivity however because 
removal of agrin (the major heparan sulphate proteoglycan in the GBM) did 
not cause albuminuria in mice under basal conditions or under stress from 
albumin overload.119  
 
1.1.9.4 Podocytes  
Mature podocytes consist of three segments: the cell body, major processes 
and the foot processes.120 Foot processes can be divided into anchoring foot 
processes (originating directly from the podocyte cell body) and ordinary foot 
processes, which originate from major processes.120 Podocytes have a 
number of roles within the GFB.  
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Figure 1-6 The podocyte 
The podocyte covers the outside of the glomerular basement membrane (GBM) and 
sits within the urinary space (US). The luminal border (L) of the GBM is covered by 
the fenestrated (F) endothelial cells (EC). The podocyte cell body is supported by 
modified ‘anchoring’ foot processes (numbers 4,6 and 8) above the sub-podocyte 
space (SPS). The exit point from the sub podocyte space (arrow) may also 
represent a point of flow limitation. From the cell body major processes (MP) radiate 
out before dividing into secondary processes and finally foot processes. Figure 
adapted from Neal et al.120 
 
1.1.9.5 The podocyte contribution to the GBM 
Podocytes are the primary source of the GBM laminin and collagen 4.6 These 
components are vital to GBM function as illustrated by two human genetic 
conditions. Pierson syndrome was first described in the 1960s by Pierson et 
al, describing a severe congenital nephrotic syndrome with an associated iris 
dilator aplasia and an abnormal ocular lens in two babies that died 2 weeks 
after birth.121 This defect was later mapped to laminin β2. The generation of 
laminin β2 null mice facilitated a more detailed study of the pathogenesis of 
this mutation. Interestingly, early (proteinuric) disease in this model occurs in 
the absence of podocyte foot process effacement. Suggesting that the 
resulting alteration in the GBM structure itself increases protein loss across 
the GFB, with foot process effacement occurring later possibly as a result in 
increased fluid flow or protein leakage.117  
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Figure 1-7 Podocyte positioning within the glomerulus and 
podocyte foot process structure 
A Helium ion scanning electron microscopy can be used to image the surface of 
glomeruli (rat) Bar = 20μm B. Podocytes may be tethered to the parietal epithelial 
cells, when the glomerulus is removed from the Bowman’s capsule the tethering 
strands are left in situ (arrows). Bar = 10μm.C Higher magnification image of the 
complex inter-digitation of podocyte foot processes Bar = 2μm D. Filamentous Nano 
protrusions from the foot processes project into the urinary space Bar = 0.5μm, the 
function of the structures is as yet unknown. Figure adapted from Rice et al.115 
	
Alport’s syndrome is caused by mutations in collagen IV. The syndrome 
typically results in glomerular, ocular and auditory lesions.117 This syndrome 
is largely due to an X-linked mutation, but autosomal forms also exist.117 
Alport’s syndrome results in end stage renal failure, although ACE inhibition 
and blood pressure control may help to slow the progression of the 
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disease.117 Thus both collagen IV and laminin are vital to the effective 
function of the GBM and the filtration barrier as a whole. 
 
1.1.9.6 The contribution of the slit diaphragm to the GFB 
Podocytes do not just synthesise GBM components, they also appear to 
have a direct role in the GFB. The complex interdigitating foot process 
network creates the slit diaphragms (figure 1.8). These modified tight 
junctions contribute to GFB permselectivity. The slit diaphragm has been 
highly conserved through evolution with the insect nephrocytes employing 
similar proteins and performing a similar role in haemofiltration.122 Damage to 
the podocytes in renal disease is an area of intense research. Research in 
this area has been aided by the characteristic histological changes that occur 
in response to glomerular injury. Podocyte injury results in foot process 
effacement, which is considered to be a common feature in all glomerular 
disease.123 Genetic mutations of components of the slit diaphragm nephrin 
(NPHS1) and podocin (NPHS2) are associated with hereditary forms of 
nephrotic syndrome highlighting the importance of the slit diaphragm in the 
GFB.124 Whilst podocyte injury clearly results in albuminuria, the relative 
contribution of the various GFB components to albumin permselectivity in 
health is more difficult to study. This is an important question because the 
podocyte performs many roles within the GFB – secreting GBM components, 
communicating with endothelial cells and contributing to the filtration barrier 
directly (slit diaphragms). Affecting any of these roles could result in 
albuminuria, but each has very different therapeutic targets. Historically it 
was thought that the slit diaphragm was the major rate-limiting step of the 
glomerular filtration of albumin.  
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Figure 1-8 Podocyte foot proceses and slit diaphragm structure 
Podocyte foot processes form a complex interwoven plate, covering the exterior of 
the GBM. The structure of the podocyte slit diaphragm is not fully understood. 
Highly detailed images taken using helium ion electron microscopy may help 
develop this field A. The role of the Nano projections (indicated by white arrows) 
and surface irregularities (black arrows) has yet to be investigated. (Bar = 120nm) 
B. The distance between fibres within the sieve plate may be larger than previously 
believed. (Bar = 100 nm). Figure adapted from Rice et al.115 
 
However, this finding is based on mathematical models of the GFB that may 
have used data that under estimated the gap between fibres within the slit 
diaphragm. When Drummond, Deen and Edwards et al modelled the GFB 
they used the observations of Rodewald and Karnovsky who believed that 
the average gap between parallel fibres within the slit diaphragm was 4nm – 
almost half the radii of albumin.116 However more recent imaging using 
scanning electron microscopy and helium ion scanning microscopy have 
reported the gaps to be significantly larger (between 12.1 - 22 +/- 8nm).115,125 
When the increased width between fibres is factored into calculations the 
relative contribution of the podocyte slit diaphragm to the total resistance of 
the GFB to the passage of proteins is dramatically reduced (to less than 
1%).116 If the contribution of the slit diaphragm is less than we historically 
believed then proteinuria in the absence of podocyte effacement is possible. 
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This appears to be consistent with the findings in early diabetes, genetic 
disease and preeclampsia where albuminuria can occur in the absence of 
foot process effacement, suggesting that alterations to other components of 
the GFB may be also be important and affected earlier in the disease time 
course.126,127  
 
1.1.9.7 Foot process effacement as a protective strategy 
Extending this work, Wilhelm Kriz and Kevin Lemley proposed that podocyte 
foot process effacement might represent adaptive remodelling not a direct 
pathological insult.128,129 They argue that podocytes position, outside the 
GBM, and their unique structure adhering to the GBM, exposes them to the 
danger of being lost into the primary filtrate as viable cells. From this 
hypothesis the authors argue that increased glomerular filtrate – as would be 
expected in glomerular hypertension or when other components of the GFB 
are damaged, results in increased strain on podocyte adhesion to the GBM. 
As a result they believe podocytes remodel (efface) in an attempt to prevent 
their terminal detachment.128,129 If this hypothesis is correct then podocyte 
effacement should encourage researchers to look ‘upstream’ for damage to 
the GFB whenever podocyte effacement is seen and not label the pathology 
as podocyte specific. 
 
1.1.9.8 Cellular interactions within the GFB 
Considering components of the GFB in isolation oversimplifies this complex 
biological unit. The cells of the GFB constantly communicate with each other 
to maintain the functional filtration unit. The communication pathways that 
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have been studied in most detail include; podocyte production of vascular 
endothelial growth factor (VEGF) and angiopoetin 1 and endothelial 
production of nitric oxide, these pathways are discussed below. 
 
1.1.9.9 Podocyte to endothelial communication 
VEGF produced by podocytes, signals to GEnC via VEGF receptors. VEGF 
was originally identified as a microvascular permeability factor. It was later 
found to affect fenestrations on endothelial cells, even inducing fenestrations 
in systemic endothelial cells where they are not normally present.130 The 
effect of blocking VEGF in the glomerulus became clinically evident when 
anti-VEGF therapy was trialled in cancer therapy, with patients rapidly 
developing proteinuria and hypertension, which in retrospect, has been 
attributed to impaired glomerular filtration as a result of alterations in 
fenestration density.131 In monkeys, however, low dose vitreal injection of 
aflibercept (a soluble decoy receptor that binds VEGF used in macular 
degeneration and metastatic cancer therapy) actually increased glomerular 
endothelial fenestrae density after 24 hours.132 Overall either over or under 
expression of VEGF-A (the most common isoform of VEGF) from podocytes 
appears to cause damage in the longer term. Inducible deletion of podocyte 
VEGF-A accelerated mouse diabetic nephropathy and endothelial injury,133 
whilst over expression of podocyte VEGF-A also worsened diabetic 
nephropathy.134 These data suggest that VEGF-A production by podocytes is 
finely and dynamically regulated and any impairment in this regulation can 
result in glomerular damage. Podocytes and mesangial cells within the 
glomerulus also express Angiopoetin 1. Angiopoetin 1 activates the tyrosine 
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kinase receptor (Tie2) on GEnC. Angiopoetin 1 deficient mice (induced in 
adulthood) had no phenotype but additional stress in the form of diabetes led 
to marked glomerular pathology. Interestingly selective knock down of 
Angiopoetin 1 in either podocytes or mesangial cells alone, however, was 
insufficient to generate this exaggerated response to diabetic disease.135  
 
1.1.9.10 Podocyte mediated regulation of the endothelial 
glycocalyx 
Both VEGF and angiopoetin 1 appear to help regulate the glycocalyx on the 
endothelial cells. Exogenous VEGF(165)b (an anti-angiogenic VEGF-A splice 
variant) reduced features of diabetic nephropathy in both type 1 and type 2 
diabetic mouse models. Biweekly injections of VEGF(165)b normalised 
glomerular permeability and prevented glomerular glycocalyx damage.136 
Salmon et al demonstrated that angiopoetin-1 altered microvascular 
permeability in frog mesentery vessels through modification of the endothelial 
glycocalyx.137 It seems likely therefore that podocyte injury will lead to 
endothelial glycocalyx dysfunction and potentially alter GEnC fenestration 
density, altering the overall permeability of the GFB. 
 
1.1.9.11 Endothelial to podocyte communication 
Endothelial cells communicate with podocytes across the GBM. This was 
elegantly demonstrated using endothelial nitric oxide synthase (eNOS) knock 
out mice. eNOS is located in the endothelium of the arterioles and capillaries 
of the glomerulus; podocytes do not express this enzyme.138 In diabetic mice 
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eNOS knock out, however, increased podocyte injury suggesting podocyte 
dependence on endothelial derived nitric oxide (NO). The increased RhoA 
activity seen in podocytes exposed to media mimicking the diabetic eNOS 
knock out state suggested that direct paracrine communication from 
endothelial cells to podocytes might have been responsible for these 
changes.138 Co-culture of GEnC exposed to laminar shear stress and 
podocytes maintained beneath a semipermeable membrane suggested that 
a permeable factor was secreted from GEnC in response to shear stress. 
This factor seems likely to have been nitric oxide, but this was not 
confirmed.139 Endothelial specific knockdown of krüppel like factor 2 (KLF2), 
a major regulating factor in cellular adaptation to shear stress, resulted in 
increased podocyte loss following uninephrectomy.140 KLF2 is known to 
regulate eNOS synthase, but as a major regulating factor many other 
potential signalling molecules may have been affected in addition. In 
summary it seems likely from these data therefore that podocyte injury will 
affect the endothelial glycocalyx, but also that glycocalyx injury could directly 
affect the podocyte through reduced NO production. These findings have 
direct relevance when studying a non-specific insult such as 
mineralocorticoid stimulation. In particular they make the interpretation of 
knockout studies difficult when histological assessments such as podocyte 
effacement are used as endpoints. 
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1.1.10 The renal tubules 
Glomerular filtrate enters the Bowman’s space before flowing into the 
proximal convoluted tubule.2 Proximal tubules (PT) reabsorb large quantities 
of sodium, chloride, glucose, bicarbonate, amino acids, protein urate and 
water.2,141,142 To facilitate this role, a striate brush border covers the cells of 
the proximal tubule with microvilli increasing the effective surface area (figure 
1.9).115 A typical human kidney contains approximately a million nephrons, 
on average the PT is approximately 14mm long, resulting in a total PT 
surface area of >50m2. This area reabsorbs 65% of the filtered sodium ions 
and over a 160 litres of water per day.2  
Figure 1-9 The proximal tubule 
The proximal tubules have a brush border (BB) containing microvilli (arrows) that 
massively increases their surface area to optimise the reabsorption of filtered 
plasma contents, with increasing magnification this border is illustrated in figures A-
D (Bars = 5,1,0.5 and 0.1 µm respectively). Figure adapted from Rice et al115 
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The PT terminates in the outer medulla as the tubule diameter reduces and 
the epithelial cells flatten to form the loop of Henle. This ‘loop’ of tubule 
continues into the renal medulla before ascending back to the renal cortex. 
The accompanying capillaries enable a counter-current exchange of urea 
and electrolytes to occur.2 This helps maintain a hypertonic extracellular 
space in the medulla. The filtrate is concentrated in the descending limb by 
water moving down the osmotic gradient, becoming hypertonic. The thick 
ascending limb is impermeable to water but continues to allow urea to diffuse 
out, and sodium and chloride ions to be actively pumped out, of the tubule 
lumen, rendering the filtrate hypotonic compared to plasma. The thick 
ascending loop of Henle returns to the glomerulus and passes between the 
afferent and efferent arterioles. As they cross, the cells within the wall of the 
afferent arterioles specialise, enlarging to become the macula densa. 
Adjacent to these cells are the juxtaglomerular cells, also known as granular 
cells, which secrete renin. Together these specialist cells become the 
juxtaglomerular apparatus. Reductions in the delivery of sodium and chloride 
to the distal tubules result in increased renin secretion.1,2 After the macula 
densa the tubules become the distal convoluted tubules (DCT). The DCT are 
approximately 5mm in length, together with the 20mm long collecting ducts, 
they function to fine tune the final level of filtrate absorption. The principal 
cells of the collecting duct facilitate sodium absorption using the charge 
gradient to allow sodium to be absorbed even when the tubular concentration 
is as low as 5mmol/l. Aldosterone is the key regulator of this process, binding 
to MRs increases the number of ENaC channels to facilitate sodium uptake 
from the lumen.2,143 This ‘traditional’ role for aldosterone is well established, 
but aldosterone has many other influences on glomerulus.  
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1.1.11 Glomerular permeability  
As discussed the cells and the structure of the glomerulus are highly 
specialised, however the forces responsible for glomerular filtration remain 
the same as those involved in all other capillary beds. In the absence of a 
vessel wall restricting the movement of solutes or pressure gradients, Fick’s 
first law of diffusion applies. 
 
   Js ( Diffusion) = -DA(∆C/∆x) 
 
Js (Diffusion)= rate of solute movement resulting from diffusion 
D  = diffusion coefficient* 
A = surface area 
∆C = concentration difference 
∆x = the distance through which diffusion occurs 
 
*Proportional to the squared velocity of particles, influenced by temperature, fluid 
viscosity and the Stokes-Einstein radius (size) of the particles. 
  
However, when modelling the transit of water and solutes in complex 
biological systems, their movement is frequently restricted (by membranes) 
and hydrostatic pressure gradients exist. The passage of solutes is then 
dependent on both diffusion and convection (the trans-capillary flow of 
molecules as a result of ‘solvent drag’). The relative contribution of these two 
discrete mechanisms is represented by the Peclet number, a dimensionless 
ratio. This number is influenced by the diffusional hindrance factor, filtrate 
velocity, membrane thickness and the solute diffusivity in bulk solution 
value.109 Solute size therefore significantly contributes to the Peclet number.  
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1.1.11.1 Water and small solute permeability 
Biological membranes allow small molecules (with low Peclet numbers) and 
water to freely equilibrate by diffusion.109 The filtration rate of water is 
therefore governed by the hydrostatic pressure gradient across the 
membrane and the osmotic gradient across the membrane. Within the 
glomerulus, in the absence of urinary obstruction, the primary filtrate drains 
away from the Bowman space continually, limiting the influence the osmotic 
pressure within the primary filtrate. However, as water leaves the glomerular 
capillary, the effective concentration of the macromolecules within the 
plasma increases. The net pressure for ultrafiltration, (accounting for 
estimated oncotic pressures of 28mmHg at the afferent end of the glomerular 
capillary bed and 35mmHg at the efferent end capillary bed), are estimated 
at 17 and 8 mmHg respectively.109 
 
1.1.11.2 Convection of larger molecules 
As the effective size of molecules increases diffusion becomes less important 
than convection for transit across a membrane (resulting in the higher Peclet 
numbers seen for macromolecules). Estimates suggest that 75-90% of 
albumin transit across capillary walls is via convection.144 For molecules 
larger than albumin convection is responsible for almost 100% of passage 
across the capillary wall.144 The rate of convection at fixed hydraulic and 
osmotic pressures is represented by the equation: 
 
Js (Convection) = Lp(1- σ)Cc 
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Js (Convection)  = rate of solute movement resulting from convection  
Lp = hydraulic conductivity of a membrane or capillary  
σ  = the reflection coefficient  
Cc  = the capillary solute concentration  
 
Where the reflection coefficient describes the permeability of a specified 
substance through a capillary wall. A reflection coefficient of 1 indicates a 
substance does not pass through a membrane, whilst a coefficient of 0 
indicates the membrane is freely permeable.144 
 
1.1.11.3 Studying water permeability 
Starling’s seminal work began by looking for an explanation as to how fluid 
could move back, from the interstitium, into the systemic circulation. Whilst 
trying to explain this phenomenon he developed the concept that vessel 
walls might be freely permeable to salts and small molecules in solution, 
whilst remaining relatively impermeable to larger proteins. The selectivity of 
the membrane was then predicted to result in the generation of oncotic 
pressure gradients to counter hydrostatic gradients.113 This model is 
represented mathematically by the Starling equation. 
 
Jv=LpS([Pc-Pi]- σ[πp-π i ]) 
  
Jv  = trans-endothelial solvent filtration volume per second (m3s-1) 
Lp = hydraulic conductivity of the membrane (m2 s kg-1) 
S = surface area for filtration 
Pc = capillary hydrostatic pressure 
Pi = interstitial hydrostatic pressure 
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σ  = reflection coefficient 
πp = plasma oncotic pressure 
πi = interstitial oncotic pressure 
 
1.1.11.4 Revising Starling’s Theory 
Early work testing Starling’s model was conducted on the frog mesentery, 
bathed in physiological salt solutions (interstitial osmotic pressure was almost 
zero).113 The data generated using these systems suggested Starling’s law 
was correct. However when subsequent investigators adjusted the models to 
account for the true interstitial osmotic pressures, the net filtration value 
became too high for Starlings law to be considered correct.145 As a result 
Starling’s law had to be adjusted. In the adjustment tissue fluid proteins had 
to exert a lower osmotic pressure than a simple membrane model of diffusion 
would allow. Mathematical modelling and intricate measurements of 
molecular movement have subsequently helped us develop a number of 
models to improve our understanding of systemic capillary permeability. 
 
1.1.11.5 Pore theory 
Pore theory developed to describe the variable resistance to water (and 
small solutes) and macromolecules (such as proteins) as they crossed the 
capillary wall.145 Mathematically modelling the movement of solutes of 
variable size across capillaries provided early quantitative estimates of the 
size limiting structures within the capillary wall.145 Work studying a capillary 
(1mm long and 5µm diameter) from a skeletal muscle suggested overall 
solute exchange could be modelled to have occurred through 5-10 000 small 
pores with a radius of 4-5nm (close to the Stokes-Einstein radius of albumin 
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(3.5nm)) combined with 1 or 2 larger pores of 20-30nM radius.146 The small 
pores in this model contributed to hydraulic conductivity by allowing diffusion 
whilst the larger pores determine the permeability to macromolecules by 
allowing convection.  
The development of pore theory began the search for evidence of the 
biological structure within the biological tissue that could ‘fit’ with this model. 
However, electron microscopy initially failed to identify a biological structure 
that fitted with the developing theory.145 Groups have subsequently 
discovered that specific fixation techniques and careful tissue handling were 
needed to preserve the relevant structures. Subsequent methods have been 
developed using fluorescently labelled macromolecule exclusion and 
perfusion-fixation electron microscopy. These new techniques have 
suggested that the glycocalyx and adsorbed plasma proteins together form a 
significant structure within the capillary lumen that could act as a 
macromolecular sieve.109,113,147,148 This demonstration resulted in a further 
revision to the model of filtration. C. Michel and S. Weinbaum proposed this 
revision almost simultaneously.149,150  
 
1.1.11.6 Fibre-matrix: Junction-break model 
Based on mathematical modelling and experimental data, the glycocalyx-
junction-break model suggested that the glycocalyx formed the principal 
molecular sieve of the capillary wall. The ‘pores’ suggested by the earlier 
mathematical models were in fact the pathways that existed between the 
interwoven fibres of the glycocalyx structure, with the larger pores in the 
model representing areas of glycocalyx damage or remodelling.145 When the 
glycocalyx is considered in the mathematical models a solution can be made 
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that explains the relatively low net macromolecular transit rates seen in life. 
As fluid passes through the glycocalyx it is ‘funnelled’ to breaks in the 
underlying cell layer. Because the glycocalyx depletes the concentration of 
macromolecules within the filtrate, a zone beneath the glycocalyx, just above 
the cell membrane, is maintained with low oncotic pressure. Modelling the 
gradient between this protein depleted plasma and the interstitium predicts 
flow rates that correspond closely to the biological measurements of Curry et 
al.145  
 
1.1.11.7 Two layer fibre-matrix model 
The final revision to the model has been made recently to account for the 
changes seen when the glycocalyx is altered. If the glycocalyx consisted of a 
uniform structure then removal of 400-500nm of material would be expected 
to dramatically increase water and protein transit. However, this is not seen 
in experimental models.151 The two layer fibre-matrix model proposes a 
dense 200nm branch-like inner layer formed from HS rich glycoproteins 
associated with the endothelial cell membrane, and an outer gel-like layer up 
to 1µm thick.151 The outer layer contains adsorbed plasma proteins and 
hyaluronan. The inner layer is predicted to form the primary barrier to 
macromolecules, whist the outer layer limits cellular access to the inner layer, 
repelling red cells and leukocytes.  
 
1.1.11.8 Application to the glomerulus 
The glomerulus has an additional layer of complexity compared to systemic 
endothelium. The presence of plentiful fenestrae, a thick glomerular 
basement membrane and podocytes, with potentially important slit 
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diaphragms, makes studying the influence of the individual layers of filtration 
barrier complicated. The sieving coefficient of each layer will be influenced by 
the sieving coefficient of all the subsequent layers, as they dictate the 
permeability gradients across that layer. The mathematics of modelling the 
multiple layers of the GFB are beyond the scope of this thesis, however they 
suggest that the most selective layer of the GFB is not the slit diaphragm.109 
The relative contribution of the GBM and the glycocalyx is however 
impossible to calculate currently.109 As our working knowledge of the 
glycocalyx develops the model will continue to be refined and developed. 
 
1.1.11.9 Methods to study glomerular permeability to 
macromolecules 
The most widespread method used to derive a measurement of the 
effectiveness of the GFB in retaining plasma proteins is urine analysis. 
Testing for albuminuria has become a key part of screening for diabetic 
nephropathy and other common glomerular pathologies (and is discussed in 
detail below). Adjustments can be made to account for the concentration of 
the urine by studying the ratio between albumin and creatinine – a freely 
filtered protein that is not taken up or metabolised by the tubules in significant 
quantities. However in rodent models of human disease it has been shown 
that the renal tubules significantly alter the quantities of albumin in the urine, 
making the interpretation of the results more difficult.141 Micropuncture 
studies can be used to study glomerular pressures, flow and solute 
permeability.109 However the use of micropuncture techniques to study 
albumin handling is more difficult. Sampling from the proximal tubules will 
underestimate albumin filtration due to uptake by the proximal tubular cells. 
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In addition adsorption of the charged protein to the glass pipette, and the 
inherent trauma associated with the technique can also confound results.109 
In isolated perfused glomeruli, due to the inherent difficulties associated with 
perfusing whole blood (haemolysis, immune cell activation, compliment and 
clotting activation), perfusion is generally with colloid solutions. However the 
use of these solutions results in greatly reduced oxygen delivery to the 
glomerulus and ischaemia confounds the resulting data.109 To study filtration, 
again albumin uptake by the attached tubule has to be inhibited, however 
tubular toxins increase glomerular albumin permeability and therefore cannot 
be used.109 Isolated (non perfused) glomerular permeability assays can 
produce consistent data free from the influence of tubular albumin uptake, 
and give a good indication of the GFB permeability.152 One of the assays 
strengths is its isolation from the influence of haemodynamic changes within 
the glomerulus, letting users study ‘pure’ permeability changes. However this 
is also a weakness of the assay, the absence of hydrostatic pressure 
prevents convection and so only one element of glomerular filtration is 
studied. In addition the inherent problems of induced ischaemia and potential 
damage to the tissue during extraction also still remain. The use of 
multiphoton microscopy to study the glomerular sieving coefficient (GSC) in 
real-time in live, anaesthetised animals is currently the gold standard 
measure of glomerular permeability.153 This method has been used in this 






1.1.12 Albuminuria; a predictor disease progression 
In humans the presence of albuminuria is associated with an increased risk 
of progressive renal disease.154-156 In addition the level of reduction in 
albuminuria following an intervention (for example starting to take an ACE 
inhibitor) correlates well with the degree of long term renal protection 
afforded.157 The flip side of this finding is that residual albuminuria following 
an intervention in patients is the strongest risk factor for renal disease 
progression.157  
Albuminuria also strongly predicts systemic vascular disease.158 Even in 
patients with known vascular disease or high-risk diabetes, a two-fold 
increase in urine albuminuria (which occurred in 28% of enrolled patients) 
was associated with a 50% increase in mortality.159 The causal / associative 
link between albuminuria and systemic vascular disease is being actively 
sought but glycocalyx damage is an attractive explanation.112,160 
 
1.1.13 The controversy of renal tubules and proteinuria 
The mechanism of albuminuria has been well debated. The two polar views 
are a glomerular-centric view and a proximal tubule-centric view.161 Evidence 
has been published to support both viewpoints and I have already discussed 
some of the evidence that suggests that glomerular damage results in 
albuminuria. However, low-level albumin leakage across the filtration barrier 
may be a vital energy source for the proximal tubules carrying the free fatty 
acids needed to supply energy to facilitate active tubular uptake of filtered 
material.142 In addition evidence to support the role of the proximal tubule in 
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modulating detectable albuminuria has also increased over the last 
decade.141 The use of genetic knock down studies has added to this field 
following the demonstration that altering the expression of key genes in the 
proximal tubules appears to dramatically alter the final level of 
proteinuria.162,163 These alterations are reported to result in albuminuria 
without detectable changes to the GFB. It should be noted, however that 
neither study looked at the glomerular endothelial glycocalyx and so 
secondary changes within the GFB cannot be excluded. 
 
1.1.13.1 Potential pathways for tubular albumin uptake 
The current consensus is that there are multiple pathways through which the 
PT cells can remove albumin from the urinary filtrate. The FcRn pathway 
appears to facilitate trans-cytosis of albumin, allowing albumin to be returned 
to the circulation intact, whilst the megalin-cubilin complex appears to offer a 
lower volume route of albumin retrieval.141,161,164 The impact of tubular 
albumin handling has been studied by a number of groups using diabetic 
models of renal disease. OVE26 (OVE) diabetic mice have both increased 
glomerular albumin leakage and evidence of impaired tubular albumin 
reabsorption.165 This study found diabetic mice excreted 20 times more 
albumin in urine, but only 3 times more 70KDa dextran. The authors suggest 
that this is evidence that alterations in the GFB were not the only 
mechanisms altering the final urine concentrations, but alterations in the 
charges of the two molecules were neglected. It is also worth noting that it is 
the increased level of dextran in the urine of the control FVB mice that 
accounts for the variation in fold change (again suggesting that charge may 
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have altered the filtration rate). However labelled albumin clearly 
accumulated in the PT cells and the level of accumulation was variable 
between nephrons in the diabetic mice. Some proximal tubule segments 
became saturated with accumulated albumin, possibly correlating with the 
subset of OVA glomeruli that developed severe albumin leakage.165,166 The 
megalin-cubulin complex is also implicated in the PT-mediated reabsorption 
of albumin. Tamoxifen inducible megalin knock out mice (with 92% 
reductions in expression) displayed a 16-fold increase in urinary albumin. 
The authors estimated that in STZ induced diabetes, glomerular albumin 
filtration increased 1.9-fold but PT albumin absorption increased only 1.8-
fold, failing to ‘keep up with demand’ resulting in a fall in efficiency to 86%.167  
 
Taking these data together with a our current understanding of the GFB it 
seems likely that both glomerular leakage and impaired tubular reabsorption 
can contribute to albuminuria and the relative contribution of the two 
pathways will alter depending on the pathological insult and its duration. 
Interestingly aldosterone has been shown to increase apoptosis in proximal 
tubular cells via TNFα.168 In mouse models of renal disease albuminuria is 
used as a predictor of progressive renal disease and is believed to correlate 
with disease severity.169 However, species (and even strain) variation should 
be considered when interpreting urinary albumin results. Variations in the 
albumin absorptive capacity of the tubules may influence the results of 
studies – particularly when micro-albuminuria is being studied.  
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In humans it is the conditions with low-level albuminuria such as early 
diabetic nephropathy where albuminuria levels predict disease progression 
most strongly. It is not know if the tubules in human kidneys significantly alter 
urine albumin levels in disease. However, in mice the tubular handling of 
albumin makes albuminuria a less useful marker in early glomerular disease 
models. Direct study of the glomerular permeability to albumin is therefore 
the ideal method in mice, and comparing this data with total albuminuria data 
may reveal important information about the sites of pathology in disease 
models.  
 
1.1.14 Aldosterone and the GFB 
The effects of aldosterone on the GFB can be divided into processes that are 
believed to affect multiple cells types and cell-specific effects. Activation of 
MR by aldosterone stimulates the generation of reactive oxygen species 
(ROS). These include superoxide and hydrogen peroxide which, in-turn, 
activate the pro-inflammatory transcription factors activator protein (AP)-1 
and nuclear factor kappa β (NFΚβ).20 Aldosterone also induces mitochondrial 
dysfunction. Mitochondria are both a source and a target of ROS. 
Mitochondrial DNA encodes for 13 vital proteins needed for oxidative 
phosphorylation, however it is prone to oxidative stress due to its location on 
the inner mitochondrial membrane (a site of ROS production) and because 
mitochondrial DNA lacks histone coverage.170 In vivo the use of the 
mitochondrial respiratory chain inhibitor rotenone prevented proximal tubule 
cells from undergoing epithelial-mesenchymal transformation (an effect 
attributed to ROS) and prevented aldosterone-induced podocyte injury.170,171 
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To date no groups have studied the effect of aldosterone on GEnC ROS 
production, but groups have confirmed that other endothelial cell lines do 
produce ROS in response to aldosterone.172  
 
1.1.14.1 Aldosterone’s effect on podocytes 
Podocytes express MR at very low levels in health, however a dramatic up-
regulation of MR expression is seen in response to injury or following in vitro 
culture.173 MR stimulation on podocytes results in the generation of 
ROS.171,174 Although MR activation increased blood pressure in these 
animals hydralazine (an antihypertensive medication working remotely from 
RAAS) did not prevent podocyte damage in contrast to eplerenone (MR 
inhibitor) suggesting hypertension was not the cause of the renal injury in this 
model.171  
In vitro aldosterone down regulated nephrin in cultured podocytes. Rotenone, 
a mitochondrial respiratory chain complex 1 inhibitor, dramatically reduced 
nephrin loss and ROS, suggesting the mitochondrial ROS generation in 
response to aldosterone may be mediating this effect.174 In vivo, aldosterone 
resulted in albuminuria, foot process effacement and nephrin and podocin 
protein down-regulation, suggesting a direct action on the podocyte.174 
Interestingly the proliferator-activated receptor-ϒ (PPARϒ) overexpression 
and the PPARϒ agonist rosiglitazone also prevented podocyte injury in this 
model.174 Rosiglitazone has been shown to increase glomerular VEGF 
expression and to improve systemic flow-mediated vasodilation (an effect 
widely attributed to endothelial glycocalyx) in blood vessels independently 
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from changes in glucose control, so glomerular protection from aldosterone 
by rosiglitazone may due to both endothelial and podocyte actions.174,175  
It is possible that podocytes produce substances capable of damaging the 
glomerular glycocalyx, however, to date no groups have looked at podocyte 
matrix metalloprotease (MMP) expression changes in response to 
aldosterone. Van den Hoven et al have looked at podocyte expression of 
heparanase following aldosterone, Ang II and ROS. All three stimuli 
increased podocyte heparanase mRNA and protein expression 2-3 fold. The 
effect of Ang II was blocked by an ARB, whilst the effect of high dose 
aldosterone was blocked by spironolactone (MR inhibitor).176 These findings 
may have direct relevance to the conclusions of the study looking at 
endothelial MR knockout by Lother et al and this is discussed further in 
chapter 7.177  
 
1.1.14.2 Aldosterone and the Immune system and its relevance to 
endothelial function 
Macrophages, T-lymphocytes and B-lymphocytes all express MR.178,179 The 
role of MR in immune cells has yet to be investigated fully. Macrophages do 
not express 11β HSD2 and so it seems likely that MR receptors on these 
cells are largely activated by glucocorticoids.178 It should be noted however 
that effects of glucocorticoids acting via MR on this cell line will still be 
prevented by MR blockade, and whilst some authors conclude that effects 
prevented by MR inhibition are ‘aldosterone’ dependant, this is not the 
always the case. In vitro activation of MR on mouse macrophages appeared 
to help activate the macrophages, increasing the expression of M1 subtype 
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markers tumour necrosis factor alpha (TNFα), RANTES (regulated on 
activation, normal T cell expressed and secreted), monocyte chemotactic 
protein 1 (MCP1) and interleukin 12 (IL-12). Spironolactone also prevented 
the induction of these markers in response to lipopolysaccharide (LPS).178 
These results were supported by the demonstration that macrophages from 
macrophage MR knockout mice have reduced M1 surface markers and 
reduced responsiveness to LPS.178 These effects could be highly relevant in 
renal disease where recent studies have shown that activation of 
macrophages to the M1 subtype is a key step in type 2 diabetes / obesity-
related chronic inflammation.180 These effects also need to be considered 
when studying the endothelial glycocalyx. Direct damage to the endothelium 
cannot be differentiated from secondary immune cell mediated damage in 
the absence of tissue specific knockout studies. 
 
1.1.14.3 Mineralocorticoid knockout studies 
Endothelial mineralocorticoid knock down in the heart protected mice from 
deoxycorticosterone acetate (DOCA -a synthetic MR agonist) induced 
cardiac fibrosis.31 However in the kidney despite achieving >80% knock 
down of MR mRNA in kidney endothelial cells the same protection was not 
seen.177 This paper is discussed in detail within chapter 7 but based on this 
work, isolating and targeting MR on endothelial cells alone within the 
glomerulus may not be a successful therapeutic strategy, suggesting that 
new therapeutic targets are needed. 
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The endothelial glycocalyx 
1.1.14.4 Nomenclature 
Glycocalyx literally translates from the Greek for ‘sugar coat’ glykys = sweet, 
Kalyx = husk. Confusion has arisen from the nomenclature used to describe 
the glycocalyx. Some groups have used the term endothelial surface layer to 
describe the combination of the directly adherent components and the 
adsorbed plasma proteins, whilst using the term glycocalyx to refer only to 
the covalently bound components. This division fits well with the two layer 
fibre-matrix model of filtration, however with the techniques currently 
available to study this layer, the distinction is unhelpful in practical terms. 
Currently we cannot reliably separate the roles or the structure of the 
adherent components from that of the adsorbed components and so I will 
use the term glycocalyx to refer to the structure as a whole. A sugar and 
protein coat is detectable on many single cell organisms and on multiple cell 
types within vertebrates, however I will focus on the glycocalyx found on 
vascular endothelial cells because this structure has the greatest relevance 
to this project and the endothelial glycocalyx has been relatively well studied. 
 
1.1.15 Endothelial glycocalyx structure 
The adherent structure of the endothelial glycocalyx includes proteoglycans, 
glycoproteins and glycolipids.181 Proteoglycans hold glycosaminoglycans 
(GAGs) to the cell surface. Heparan sulphate (HS), chondroitin sulphate (CS) 
and hyaluronan (HA) are the major GAGs within the glycocalyx.181  
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1.1.15.1 Glycosaminoglycans 
Glycosaminoglycans (GAGs) are heteropolysacharides with repeating 
disaccharide sub-units.113 It is the specific combinations of these 
disaccharide repeats that results in the GAG families heparan sulphate (HS), 
chondroitin sulphate (CS) (sulphated GAGs) and hyaluronic acid (HA) (non-
sulphated).113 HS and CS chains vary in length between 50 and 150 
disaccharides with an average molecular weight of 30kDa.113 HS and CS are 
covalently attached to carrier (core) proteins, collectively these proteins are 
known as proteoglycans. HS attaches to syndecans 1 and 4, glipican 1, 
versican and thrombomodulin.181 CS attaches to syndecan 1 at two specific 
binding sites but does not attach to glipican-1.113 HS biosynthesis occurs in 
the Golgi apparatus. Synthesis begins with a core protein to which 
pentasaccharide linkages are added at serine residues. Exostosin (EXT) 1 
and 2 subsequently add alternating N-acetyl-glucosamine (GlcNAc) and 
glucuronic acid (GlcA) units to the penatasaccharide links. The final structure 
is also modified through modification of the sulphation pattern, for example 
with removal of 6-O-sulphate groups altering the function of HS.182 CS is 
synthesised as a galactosaminoglycan polymer consisting of N-
acetylgalactosamine alternating with glucuronic acid.183 In contrast to HS and 
CS, HA is a much larger molecule (up to 1000kDa) and variations in its size 
may alter its function. The turnover of HA is very rapid, with 1/3 of HA within 
the human body (estimated at 15g in a 70kg human) being metabolised 
every 24 hours.184 Uniquely HA is synthesised at the cell membrane and is 
not attached to a core protein. HA maintains a negative charge due to 
carboxyl groups (in contrast to HS and CS where sulphate groups generate 
the charge). As a result the charge density of HA is considerably lower than 
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that seen of HS or CS. HA receptors include CD44 and hyaluronan mediated 
motility receptor (HMMR).113 There are three main HA synthase enzymes, 
hyaluronan synthase (HAS) 1, 2 and 3. HAS-1 and 2 produce high molecular 
weight hyaluronan (>500kDa) whilst HAS-3 produces low molecular weight 
hyaluronan.185 The chain length of HA appears to modulate its function, high 
molecular weight HA is considered anti-inflammatory, whilst low molecular 
weight HA increases on the surface of inflamed endothelial cells to promote 
immune cell activation and migration.186 In addition to these relatively large 
adherent molecules the glycocalyx structure also includes small adsorbed 




Syndecans 1, 2 and 4 are all expressed on the surface of endothelial cells.113 
All syndecans have an N-terminal ectodomain (containing the GAG 
attachment sites) and a C-terminal cytoplasmic domain linked by a single 
trans-membrane segment.187 Syndecan 1 is largely expressed on epithelial 
and plasma cells, but is also present on endothelial cells.187,188 Syndecan 2 is 
mostly expressed on mesenchymal cells. Syndecan 3 is expressed in mature 
neural tissue but it is not thought to be expressed within the endothelial 
glycocalyx (although it is expressed more widely in developing tissue). 
Syndecan 4 is widely expressed on many cell types.187,188 Syndecans 1 and 
3 carry both HS and CS side-chains, but syndecans 2 and 4 tend to have 
only HS chains. The cytoplasmic domains of the syndecans consist of two 
conserved regions (C1 and C2) and a variable region (V). These regions 
associate with the actin cytoskeleton and intracellular kinases. Syndecan 4 is 
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a key glycocalyx component and a key mediator of cell adhesion, 
mechanotransduction, migration and proliferation.189 On endothelial cells 
syndecan 4 has been shown to be vital for the detection / cellular response to 
shear stress.190 As the predominant proteoglycan within the endothelial 
glycocalyx its removal also results in a significant reduction in cell surface HS 
(38%) and an associated 37% increase in albumin passage across cultured 
endothelial monolayers.191 Syndecan 4-null mice have impaired 
macrovascular angiogenesis.192 Chronic loss of syndecan 4 from the 
endothelial cell surface has also been linked to failure of macrovascular 
angiogenesis in diabetes, contributing to the impairment found in diabetic 
db/db mice.192 The shed ectodomains of syndecan 4 promote immune cell 
recruitment.193 This process has been linked with a protective role during 
acute insults including bacterial pneumonia and LPS-induced cardiac 
dysfunction.193,194 However the role of these shed fragments in chronic 
inflammatory states, such as diabetes, have not been investigated to date. 
 
1.1.15.3 Glipicans 
Only glipican 1 is expressed on the endothelial cell surface.113 Glipican 1 has 
4 binding sites for heparan sulphate. Glipican 1 is localised to lipid rafts 
involved in vesicle formation and transport, including caveoli.113 Interestingly 
glipicans attachment to membrane rafts by glycosylphosphatidylinositol 
allows glipican 1 to move across endothelial cells surfaces in response to 
acute shear stress.188 Glipican 1 is also one of the key mechanosensitive 
molecules within the glycocalyx (see below).195  
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1.1.16 Endothelial glycocalyx function 
1.1.16.1 Shear stress 
Shear stress is the dragging force that is applied to the cell surface as fluid 
(blood in vivo and tissue culture medium in vitro) moves across the surface. 
To date at least ten candidate mechanosensitive molecules have been 
identified within the glycocalyx.196 Conflicting data has emerged from 
enzymatic degradation studies and gene deletion studies making isolation of 
the most important mechanosensitive molecules difficult.197 Specific RNA 
knock down and mouse knock out models are helping to fill this void in our 
knowledge but all these techniques are limited by the ability of the glycocalyx 
to rapidly remodel following an insult, and the influence of non-specific 
changes indirectly affecting shear sensitivity.190,198 A recent study using 
atomic force microscopy to ‘pull’ on specific glycocalyx components in an 
attempt to elicit production of NO suggested that glipican 1 and HS may be 
key shear-sensitive molecules.195 It should be noted however that HS 
interacts with syndecan 4, versican and thrombomodulin and these 
molecules were not excluded as shear responsive.195 The ability of HUVEC 
endotheial cells to align in response to shear stress also appears to be 
dependant on sydecan 4.190 In addition in vivo murine syndecan 4 knock 
down has been shown to prevent endothelial cell alignment within the aorta, 
again suggesting syndecan 4 may be a key glycocalyx mechanosensor.190 
Krüppel-like factors (KLFs) are a family of transcription regulators. Among 
them KLF2 is a key regulator of shear stress responses. KLF2 mediates the 
shear stress-dependant phenotype of endothelial cells.199,200 Our lab has 
previously established that chronic shear stress induces KLF2 in CiGEnC 
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and this master regulator is a good marker of cells ability to sense shear 
stress.139 
The clinical relevance of shear stress has been demonstrated in a number of 
longitudinal studies.201 The detection of laminar shear stress appears to be 
protective provided the magnitude remains within physiological limits. In 
contrast turbulent (non-laminar) shear stress and very high laminar stress 
appear to have a negative effect. The presence of turbulent arterial flow at 
arterial branch points is thought to explain the predisposition for atheroma 
formation at these points.190 Damage to the glycocalyx, and loss of the 
protective signalling that result from laminar shear stress, may therefore 
explain the widespread distribution of atheroma seen in diabetic patients, 




The endothelium plays a key role in regulating the movement of fluid and 
macromolecules from the blood into the tissues. As discussed previously, 
mathematical modelling of the capillary wall suggests that the glycocalyx is 
vital to regulating vessel permeabilty.113,149 In continuous capillaries, 
fenestrated capillaries and glomerular capillaries there is evidence that the 
endothelial glycocalyx forms an important permeability barrier.112 A number 
of charged glycocalyx components appear to be important in the regulation of 
protein permeability including sialic acids and HS.203,204 Results have 
conflicted however depending on the methods used to remove glycocalyx 
components and the vascular bed studied. Rapid removal of glycocalyx HS 
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using human heparanase or heparanase III increases albumin passage 
across endothelial monolayers.204 However genetic knock down of 
endothelial syndecan 1 (a HSPG) did not result in albuminuria.205 In addition 
mice lacking endothelial EXT-1 – a key enzyme in generating the HS chain 
also did not become albuminuric (according to unpublished data).182 The 
time-scale difference between the methods of HS reduction may be key. The 
relatively slow knockdown of HS in genetic models may allow compensatory 
adaptations to occur e.g. up-regulation of other glycocalyx components, in 
contrast to the effects of rapid enzymatic removal of glycocalyx components. 
Despite the evidence suggesting a limited unique role for endothelial HS, the 
effects seen from modulating heparanase suggest that HS still has a role in 
glomerular permeability.182,206 These effects may be through the actions of 
other cell types however and can’t be attributed to the glycocalyx. In addition, 
the specificity of heparanase enzymes in vivo has to be questioned, removal 
of HS has been shown to increase syndecan 1 and 4 loss and may result in 
other components being lost from the glycocalyx structure.207 In contrast 
enzymatic degradation of hyaluronan did not result in detectable changes in 
micro-vascular permeability, however these results again conflict with the 
findings of Haraldsson et al who found that hyaluronidase increased 
glomerular albumin transit 5.6-fold, indicating tissue specificity for this 
effect.208,209 Together these data suggest that the way in which individual 
glycocalyx components are studied may dramatically influence the outcome 
of permeability experiments and to date a firm conclusion regarding the 
importance of the endothelial glycocalyx as a whole cannot be made. As 
discussed previously these conflicting findings may be the result of tubular 
albumin uptake countering any increase in glomerular albumin leakage 
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generated by such a glomerular specific insult. The results of an ex vivo 
glomerular albumin permeability assay would be very informative in these 
models.152 
 
1.1.16.3 Sodium Buffer 
The negatively charged GAGs within the glycocalyx offer a binding site for 
sodium ions. In the skin it has been shown that GAGs bind a significant 
quantity of sodium, rendering it osmotically inactive.210 The capability of the 
glycocalyx to store sodium in an osmotically inactive state has lead a number 
of groups to suggest that the glycoclalyx may buffer acute fluxes in plasma 
sodium level e.g. after a salty meal.211 The glycoclayx is estimated to be able 
to buffer 30mmol of sodium.212 This measurement was based on the ability of 
the glycocalyx on cultured cells to buffer sodium fluxes. In vivo the glycocalyx 
is reported to be considderably thicker and is likley to have proportionally 




Early studies on the glycocalyx revealed that hypertonic saline could induce 
coagulation. Heparan sulphate, the most abundant GAG within the 
endothelial glycoalyx is a potent regulator of the coagulation cascade.214 HS 
binds antithromin via a pentasacharide sequence found in between 1 and 
10% of the GAG side chains. The binding of antithrombin results in a 
conformational change that enhances its reactivity with thrombin promoting 
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complex formation between the molecules, inhibiting thrombosis.215 
Interestingly hyaluronic acid accumulation through knock out of the enzyme 
hyaluronidase 2, results in a thrombotic angiopathy suggesting that altered 
expression of other key glycocalyx components can alter the coagulation 
cascade as well.216 
 
1.1.16.5 Immune cell transit 
The measured height of the endothelial glycocalyx ranges dramatically 
depending on the method used to assess it but estimates range from 200nm 
to 2µm. In contrast the P and E-selectins induced on post capillary venules 
(the major site for neutrophil extravasation) measure less than 50nm from the 
endothelial cell membrane.217 This suggests that direct interaction of 
neutrophils and endothelial selectins will only occur at sites where the 
glycocalyx is compressed by the traversing neutrophil (e.g. in capillaries), or 
when the glycocalyx is shed. TNFα and lipopolysaccharides (LPS) both 
cause glycocalyx shedding and result in increased neutrophil 
attachment.218,219 Heparanase induces neutrophil rolling and adhesion and 
dramatically reduces the height of the glycocalyx.220,221 The alteration of 
specific HS domains has also been shown to influence leukocyte influx in a 
model of antiglomerular basement membrane glomerulonephritis.222 
Indicating that not only the quantity of these GAGs but also their structure 
may have an effect on leukocyte transit. A graphical representation of our 
current understanding of how the endothelial glycocalyx contributes to 




Figure 1-10 Leukocyte adhesion and the endothelial glycocalyx 
This summary diagram illustrates potential ways in which the glycocalyx could 
modulate immune cell transit. Loss of charge repulsion will allow immune cells to 
approximate closer to the endothelial surface. Loss of glycocalyx ‘cover’ over the 
integrins may facilitate immune cell tethering and adhesion. 
 
The therapeutic potential of modulating this process is being actively 
investigated. Preservation of the mesenteric glycocalyx using low molecular 
weight heparin has been shown to reduce white blood cell adhesion.223 This 




1.1.17 Identified mechanisms of glycocalyx damage  
The endothelial glycocalyx performs a number of vital functions in health 
(outlined above). However glycocalyx shedding appears to be a key step in 
the body’s acute inflammatory response, facilitating immune cell and 
complement extravasation. Glycocalyx damage is also seen in when tissues 
are ischaemic or hypoxic or under stress in diabetes or renal disease.224 In 
these settings glycocalyx loss can be maladaptive. 
 
1.1.17.1 Heparanase 
Heparanase is an endo- β (1-4) D-glucuronidase that is widely expressed in 
health and can be further induced during the inflammatory response.225 The 
pro-form of heparanase is a 65kDa inactive precursor, which is transformed 
by proteolytic cleavage to the active form consisting of a 50kDa subunit and 
an associated 8kDa subunit. Heparanase specifically cleaves the 
carbohydrate chains of HS to release HS fragments of 5-7kDa.182 
Heparanase up-regulation has been linked with a number of renal 
pathologies, including diabetic nephropathy, IgA nephropathy, minimal 
change disease, membranous nephropathy, sepsis, and ischaemia 
reperfusion related glomerular injury.182 Heparanase secretion is seen in 
response to multiple stimuli from both podocytes and GEnC.176,182 Whilst the 
direct role of heparan sulphate in the charge specificity of the GFB is still 
debated, the importance of heparanase in proteinuric renal disease is well 
established.182,206 In addition heparanase has become an attractive 
therapeutic target in cancer therapy, atherosclerosis and coronary artery 
	 87	
disease.226 Heparanase inhibition as a glycocalyx protection strategy is 
discussed in detail below. 
 
1.1.17.2 Matrix metaloproteases (MMPs) 
To date the mammalian MMP enzyme family contains 24 functionally and 
structurally related enzymes.227 All MMPs share a highly conserved catalytic 
domain containing a zinc binding region.227 MMPs are classified into 5 
groups based on their substrates and structure. 
• Collagenases (MMP-1, 8 and 13) 
• Gelatinases (MMP-2 and 9) 
• Stromeolysins (MMP-3, 10 and 11) 
• Minimal MMPs (MMP-7 and 26) 
• Membrane Type (MT-MMPs, including MMP14) 
 
Due to the broad range of substrates MMPs are important regulators of many 
cellular processes. Collectively they degrade all the structural components of 
the extracellular matrix. MMPs are tightly controlled at the level of 
transcription, activation and inhibition.227 MMPs are generally expressed at 
low levels in health, however inflammatory cytokines, growth factors and 
hormones can all result in their rapid induction.228 Some MMPs are 
membrane bound, however those that are secreted interact with extracellular 
matrix components and concentrate in the peri-cellular space.227  
 
1.1.17.3 A disintegrin and metalloproteinase (ADAM) 
ADAMs typically remain attached to the cellular membrane functioning as 
transmembrane proteases. This makes them ideally placed to influence the 
	 88	
endothelial glycocalyx structure. Relatively little is known about the 
substrates of these enzymes but ADAM-17 has been shown to cleave 
syndecan-1 and 4229,230 Investigating if ADAMs influence the glycocalyx and 
play a role in known pathologies such as diabetes will be key areas of 
glycocalyx research in the future. 
 
1.1.17.4 Tissue inhibitors of matrix metalloproteinases (TIMPs) 
The final regulatory step for MMP activity is controlled by tissue inhibitors of 
matrix metalloproteinases (TIMPs). The 4 known TIMPs collectively inhibit all 
the known MMPs by binding to their catalytic sites.227 The N-terminal of 
TIMPs inhibit MMPs by interacting with the active site inhibiting their catalytic 
activity. TIMPs 1, 2 and 4 are secreted as soluble factors whilst TIMP 3 binds 
to GAGs preventing the more localised action of MMPs.231 TIMPs are 
regulated through gene expression, protein endocytosis and degradation. 
TIMPs are constitutively expressed in most tissues but their expression can 
be further induced by cytokines, growth factors and microRNA.231 Whilst all 4 
TIMPs inhibit MMPs, TIMP-1 does not appear to inhibit membrane type 





Figure 1-11 Syndecan 1 and Syndecan 4 cleavage sites 
By analysing the structure of syndecans 1 and 4 predictions can be made about 
potential cleavage sites within their structure. Within the syndecan 4 ectodomain 
multiple cleavage sites exists where MMP2, MMP9 and MMP 14 (MT1-MMP) can 
potentially bind and cleave the structure. (Red lines indicate heparan sulphate (HS) 
chain attachment points.) Figure adapted from Manon-Jensen et al.232 
 
1.1.17.5 Syndecan ectodomain shedding 
The ectodomains of syndecans are continually shed into the circulating 
plasma.232 The rate of shedding, however dramatically increases in response 
to specific stimuli.191,232 There is some debate about whether constitutive 
shedding and the increased shedding seen during inflammation result from 
the same mechanism.192 Loss of the syndecan ectodomains results in 
removal of GAGs from the glycocalyx in addition to loss of the syndecan 
molecule. A recent study in vitro demonstrated that all tested MMPs (MMP-2, 
3, 7, 9 and 14 (Membrane type 1-MMP)) in addition to thrombin and plasmin 
were capable of cleaving syndecan 1 and 4 ectodomains (figure 1.11).232 
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Interestingly loss of the HS chains from the syndecan ectodomain also 
increased the rate of syndecan ectodomain shedding.207,233 The precise 
mechanism through which this occurs is not yet clear. HS can bind and 
inhibit ADAM12, however this inhibition occurs in the presence of exogenous 
HS, which did not preserve syndecan ectodomains in the above studies. It 
seems likely that the presence of GAG side chains may prevent MMPs from 
reaching their potential binding site close to the plasma membrane, but this 
has yet to be established. These results do imply that caution should be used 
when interpreting studies that use heparanase. Although this enzyme is 
highly specific, the down stream consequences of its use will be syndecan 
ectodomain loss as well as HS loss. 
 
1.1.17.6 Hyaluronidase 
HA is degraded by endoglucosaminidases. The two enzymes largely 
responsible for HA degradation in somatic tissue are hyaluronidase 1 
(HYAL1) and 2.234 Although HYAL1 is present in the plasma, it only becomes 
active when the pH is <4, which only occurs within the cell following 
endocytosis.235 HYAL1 has been implicated in glycocalyx damage in diabetic 
models of kidney disease, with HYAL1 knock out mice exhibiting an 
increased glycocalyx depth and reduced albuminuria in STZ induced diabetic 
mice.235 Interestingly HYAL 2 deficient mice develop a thrombotic 
microangiopathy.216 In addition ROS have also been reported to result in a 
reduction in HA chain length.236 ROS generation has also been shown to 
modulate the glomerular endothelial glycocalyx through alterations in GAG 
shedding and so this common pathway could alter multiple components of 
the endothelial glycocalyx.237 
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1.1.18 Studying the endothelial glycocalyx 
As discussed in the sections above multiple methods have been used to try 
to study the function of the endothelial glycocalyx. Whilst separating the 
function of the glycocalyx from other cellular components remains a 
challenge, correlating changes in cellular function with changes in the 
composition of the glycocalyx give us some indication of how the glycocalyx 
responds and influences pathological models. Quantification of the 
endothelial glycocalyx is technically difficult but measures can be derived 
using a number of methods. Individual components of the glycocalyx can be 
quantified using specific antibodies. Conjugating specific antibodies to 
florescent compounds and imaging non permeabolised cells or tissues using 
confocal or multiphoton microscopy ensures that cell surface targets only are 
imaged / quantified.191,238,239 Specific antibodies give detailed information 
about the expression of components of the glycocalyx but they do not give us 
information about the structure as a whole. Alcian blue binding assays have 
been used in vivo and on ex vivo tissues to assess the negative charge 
generated by the glycocalyx.238 However these assays only quantify the 
charge of components remaining on the cell surface, and do not directly 
measure the glycocalyx structure.  
 
1.1.18.1 Electron microscopy 
Combining alcian blue labelling with electron microscopy has become the 
gold standard method for glycocalyx assessment. The fragility of the 
glycocalyx and the high polysaccharide content have, however introduced 
considerable challenges when using this technique. The fragility of the 
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glycocalyx means that the structure, or at least part of it, is rapidly shed in 
response to inflammation or hypoxia.224 As a result careful anaesthesia and 
optimal tissue perfusion must be maintained to ensure the glycocalyx is still 
attached to the cell surface at the time of tissue fixation. Polysaccharides 
react poorly with standard electron microscopy post-fixation stains. This 
means the glycocalyx allows the electron beam to freely pass through its 
structure, with the result that no image can be generated without additional 
staining.181 Ruthenium red and osmium tetroxide were the first additional 
stains to be used successfully.181 Subsequently alcian blue has become the 
most frequently used glycocalyx electron microscopy label. When this label is 
introduced simultaneously with a fixative, such as gluteraldehyde, the 
glycocalyx can be reliably imaged.136,181,203 However, the depth of the 
glycocalyx seen using electron microscopy is markedly lower than the 
measurements generated using other techniques, ranging from 20-100nm.239 
This thin structure may be the result of the dehydration steps needed to 
perform electron microscopy, collapse of the structure in the absence of 
plasma proteins or a fixation artefact.181,239 
 
1.1.18.2 Tracer exclusion 
Tracer exclusion allows a direct measurement of the glycocalyx to be made 
in vivo by measuring the area at the vessels periphery into which large 
labelled molecules cannot enter. This technique was developed by Vink et al 
using a 70kDa FITC conjugated dextran plasma ‘tracer’.240 Using this method 
the glycocalyx was estimated to be approximately 0.5µm thick, a figure 5 
times larger than that measured using electron microscopy. Subsequent 
measurements using laser scanning confocal microscopy and multiphoton 
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microscopy have suggested that the glycocalyx may be even thicker, with 
estimates now ranging up to 4.5µm in large vessels such as the mouse 
carotid artery.239 This method requires vascular access and can only be used 
in live perfused animals where a vascular bed has been exposed for imaging 
e.g. rat mesentry.239 Using tracer exclusion (FITC-BSA or TRITC-dextran) 
and fluorescently tagged anti HS-antibodies in the same mesenteric micro 
vessels Yen et al demonstrated a glycocalyx that is approximately 1µm thick, 
with excellent agreement between the 3 techniques.239 
 
1.1.18.3 Lectin staining 
Lectins, specific carbohydrate binding proteins, recognise highly specific 
sugar units and their 3D conformations. Wheat germ agglutinin (WGA) has 
been used to quantify the glycocalyx in a number of vascular beds.160,203 This 
lectin binds to sialic acid residues throughout the glycocalyx structure.203 
Lectin labelling appears to be highly tissue and site specific and as we 
discover more about the targets of the individual lectins they are likely to 
become a valuable tool with which to examine the glycocalyx in vivo and on 
ex vivo tissues. 
 
1.1.18.4 Atomic force microscopy 
Atomic force microscopy (AFM) uniquely lets us study the mechanical 
properties of the glycocalyx and its height. Using specially adapted AFM 
cantilevers force/distance curves can be generated as the AFM contacts the 
glycocalyx and underlying cell membrane. Using this method in Db/Db mice 
aged 11 weeks old, the elastic modulus of the aortic endothelial cells 
glycocalyx (176Pa) and the underlying cells membrane (811Pa) were 
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measured and the glycocalyx thickness estimated at 940nm.241 In contrast, in 
19 week old Db/Db mice ‘hard’ areas were frequently found, which were 
considered devoid of glycocalyx. In these areas the initial contact elastic 
modulus (where glycocalyx would have been) was 1.7kPa with a peak 
stiffness of 11kPa at the cell membrane.241 Using this technique to map the 
glycocalyx thickness, stiffness and distribution gives a uniquely detailed 
insight into how the glycocalyx reacts to pathological stimuli, however it can 
only be used on carefully prepared in vitro or ex-vivo tissue. 
 
1.1.18.5 Glycocalyx structural assessment summary 
In summary, although technically difficult, there are now a number of 
methods available with which to study the structure of the glycocalyx. From 
simple measurements of depth, through to complex studies of the elastic 
modulus of the structure, each technique has generated data that has helped 
us to increase our understanding of the complex glycocalyx structure. As 
these techniques develop further our knowledge and understanding of the 
glycocalyx will continue to evolve as we discover an increasing level of detail 
about this fascinating structure. 
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1.1.19 Aldosterone may impair glycocalyx function 
1.1.19.1 Flow mediated dilatation 
Aldosterone disrupts flow-mediated dilatation (FMD) defined as the 
endothelium-dependent process facilitating the relaxation of a vessel in 
response to shear stress. FMD occurs as endothelial cells respond to the 
movement of fluid over their luminal surface by producing NO. Endothelial 
dysfunction, detected by altered FMD, is an important independent risk factor 
for cardiovascular disease and remains clinically significant once 
adjustments have been made for underlying common pathologies such as 
diabetes242,243 smoking244,245 or hypertension.246 Patients with high circulating 
levels of aldosterone have impaired FMD.247 In addition, elevated levels of 
biomarkers of endothelial dysfunction (von Willebrand Factor, intercellular 
adhesion molecule-1 (ICAM-1), ox-LDL) are seen in hyperaldosteronism.60 
Patients with a relative excess of aldosterone, compared to renin levels, also 
have impaired NO mediated vasodilatation.248 More recent data has 
confirmed that patients with a primary adrenal adenoma (Conn’s disease) 
have impaired endothelial function. This effect remains significant even once 
the effects of hypertension have been controlled for through comparison with 
matched patients with idiopathic hypertension.249 Fortunately, endothelial 
dysfunction due to MR stimulation appears to be reversible. Spironolactone 
increases endothelial-dependent flow mediated dilatation in patients with 
heart failure, even when used in addition to other medical treatments.250 The 
endothelial glycocalyx is integral to the process of flow-mediated 
dilatation.188,196 How aldosterone affects the glycocalyx has yet to be 
established however. 
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1.1.19.2 Aldosterone Increases permeability to macromolecules 
Aldosterone excess in humans is linked to proteinuria.60 This relationship is 
seen in both primary and secondary hyperaldosteronism.65,66,78,251 In humans 
this finding is complicated by the associated hypertension that results from 
tubular MR activation. However, in vitro aldosterone at a dose of 10-9mol/l 
increased the endothelial permeability to proteins <70Kda within 60minutes 
both in cultured HUVECs and in ex vivo arteries.252 In animal studies 
normalising the blood pressure of animals given aldosterone with agents not 
targeting RAAS components failed to prevent renal fibrosis and was 
ineffective at reducing urinary protein loss.253,254 These data suggest 
increased glomerular permeability may be responsible for albumin leakage 
following aldosterone excess, rather than the hypertension. The impact of 
aldosterone on the specialized cells of the renal glomerulus has been also 
been studied by a number of groups.112,160 Podocytes, a key part of the 
filtration barrier, express MR and are damaged by elevated aldosterone.255 
However podocyte-specific MR knock out mice still become proteinuric.256 
Systemic aldosterone blockade in these animals remained effective, reducing 
glomerular injury, suggesting other cell types are more important in the 
pathogenesis of proteinuria in response to MR stimulation.256 The increased 
permeability of the systemic endothelium in response to aldosterone, and the 
associated glycocalyx remodelling, hint towards the importance of the 
glomerular endothelial glycocalyx in the pathogenesis of proteinuria, but to 
date this has not been studied. 
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1.1.19.3 Aldosterone promotes inflammation  
The ability of white blood cells to egress from the vascular compartment to a 
site of tissue injury or infection is an essential part of the innate immune 
system (see figure 1.10). However when the regulation of this process 
becomes defective, unwanted inflammation and fibrosis may occur. 
Aldosterone exposure rapidly increased the adhesion of polymorphonuclear 
leukocytes to the HUVEC surface.257 These effects were maximal within one 
hour of aldosterone exposure. Increased protein expression of vascular cell 
adhesion molecule 1 (VCAM-1), e-selectin and ICAM-1 were thought to be 
responsible for the effect.257 It is important to note that the expression of cell 
adhesion receptors is also regulated by shear stress.258 As highlighted 
previously, the glycocalyx is intimately involved in this process and so 
damage to the glycocalyx structure, which limits the endothelial cells’ 
protective response to shear, may also result in the cell surface becoming 
more adhesive.258 This data when combined with the observation by 
Oberleithner et al, that the systemic glycocalyx becomes thin and looses HS 
from its structure in response to aldosterone and salt exposure,259,260 
suggests that the transit of white blood cells from the circulation may 
increase in response to aldosterone. This may be due to increased adhesion 
molecule expression, loss of shear sensitivity and increased adhesion 
molecule exposure due to reduced expression of other glycocalyx 
components such as HS. 
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1.1.19.4 Aldosterone promotes atherosclerosis  
Elevated aldosterone levels, even within the ‘normal range’, are strong 
predictors of cardiovascular disease risk.73 This effect remains even when 
adjusted for baseline atheroma.74 Atherosclerosis is a systemic vascular 
inflammatory disease initiated by cardiovascular risk factors that cause 
endothelial cell damage.261 Activated endothelial cells recruit leukocytes to 
the endothelial wall, typically in areas of low shear stress.261 High circulating 
levels of aldosterone are linked to an increased rate of atherogenesis, 
particularly in areas of the circulation that experience low shear stress e.g. 
vessel bifurcations etc. In a mouse model with elevated circulating 
aldosterone at levels insufficient to cause BP alteration, aldosterone 
increased recruitment of activated monocytes and T cells to atheroma-prone 
areas, promoting atheroma formation.22 Thus the formation of atheroma may 




1.1.20 Evidence for glycocalyx protection as a clinical therapy 
1.1.20.1 Sulodexide 
Sulodexide is derived from 80% porcine heparin and 20% dermatan 
sulphates.224 It can be given orally and is thought to provide precursors for 
the synthesis of GAGs. Suledexide therapy has been shown (In a small scale 
clinical study) to increase the depth of the glycocalyx after 2 months therapy 
in diabetics.262 However no lasting renal protection was detected in a larger 
subsequent study.263 More recent work has shown that sulodexide may be of 
benefit in animal models of sepsis, where it conserves the glycocalyx and 
improves its subsequent restoration even when given 2hours after the onset 
of sepsis.264 
 
1.1.20.2 Clinical glycocalyx protection in practice 
Multiple drugs already used clinically could mediate some of their effects 
through protecting the glycocalyx. Hydrocortisone is the name used for 
therapeutic synthetic cortisol. It is a potent glucocorticoid used clinically in 
multiple inflammatory conditions.265 Glucocorticoids act via the glucocorticoid 
receptor to mediate pleotropic effects including immune cell modulation. The 
diverse actions of glucocorticoids are due to the number of responsive genes 
(estimated to be between 1000 and 2000) altered following glucocorticoid 
receptor activation.265 In vivo glucocorticoids reduce the numbers of B and T 
lymphocytes largely through inhibiting NF-κB. In vitro there is evidence that 
hydrocortisone preserves the endothelial glycocalyx from TNFα induced 
shedding.266 There is also evidence that glucocorticoids can help to preserve 
the glycocalyx following knee replacement surgery and neonatal cardiac 
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surgery.267,268 Whether preserving the glycocalyx from such acute insults had 
a lasting clinical impact was not assessed. Animal models have also 
suggested that the volatile anaesthetic sevoflurane may help preserve the 
endothelial glycocalyx during ischaemia/ reperfusion type insults.269,270 A 
meta-analysis of clinical trials looking at sevoflurane preconditioning for 
coronary artery bypass grafting concluded that there was evidence that 
sevoflurane could reduce post operative troponin levels and concluded that a 
large RCT was needed.271 The hawthorn extract WS 1442 is used as a 
herbal remedy in cardiac disease.272 The mechanism of action is unknown 
but it appears to improve endothelial function and has been shown to 
preserve the endothelial glycocalyx in mice, suggesting that glycocalyx 
protection may mediate some if its effects.273 
 
1.1.20.3 Future Targets 
The finding that MMPs are commonly up-regulated in inflammation has made 
them a tempting drug target.274 However MMPs are also intimately involved 
in physiological processes including wound healing, immune responses and 
angiogenesis.274 For this reason broad-spectrum inhibitors proved to be 
poorly tolerated in clinical trials, with patients developing musculoskeletal 
pain and inflammation.274 More specific inhibitors have since been developed 
including MMP2/9 inhibitor (2R)-2-[(4-Biphenylylsulfonyl) amino]-3-
phenylpropionic acid (compound 5a).275 This compound has an IC50 (µM) of 
0.24 (MMP-2) and 0.31 (MMP-9).276 Whilst the chemists that developed this 
compound did not check its specificity they did check the specificity of 
multiple closely related compounds and all had IC50 value >1 against MMPs 
1,3 and 7, ACE, endothelin converting enzyme (ECE) and NEP (neutral 
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endopeptidase). This suggests that sulphonamide derivatives containing 
biaryl, triple bond, tetrazole, or amide groups are specific inhibitors of MMP 2 
and 9.276 Monoclonal antibodies directed at MMPs result in highly specific 
inhibitors and are currently under development. It is hoped they will provide 
the next level of specificity and as a result they may have a more tolerable 
side effect profile.274 The monoclonal MMP 9 inhibitor GS-5745 has been 
studied in phase one and two trials for solid organ tumours and ulcerative 
colitis (UC) and appears to be well tolerated.274 However the phase 2 and 3 
combined trial in UC was terminated early due to a lack of efficacy in the first 
150 patients that entered the study.274 A trial evaluating GS-5745 in gastric 
cancer (phase 2/3) is on-going and results are awaited from a similar trial 
completed in Crohn’s disease patients (awaiting publication).274 
 
Multiple heparanase inhibitors are undergoing clinical trials in cancer patients 
currently.226 Modified heparins or oligosaccharides that act as heparin 
mimetics have proved the most attractive therapeutics to date. Compounds 
include PI-88, SST0001, PG 545 and M402.226 Heparanase is widely 
expressed however and has multiple sites of action. Surprisingly a limited 
number of studies have specifically looked at the endothelial glycocalyx 
following heparanase blockade in vivo. Low molecular weight heparin 
(LMWH) acts as a competitive substrate for heparanase and has been used 
as a heparanase inhibitor in Wister rats.223 During this study the shedding of 
the glycocalyx in mesentery vessels was studied using intravital microscopy. 
The authors confirmed that LMWH inhibited glycocalyx shedding in response 
to the chemo-attractant fMLP.223 Surprisingly, to date, no one has studied the 
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impact of heparanase inhibitors in diabetic nephropathy or other common 
renal pathologies. However work by Gil et al has shown that heparanase 
knock down in mice prevented the development of diabetic nephropathy and 
so this therapeutic strategy does present an attractive potential therapeutic 
pathway.206 
 
The current clinical strategies aimed at protecting the glycocalyx have lacked 
specificity. Many of the targets implicated in shedding the endothelial 
glycocalyx also perform many other important roles and shedding the 
glycocalyx may itself perform a physiological role. Thus to find effective 
therapeutic options specific molecular targets need to be found and in the 
case of short term insults such as ischaemia reperfusion or sepsis the timing 
of when to administer these agents will need to be studied in detail.  
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Mineralocorticoid receptor inhibition in diabetes 
mellitus 
	
1.1.21 Diabetes Mellitus (diabetes) 
Diabetes mellitus is a group of metabolic disorders characterised by 
hyperglycaemia resulting from insulin hypo-secretion or insensitivity.277 The 
current working classification of diabetes was proposed by the American 
Diabetes Association in 1997. This places patients into groups including; type 
1, type 2, other and gestational diabtetes.277 Type 1 diabetes represents 5-10 
% of the total population of diabetic patients and is due to autoimmune 
mediated destruction of the β cells of the pancreas.278 Type 2 diabetes 
represents the other major form, with an estimated prevalence of 8.3% in 
adults aged between 20-79 years old.277 However, the prevalence is 
expected to rise to >10% by 2035.277 The hallmark of type 2 diabetes is 
insulin resistance in peripheral tissues. The insulin resistance cannot be 
compensated for by the β cells of the pancreas due to additional defects in 
the function of these cells.279 In type 2 diabetes the diagnosis is often 
delayed because patients initially remain relatively asymptomatic. This delay 
has hampered the study and treatment of early type 2 diabetes. 
 
1.1.22 Diabetic nephropathy 
Diabetic kidney disease is the most common cause of end-stage renal 
disease in the developed world.280 Diabetic nephropathy is usually diagnosed 
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on the basis of clinical findings including micro-albuminuria and the patient’s 
history. A renal biopsy is rarely performed in these cases.281 When biopsies 
are performed changes associated with diabetic nephropathy include 
mesangial expansion, glomerular and tubular basement membrane 
thickening and glomerulosclerosis.282 As an area of intense research interest, 
multiple pathogenic mechanisms have been identified as contributors to 
diabetic nephropathy. End-stage fibrotic changes within the diabetic kidney 
are contributed to by haemodynamic changes, ischaemia, oxidative stress, 
inflammatory processes and over activation of RAAS.282 Haemodynamic 
changes result in glomerular hyperfiltration. Hyperglycaemia causes 
glomerular afferent arteriole dilation by altering the release of insulin-like 
growth factor 1, NO and VEGF and prostaglandin.282 Renal tubular function 
is also altered early in the pathogenesis of diabetic nephropathy. Increases in 
the filtered load of glucose result in increased expression of the sodium 
glucose co-transporter 2, increasing both sodium and glucose uptake from 
the tubular fluid. This reduces the sodium concentration delivered to the 
macula densa resulting in dilatation of the afferent arteriole via 
tubuloglomerular feedback.283 In addition hyperglycaemia and 
hyperinsulinaemia promote cellular dysfunction via increased ROS, activation 
of protein kinase C and generation of advanced glycation end-products.284 
Finally inflammatory factors such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) increase inflammatory cell infiltration 
contributing to the final fibrotic damage seen in renal disease.282 
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1.1.23 Current clinical management of diabetic nephropathy 
Diabetes management guidelines advocate adherence to strict glycaemic 
and blood pressure targets. Inhibition of the RAAS system is advised in both 
albuminuric and non-albuminuric patients.285,286 Whilst monotherapy to block 
the RAAS is well established in clinical practice, the addition of an MR 
inhibitor to an ACEi or ARB further reduces albuminuria.287-290 Why MR 
inhibition is effective in diabetes when serum aldosterone levels are often not 
elevated in the disease is unknown.291,292 One potential explanation is that 
glucose acts like salt, potentiating the effect of MR activation, altering the 
signalling systems.293  
The mechanisms through which MR blockade achieves the additional level of 
protection in diabetic nephropathy have also not yet been fully investigated. 
However, multiple recent publications suggest that glycocalyx injury is a key 
step in the development of diabetic nephropathy.112,294 Given that large body 
of evidence outlined previously suggesting that MR activation may lead to 
glycocalyx destruction we felt that it was reasonable to hypothesise that MR 
inhibition in diabetes could be effective because it preserves the glomerular 
endothelial glycocalyx. This explanation uniquely helps explain the reduction 
in vascular disease and albuminuria seen simultaneously when MR inhibition 
is initiated in diabetic patients, and therefore we felt this hypothesis 




The renin angiotensin aldosterone system is a highly evolved mechanism 
optimised to preserve circulating volume and perfusion pressure. However 
this system has been implicated in the pathogenesis of renal and vascular 
disease. Although therapeutic inhibitors are now available, and effective in 
slowing the development of disease, their use is limited by predictable side 
effects. 
Within the kidney a complex filter has evolved. The GFB allows remarkable 
water permeability whilst limiting the passage of charged proteins and cells. 
The GFB is composed of multiple layers and the relative contribution of these 
layers to the restriction of proteins is not fully defined. In addition the two 
major cell types of the GFB continually communicate with each other, and so 
even isolated insults are likely to affect the whole filtration barrier given time. 
Aldosterone-mediated damage to the endothelial glycocalyx represents a 
potential explanation for the observed vascular and renal disease seen 
following aldosterone excess. To date no one has studied whether 
physiologically relevant levels of aldosterone and salt damage the glomerular 
endothelial glycocalyx. In addition clinical studies have shown that MR 
inhibition is an effective therapy in diabetic nephropathy, however its use is 
limited by side effects and its mechanism of action is not fully known. A key 
action of MR inhibition in diabetes may be the preservation of the GEnC 




Simulation of mineralocorticoid receptors results in the loss of key 
glomerular endothelial glycocalyx components and causes albuminuria 
 
2.1.1 Project aims and hypothesis 
I will aim to establish or refute my hypothesis by working towards a number 
of specific aims.  
In vitro 
• Demonstrate salt and aldosterone exposure in vitro result in GEnC 
glycocalyx damage 
• Identify a potential mechanism of glycocalyx damage 
• Develop a potential therapeutic intervention to preserve the 
glycocalyx, independent of MR inhibition and therefore avoiding 
potential side effects including hyperkalaemia 
In vivo 
• Develop a model of salt and aldosterone excess  
• Test whether this model results in GEnC glycocalyx damage 
• Test whether this model develops signs of glycocalyx dysfunction 
including albuminuria 
• Develop a technique that lets us simultaneously study the GEnC 
glycocalyx and GFB permeability to albumin 
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• Attempt a therapeutic intervention in vivo aimed at maintaining the 
glycocalyx structure and test whether this prevents GFB albumin 
leakage and albuminuria 
• Finally I will investigate if MR inhibition is effective in diabetic 





In vitro studies  
3.1.1 Cell culture 
Satchell et al originally isolated and conditionally immortalised human GEnC 
(CiGEnC) at the University of Bristol and published the method and 
evaluation of the cell line in 2006.114 These cells are now considered the 
‘gold standard’ human glomerular endothelial cell line. These cells were 
originally isolated from sieved human glomeruli obtained from kidneys 
donated to research. To immortalise the cell line human telomerase reverse 
transcriptase (hTERT) and a temperature sensitive simian virus 40 large 
tumour antigen (SV40LT) construct were both introduced to the primary 
culture. Successfully transfected cells were selected through exposure to 
25µg/ml of hygromycin and continued division at the permissive temperature 
of 33°C.114 Cells were subsequently selected for on-going culture and cloning 
on the basis of visual appearance (to both light and electron microscopy), 
and response to VEGF, TNFα and expression of endothelial surface 
markers.114 
 
3.1.1.1 Culture Conditions 
Conditionally immortalised GEnC were cultured in EGM2 media (Lonza, 
Tewksbury, UK) with the EGM2-MV bullet kit. The final media contains 
hydrocortisone (0.2ml), human foetal growth factor (2ml), human endothelial 
growth factor (0.5ml), recombinant insulin-like growth factor (0.5ml) and 
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ascorbic acid (0.5ml) (VEGF and gentamicin are not added to the media 
used in these experiments). Lonza does not disclose the concentrations of 
the added supplements. The final sodium concentration of the media is 
125mmol/L. This information was disclosed to me by Lonza to facilitate this 
project, but I have been asked not to publish this information directly. Stock 
cells were maintained in T75 tissue culture flasks with a vented cap 
(Sarstedt, Nümbrecht, Germany, 83.3911) containing 10ml of media. 
ThermoFisher, Nuclon™Delta 10cm round dishes (ThermoFisher, 
Gloucester, UK, 172931) containing 10ml of media were used for shear 
experiments.  
 
3.1.1.2 Cell passaging 
At the permissive temperature of 33°C in the presence of 5% CO2 cells were 
grown in humidified incubators until approximately 80% confluence was 
reached. At this point cells could be ‘thermoswitched’ at 37°C for 5 days to 
allow cells to terminally differentiate, or cells could be trypsinised and re-
seeded into new tissue culture dishes or frozen. If cells were to be re-seeded 
the media was aspirated from their surface before a sterile physiological 
phosphate buffered saline solution was used to remove any residual media. 
Trypsin-EDTA (0.25% Lonza, Tewksbury, UK, CC5012) was then added to 
flasks and allowed to coat the cells surface, excess trypsin-EDTA was then 
immediately aspirated and cells returned to a 33°C incubator for 3 minutes. 
Light microscopy was then used to confirm that cells had entered into 
suspension before 4-5ml of new culture medium was added to the flask to 
neutralise the trypsin and re-suspend the cells. Into each new T75, or 10cm 
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dish, 1ml of cell suspension was added before increasing the final volume 
with fresh media to a total of 10ml. The new flasks were then labelled, and 
the passage number increased by 1, before returning the cells to the 33°C 
incubator. Typically each stock flask would be split into 4 or 5 T75 flasks. 
 
3.1.1.3 Cell cryopreservation 
Cells were cryopreserved to maintain the cell line and avoid excessive aging 
of the cells in-between experiments. To freeze cells a freezing solution 
containing 10% dimethyl sulphoxide (DMSO) (Sigma-Aldrich, Dorset, UK, 
276855) 40% foetal bovine serum and 50% complete cell media was used. 
This was added to a 1.8ml cryovial containing suspended cells in a 1:1 ratio. 
Cells were subsequently placed at 4°C for 1 hour, then -20°C for 30 minutes 
before placing cells in the -80°C freezer for short-term storage. For long term 
storage (>1 month) cells were subsequently transferred to liquid nitrogen. 
 
3.1.1.4 Cell Resuscitation 
To thaw cells individual cyrovials were warmed by hand until the contents 
returned to a liquid state. At this point they were returned to a T75 flask with 
a further 8.2ml of complete media. Cells were then allowed to re-attach for 4-
6 hours. Once cells were re-attached the media was swapped for fresh 
complete media to remove the traces of DMSO, and normal care resumed. 
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3.1.1.5 Maintaining osmolarity 
To negate the effects of osmotic shifts, mannitol was added to the media. In 
provisional experiments mannitol (Sigma-Aldrich, Dorset, UK) was added to 
the media of control flasks at the same time as salt and aldosterone were 
added to intervention flasks. Comparison of the ‘control’ data gathered using 
this method with cells left in standard media however revealed that acutely, 
osmotic shifts altered the mRNA expression of key target genes. To isolate 
the effects of salt and aldosterone from these acute osmotic effects I 
therefore altered my protocol to introduce mannitol to the value equivalent to 
145mM NaCl from the point of thermo-switching the cells at 37°C (5 days 
before salt or aldosterone were added). Control plates were then maintained 
in media containing mannitol for the duration of experiments, whist cells to be 
exposed to increased salt concentrations were swapped into high salt media 
of the same osmolarity. This ensured that experiments were performed under 
iso-osmolar conditions. Experiments were conducted comparing media 
containing 125mM NaCl and 145mM NaCl. These figures were selected 
based on the disclosed concentration of sodium in EBM2 media (125mM), 
and the upper limit of the physiological range of sodium in humans (145mM) 
these figures also corresponded closely with the work of Oberleithner et al.260  
 
3.1.1.6 Aldosterone  
Aldosterone was purchased from Sigma-Aldrich, Dorset, UK (A9477 – 5mg). 
Stock solutions were prepared by dissolving aldosterone in absolute ethanol 
prior to the addition of media to achieve a stock concentration of 0.1mg/ml. 
Aliquots were then frozen at -20°C and stored for a maximum of three 
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months. Serial dilution of the stock solution of aldosterone was used to 
achieve a final concentration of 0.1nM in cell media used in all experiments. 




Spironolactone (MR antagonist) was purchased from Sigma-Aldrich, Dorset, 
UK (S3378 – 1g). Spironolactone was prepared in DMSO (1ml) and stored in 
aliquots at a concentration of 0.1M at -20°C for a maximum of three months. 




Batimastat (MMP inhibitor) was purchased from Sigma-Aldrich, Dorset, UK 
(SML0041-5MG) and serially diluted prior to storage in aliquots at -20°C for a 
maximum time period of three months. A concentration of 5µM was used in 
all experiments.191 
 
3.1.1.9 Shear Stress 
To apply shear stress, cells were plated onto 10cm diameter round tissue 
culture dishes and allowed to form confluent, terminally differentiated, 
monolayers. Dishes were then placed on an orbital shaker (SSM1 Stuart, 
Stone, UK) to achieve a peak shear stress of 10dyn/cm2 calculated using the 
formula; 
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τw = α√ρη (2πf)3 
where   τw is shear stress at the dish wall in dyn/cm2 
α is radius of rotation (cm) 
ρ is density of liquid (1.005 g/ml) 
η is tissue culture medium viscosity (0.0075 dyn/cm2 at 37 °C) 
f is rotations per second 
 
Shear stress was applied for 24 hours prior to harvest. Each condition tested 
had a matched control for each experimental variable, maintained in the 
same incubator under static conditions. The optimisation of conditions used 




3.1.2 Protein collection and analysis 
3.1.2.1 Protein Extraction  
Cells were grown in T75cm2 or 10cm diameter round tissue culture dishes to 
ensure optimal protein concentrations could be achieved. To extract protein, 
cell monolayers were washed with ice cold phosphate buffered saline (PBS) 
twice, on ice, before residual PBS was removed using a p1000 pipet. 
Subsequently 300µl of ice-cold radio immunoprecipitation lysis buffer (RIPA 
Buffer, Sigma-Aldrich, Dorset, UK, RO278) with the addition of protease 
inhibitor (1:100 Sigma-Aldrich, Dorset, UK, P8340) and phosphatase 
inhibitors 2 and 3 (1:100 Sigma-Aldrich, Dorset, UK, P5726, P0044) (300 µl 
per 10cm dish / T75) was added to each dish. Cells were then incubated on 
ice prior to harvest using a cell scraper (Sarstedt, Numbrecht, Germany). 
Samples were then centrifuged (5 minutes, 13000rcf, 4°C) to remove cellular 
debris and the supernant removed to aliquots in 1.5ml eppendorfs tubes 
before being frozen on liquid nitrogen and stored at -80°C for subsequent 
use in Western Blotting and ELISAs.  
 
3.1.2.2 Culture medium harvest and concentration 
Cell culture medium was harvested to allow analysis of secreted / shed 
proteins. To prevent contamination of the samples with foetal calf serum all 
cells were washed twice with sterile PBS prior to the application of serum 
free EBM2 media +/- relevant treatments (e.g. aldosterone) for 12h. After this 
period the media was concentrated using centrifugal filters (Amicon Ultra-4), 
(Merk-Milipore, Tulagreen, Ireland). Samples were concentrated 10-fold 
resulting in 400µl of media, which was then aliquoted and frozen. 
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3.1.2.3 Western Blotting 
A standard technique for western blotting has been employed using the 
antibodies listed in table 1. 
Antibody Manufacturer Cat No 
Human MR antibody Abcam, Cambridge, UK ab62532 
Human HSD1 antibody R and D Systems, 
Minneapolis, USA 
AF3397 
Human HSD2 antibody R and D Systems, 
Minneapolis, USA 
MAB8630 
Human syndecan 4 
antibody 
Milipore, Temecula, USA ABT157 
Table 1 Antibodies used for western blotting and 
immunoflorescence 
	
Control samples were collected with consent and ethical approval from 
human kidneys prepared for transplantation but then not used for clinical 
reasons. Kidney samples were divided into tissue from the medulla, glomeruli 
and renal cortex. Dr R Ramnath kindly provided FACS isolated GEnC lysates 
to confirm the expression of MR in primary human GEnC. All samples were 
incubated with 1x sodium-dodecyl sulphate (SDS) loading buffer (100mM 
Tris-HCl, 4% SDS, 20% glycerol, 0.2% bromophenol blue, 5% 2-
mercaptoethanol pH6.8) at 95°C for 5 minutes to denature proteins. In all 
experiments 20µl of sample was loaded per well before lysates were 
separated on 10% polyacrylamide gels by a 100v potential difference for 
approximately 2 hours. Proteins were then transferred to a methanol-
activated polyvinylidine fluoride (PVDF) membrane (Fisher-Scientific, 
Loughborough, UK) in ice-cold transfer medium. Membranes were then 
blocked using 5% milk or 5% BSA solution (optimised for each antibody) in 
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PBS-tween (0.1%) pH7.4 before primary antibodies were applied (diluted in 
blocking solution). After incubation overnight at 4°C, membranes were 
washed 3 times in 0.1% TBS-Tween before incubation with HRP-conjugated 
secondary antibodies (1:5000 in 0.1% TBS-Tween) for 2 hours at room 
temperature on a rocking platform. Membranes were subsequently washed 
again 3 times before imaging. 
 
3.1.2.4 Human Syndecan 4 ELISA 
The quantity of syndecan 4 (ectodomain) was quantified on cell lysates. 
Lysates were obtained using the same protocol outlined in ‘protein 
extraction’. The concentration was then assessed using a Syndecan 4 ELISA 
kit (USCN Life Science Inc, Houston, USA). All samples were processed in 




3.1.3 RNA collection and analysis 
Two methods of RNA extraction have been employed – Trizol (Thermofisher, 
Loughbourgh, UK, Cat No 10296010) and RNAeasy columns 
(Quiagen,Manchester, UK, Cat No 74104). Time and cost pressures dictated 
the choice of method employed each time. 
 
3.1.3.1 Trizol Protocol 
Initially Trizol and chloroform were allowed to stand at room temperature for 
30 minutes. During this time a 70% ethanol solution was prepared using 
distilled water and reagent grade 100% ethanol, and cooled to 4°C and the 
centrifuge was pre-cooled to 4°C. Subsequently cell suspensions were 
thawed on ice prior to adding 1ml Trizol per sample and incubating at room 
temperature for 5 minutes. Next 200µl of chloroform per 1ml of Trizol was 
added in the fume hood prior to shaking the samples by hand for 15 seconds 
then incubating at room temperature for 2-3 minutes. Samples were then 
centrifuged at 12000rcf for 15 minutes at 4°C. The upper phase was then 
removed to new clean eppendorfs, being careful not to touch the interphase 
or the tube edge. Into this new tube 500µl of isopropanol was added per 
sample and the mix incubated for 10 minutes at room temperature. 
Subsequently the samples were centrifuged at 12000rcf for 10 minutes at 
4°C. The supernant was then removed and discarded, leaving the RNA 
pellet. The pellet was then re-suspend in 70% ethanol (4°C), vortexed then 
centrifuged at 7500rcf for 5 minutes at 4°C twice. Following these washing 
steps all ethanol was removed from the eppendorf tubes and the pellet 
allowed to air dry for 5 minutes. At this point 20µl on RNAse free water was 
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added and the sample vortexed gently. The samples were then placed on ice 
for 30 minutes prior to measuring the RNA concentration. 
 
3.1.3.2 Columns protocol and adaptations  
The standard protocol supplied with the Quiagen RNAeasy Kit (Cat No 
74104) was employed with the following amendments (which I have found 
improve RNA purity). Cells were washed twice with PBS on ice prior to 
allowing the cells to dry on ice for 5 minutes; subsequently lysis buffer was 
added per the protocol. Following the initial separation centrifugation step I 
prioritised transfer of a small clean sample to the 70% ethanol ensuring no 
contamination with the visible white stranding material. Generally 300µl of 
clean supernant was transferred for each 10cm dish. 
 
3.1.3.3 Measuring RNA concentration 
RNA was quantified in samples using a nanophotodrop 1000 spectro-
photometer (Thermofisher, Gloucester, UK). A 260/280 of approximately 2 
was deemed acceptable, indicating the presence of minimal protein or 
phenol. A 260/230 ratio of >1.6 was considered acceptable, indicating a low 
concentration of other co-purified contaminants including carbohydrates.  
 
3.1.3.4 cDNA Synthesis 
To convert RNA to cDNA a standard protocol was employed using a high 
capacity mRNA to cDNA kit (Applied Biosystems, Foster City, USA, ref 
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4387406) and 0.2 microliter tubes, flat cap, (Molecular Bioproducts 
(Thermofisher, Gloucester, UK, Cat 3412). 
 
3.1.3.5 Quantitative PCR  
Prior to use, each primer pair (table 2) was diluted into a 100-pmol/µl solution 
with DEPC water as per the eurofins genomics oligonucleotide synthesis 
report (supplied with each purchased primer pair). A working stock primer 
solution was then prepared (10µM). Preliminary tests were then performed 
on each primer pair to ensure optimal primer concentrations were used. 
Tests ensured; 
• Expected Ct values fell within the linear portion of the amplification 
curve (figure 3.1) 
• A single product was visible on the resulting melt curve (figure 3.1) 
• Negative controls produced no product within the linear amplification 
region 
Once an optimal primer concentration had been established a standard 
protocol was used for all qPCR using Fast Sybr Green master mix (Applied 
Biosystems, Foster City, USA, ref 438612). A master mix was prepared for 
each primer to be tested. This consisted of 5.5µl of Fast Sybr Green per well; 
the diluted primer mix and DEPC water to make a final volume of 9µl per 
well. This was then pipetted into each test well, and 3 negative control wells. 
2µl of cDNA solution (diluted 1:10) was then pipetted into each well, using a 
new tip each time to ensure no mixing and a consistent volume of solution 
was delivered. To the control wells 2µl of the same DEPC water was added. 
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All samples were processed in triplicate. The sample was then run using fast 
Sybr Green settings, on a StepOne Real-Time PCR system (Thermofisher, 
Gloucester, UK, Cat No, 4376357), quantitative PCR for a 96 well plate, 
normalising to ROX dye with melt curve function. Data were subsequently 
analysed prior to inclusion. Criteria for inclusion included 
• Consistency between triplicate samples or one clear outlier that could 
be excluded 
• Single product on melt curve analysis of each sample 
• Negative control wells  
 
Figure 3-1 Primer evaluation 
Before each primer sequence was used optimal primer concentrations were 
established. Melt curves were run to confirm a single product was produced at the 
end of 40 qPCR cycles and then serial dilutions of cDNA were run in triplicate to 
confirm linear amplification. 
 
3.1.3.6 qPCR analysis 
CT values were exported to excel and manually processed to generate fold 
change values. Briefly CT values were first normalised to the matched 
control gene result (GAPDH) for each experimental condition (Δ CT). Then 



















































CT). 2^ ΔΔ CT was then calculated to give the fold change in the gene of 
interest for each condition. Standard errors were calculated on ΔΔ CT values 
and then added and subtracted from the mean value prior to raising 2^ to 
give a final positive and negative standard error for each sample mean. 
Statistical analysis was performed using T-tests or ANOVA with Tukey’s post 
hoc correction on Δ CT values. Data are presented as mean values +/- SEM. 
Table 2 Gene targets and sequences used for qPCR analysis 
  
Human Primers  Forward Sequence  Reverse Sequence  
GAPDH AAGGTGAAGGTCGGAGTCAAC GAGTTAAAAGCAGCCCTGGTG 
KLF2 CAAGACCTACACCAAGAGTTCG CATGTGCCGTTTCATGTGC 
MMP2 AAGTCTGAAGAGCGTGAAGTTTGGA TGAGGGTTGGTGGGATTGGAG 
MMP9 TGTACCGCTATGGTTACACTCG  GGCAGGGACAGTTGCTTCT 
Mouse Primers  
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCAGGT 
Syndecan 4 CCCTTCCCTGAAGTGATTGA AGTTCCTTGGGCTCTGAGG 
MMP2 GCTATGTCCACTGTGGGTGGAAAT GATCCCCTTGATGTCATCATGGGATAAT 
MMP9 CCTACTCTGCCTGCACCACTAAA CTGCTTGCCCAGGAAGACGAA 
TNFα AGACCACGTCGTAGCAAACCA ACAACCCATCGGCTGGCACC 




GAPDH CCATCAACGACCCCTTCATT GACCAGCTTCCCATTCTCAG 
MMP9 CGCCAGAAGTATTTGTCATGG CTTGAAGTCTCAGAGGGTGGATC 
Syndecan 4 ACTTTGAGCTGTCGGGTT GTGGCACCAAGGGTGAAATC 
MMP2 GCTGATACTGACACTGGTACTG GCTGATACTGACACTAAACC 
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3.1.4 Light based imaging 
3.1.4.1 Immunofluorescence on cells 
Following 5 days experimental exposure cells were washed twice with PBS 
to remove traces of cell media. Cells were then incubated at room 
temperature with 4% paraformaldehyde (PFA) (Sigma-Aldrich, Dorset, UK) 
for 15 minutes. Cells were then washed again three times with PBS and 
subsequently incubated at room temperature with blocking solution 
consisting of 5% BSA. Next the primary antibodies– mouse anti heparan 
sulphate (1:100 BIO-RAD, Watford, UK, Cat No, 1698, Batch 151209), rabbit 
polyclonal anti syndecan 4 antibody (1:100 Merk-Milipore, Watford, UK, Cat 
No ABT157), or species matched IgG control antibodies were applied (50µl 
per well on 96 well plates or 20µl onto parafilm for coverslips). Samples were 
then placed at 4°C overnight in a dark, damp sealed container. Following a 
further 3 washes using PBS the species-specific secondary antibodies were 
incubated on the sample for 1 hour at room temperature. Following a final 
wash step using PBS three times the cells were either left in 100 microlitres 
of PBS (in the 96 well plates) and imaged using the plate reader (96 well) 
(Dynex Opsy MR, Chantilly, USA), or fixed using Vectashield (Vectashield 
laboratories, Peterborough, UK, Cat no H-1000) inverted onto a microscope 
slide. Slides were subsequently sealed with nail varnish and imaged 
manually (Leica DMI6000B with Leica CTR7000, Milton Keynes, Leica, UK) 
to confirm cell surface staining. Comparison was made to IgG controls. Cells 
grown on cover slips were used to confirm the specificity and pattern of 
staining using images taken manually and florescence readings from the 
plate reader were used to quantify florescence intensity. 
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3.1.4.2 Immunofluorescence on human kidney 
The protocol listed above was modified for use on frozen human kidney 
sections cut to 5µm. Kidney sections were cut from flash frozen tissue 
donated for research. Sections were placed onto poly-l-lysine coated slides 
before fixing and blocking and washing was performed as above. Human MR 
antibody (Rabbit polyclonal antibody, Abcam, Cambridge, UK, ab62532) was 
used at a concentration of 4µg/ml, human HSD2 antibody (R and D Systems, 
Minneapolis, USA, MAB8630) was used at a concentration of 10µg/ml. 
	
3.1.4.3 Imaging actin fibre alignment using Actin Phalloidin 
Actin Phalloidin staining was used to highlight the alignment of actin stress 
fibres following shear stress. Cells were cultured as per standard conditions 
on fibronectin-coated coverslips stuck onto the outermost surface of 10cm 
diameter tissue culture dishes using sterile autoclaved grease. Cells were 
then exposed to treatment conditions before 24h exposure to 10-dyn/cm2 
shear stress or static (control) conditions. 
Figure 3-2 Illustration of coverslip placement in shear stress 
experiments 
	
At the end of the experimental protocol cells were washed twice with PBS 
prior to fixing in 4% PFA for 10 minutes at room temperature. Subsequently 
Fibronectin coated coverslips were stuck to 
the dish surface using sterile grease to 
ensure no movement occurred during 24h 
10dyn/cm2 shear stress. Cover slips were 
placed approximately 5mm away from the 
dish edge in the area estimated to have 
maximal shear stress 
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cells were washed three times with PBS prior to the addition of phalloidin 
Allexa Flour 594 conjugate (1:200 Invitogen, Waltham, USA Cat no 
10135092) diluted in 1% BSA PBS solution. Following 20 minutes incubation 
at room temperature in a dark humidified container, cells were washed again 
3 times in PBS before mounting the cells using Vectashield preservation fluid 
(Vectashield laboratories, Peterborough, UK, Cat no H-1000) and nail 
varnish to seal the coverslip onto the slide. Blinded analysis was then 
conducted on images captured using a Leica DMI6000B microscope with a 
Leica CTR7000 laser (Leica, Milton Keynes, UK) using image J software. All 
images were captured with flow directed from ‘North to South’ on a virtual 
compass. Adjusting the contrast of the image to ‘skelatinise’ the image left 
only the actin visible. Linear regions of interest could then placed over actin 
fibres mirroring their orientation and length. Because it is not possible to 
detect the direction of each linear fibre, ROIs were always started at the most 
‘South Westerly’ end of the fibre. Analysis of the ROIs using image J 
subsequently revealed the actin fibres orientation relative to the direction of 
flow. After the analysis was completed I was un-blinded and exported the 
data to Excel and Prism for analysis. 
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Mouse model selection and methodology 
3.1.4.4 Mouse background selection 
All mouse work in the UK was performed in accordance with Home Office 
Guidance at the University of Bristol. DBA2J mice were initially selected for 
use in this model following the work of Dr Priyantha Kulatilake. Dr 
Kulatilake’s early data suggested that DBA2J mice were more prone to 
albuminuria than C57BL6 mice in a model of kidney disease following 
angiotensin II infusion. DBA2J were also in frequent use within the 
laboratory, being used in models of diabetic kidney disease, where it was felt 
they were more pre-disposed to glomerular damage than other mouse 
strains.295  
 
3.1.4.5 Mouse gender selection 
Male mice have been used more widely in renal research. This may stem 
from the finding that male mice develop more marked diabetic disease in 
animal models.296 The potential for variability in makers such as albuminuria 
as a result of the changing hormone profile during the oestrous cycle may 
also deter researchers from using female mice. For this project I avoided 
using female mice because of research surrounding the G-protein oestrogen 
receptor (GPER). The expression of this oestrogen receptor has been shown 
to fluctuate within the kidney during the oestrus cycle.297 This receptor has 
been suggested, by some groups, to act as an aldosterone receptor 
(although the topic remains controversial) and so it was considered sensible 
to avoid the added variability that female mice may introduce.54 Future work 
should include female mice (as a separate group) to ensure that the results 
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gathered in this project are broadly applicable, however an increased number 
of mice may be needed to adjust for the additional inherent variability. 
 
3.1.4.6 Mouse age selection 
To deliver aldosterone for 4 weeks an osmotic minipump (Alzet, Cupertino, 
USA, model 2004) was used. To use this pump it is recommended that mice 
weigh at least 20g. For this reason 6 week old mice were purchased to 
minimise housing costs at the University of Bristol. Experiments were 
initiated when mice reached 20g. 
 
3.1.5 Aldosterone dose and minipump selection 
The dose of aldosterone used in this study was chosen based on the work of 
Schreier et al.253 In this study FVB/N mice were used with subcutaneous 
minipumps implanted to deliver 0.6 µg of aldosterone per day and per gram 
of body weight in combination with 1% NaCl drinking water. These mice had 
an approximately 2.5-fold increase in plasma aldosterone levels and 
developed significant proteinuria compared to control mice in the absence of 
a significant increase in blood pressure.253 The mini pump model (2004) was 
chosen based on the delivery duration (28 days) and the solubility of 
aldosterone, which dictated the minimum volume that could be delivered per 
hour to achieve the desired dose.  
 
	 128	
3.1.5.1 Minipump insertion 
Osmotic minipumps were filled with aldosterone dissolved in a 0.1% ethanol 
saline solution or ethanol saline alone. The concentration for the solution was 
calculated from the delivery rate of the minipumps (batch dependant, 0.271 
microlitres per hour for the batch used). The solution used contained 0.025 
µg of aldosterone per 0.271µl (this is equivalent to 18.5µg per 200µl pump). 
Pumps were prepared under sterile conditions 24 hours before implantation, 
and kept in sterile 0.9% saline solution at 37°C, allowing a period of 
equilibration before surgery. To implant the minipumps full sterile procedures 
and recovery protocols were followed to ensure the chance of wound 
infection was minimised. Mice were anaesthetised using 3% isoflurane 
(induction) and 2% isoflurane (maintenance following skin incision). A 2cm2 
area on the back of the neck between the scapulae was then shaved, before 
the area was cleaned using 10% chlorhexidine and sterile saline sequentially 
three times. A sterile drape was then applied and a 8mm incision through the 
skin made using scissors. The skin surrounding the incision was then gently 
stretched with the blunt edge of the scissors and blunt dissection used to 
create a sub-cutaneous pocket approximately 4cm long. The minipump was 
then inserted into the pocket, cap first, and the position checked. The pump 
should be able to move freely without applying pressure to the wound. The 
wound was then closed with 2 staples (FST auto clip)(Fine science tools, 
Heidelberg, Germany). Postoperative anaesthesia was achieved with a 
single dose of Rhymadyl (Rhymadyl small animal for injection, Pfizer, 
Tadworth, UK,) delivered by subcutaneous injection. Wound clips were 
subsequently removed on day 10 post insertion using light (1% isoflurane) 
anaesthesia. 
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3.1.5.2 Salt delivery and dose selection 
As discussed in the introduction, increased salt intake appears to increase 
tissue damage in response to aldosterone excess. For this reason salt 
supplementation was used in this study. Salt delivery can be achieved in the 
diet or through the drinking water. The later method was selected in this 
study for simplicity and cost reasons. This method has been widely 
used,253,298,299 however using this method does introduce variability in the 
quantity of salt delivered to individual animals, with the most polyuric and 
polydipsic mice likely to receive the largest quantity of salt. This potential for 
variability should be considered when interpreting the results. The 
concentration of salt used in this study was chosen based on the 
observations of Schreier et al253 – that this dose, in combination with 
aldosterone, caused proteinuria in the absence of hypertension. 
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Outcome measures for mouse work conducted in 
Bristol 
3.1.5.3 Urine collection  
Urine was collected from all the mice at baseline (before minipump insertion), 
after 8 days and after 28 days. To collect urine mice were individually housed 
in metabolic cages with access drinking water or 1% saline ad libitum. Urine 
collection was always performed from 8am to 12am with a maximum duration 
of 4 hours. Urine samples were aliquoted at the time of collection before 
freezing at -20°C.  
 
3.1.5.4 Urine Creatinine concentrations 
For each mouse one aliquot of urine was sent to Kay Burt (senior 
biochemistry technician) at Langford Vets, University of Bristol where an 
enzymatic creatinine assay was performed.  
 
3.1.6 Urine albumin concentrations 
To establish the quantity of albumin in the mouse urine samples, an ELISA 
was used (Bethyl Laboratories, Montgomery, USA, Cat No. E90-134). This 
ELISA relies on a Goat anti-mouse albumin antibody. The recommended 
protocol was followed and all samples were run in triplicate. Absorbance was 
read on a plate reader at 450nM and final albumin concentration calculated 
from the standard curve. 
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3.1.7 Blood pressure 
Non-invasive blood pressures were recorded at baseline and day 28 under 
minimal isoflurane anaesthesia (Visitech systems, Apex, USA, BP2000 
system). It was considered important to establish that aldosterone and salt 
were not affecting blood pressure whilst mice were awake (established using 
trained mice in the USA) or whilst under anaesthesia (at a level equivalent to 
that used during multiphoton microscopy - 1% isoflurane). The protocol used 
in Bristol mirrored the protocol used for induction of anaesthesia for 
multiphoton microscopy. Briefly mice were induced using 2.5% isoflurane 
and maintained at this level whilst they were transferred to a heated stage 
and the tail cuffs applied. Mice were then covered with a dark blanket (to 
maintain heat and block out light and anaesthesia reduced to the minimum 
level to prevent movement (range 0.7-1% of isoflurane delivered in 1 litre of 
oxygen per minute). A minimum of 5 cycles of blood pressure measurement 
(that met the intrinsic inclusion criteria) were then taken and averaged for 
each mouse at each time point.  
 
3.1.8 Animal culling and sample collection 
Mice were culled on day 28 of the experiment. To allow optimal use of each 
mouse the left kidney was removed under anaesthesia before whole blood 
was collected from the left ventricle. The left kidney was then divided into 3 
pieces to be sieved for glomeruli (for RNA extraction), fixed in 4% PFA and 
flash frozen. Whole blood was removed and spun to isolate plasma (see 
below). The left ventricle was then cannulated and perfusion-fixed with a 
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gluteraldehyde alcian blue mixture (details below) to facilitate electron 
microscopy of the glycocalyx. The use of gluteraldehyde requires this 
procedure to be performed in a fume hood. 
 
Figure 3-4 Surgical Incisions 
	
3.1.8.1 Plasma isolation 
Plasma was isolated from blood taken directly from the left ventricle at the 
time of culling. To extract whole blood a 23-gauge (Becton Dickinson, 
Oxford, UK) heparinised needle is advanced into the left ventricle connected 
to a 2ml syringe. Gentle negative pressure is then applied to the needle and 
approximately 0.5ml of blood removed. The blood is then immediately 
transferred to an eppendorf on ice, before spinning at 4°C, 1500g for 15 
minutes in a centrifuge with the brake disabled. The supernant (plasma) is 
then removed and aliquoted to be stored at -80°C. 
 
Anaesthetised mice were placed onto a custom-made 
aluminium tray on top of a heat pad. The right paws are 
then stuck directly to the tray using tape. The left paws 
are stuck approximately 1.5cm above the tray ensuring 
that the mouse lies in a partial left lateral position. The 
mouse is then cleaned and draped before incision 1 is 
made, reflecting the abdominal wall superiorly. This 
incision allows access to the left kidney, which is then 
clamped, using a haemostat, and removed. Incision 2, a 
midline sternotomy, then allows access to the heart for 
blood removal and perfusion. 
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3.1.8.2 Sieving glomeruli 
Approximately half of the left kidney was sieved to extract glomeruli. This 
process involved graded sieving to extract glomeruli from the renal cortex 
and can achieve a 95% pure sample.152,300 Cubes of renal cortex were 
pushed and washed through graded sieves using the rubber plunger from a 
5ml syringe before glomeruli were collected on the final sieve with a 75µm 
mesh. The suspension of glomeruli was then spun for 10 minutes at 1000g to 
allow removal of the supernant and the pellet of glomeruli frozen for later 
processing. 
 
3.1.8.3 RNA extraction from glomeruli 
To extract RNA from mouse glomeruli the column protocol was adapted. 
Working with human glomeruli I found that very low yields of RNA were often 
retrieved, despite adequate quantities of tissue. Through a process of 
elimination I found that glomeruli were not completely lysing in the buffer RLT 
solution (the supplied Quiagen lysis buffer). To aid lysis I therefore added a 
mechanical lysis step to the protocol. After adding 600µl of buffer RLT 
solution (supplied with the RNeasy Kit) to my glomeruli in eppendorfs the 
solution was repeatedly drawn through a 30-gauge needle (Becton 
Dickinson, Oxford, UK) under high pressure. This additional mechanical 
stress helped ensure glomeruli were broken down into small fragment 
allowing the Buffer RLT to contact all cells of the glomerulus, and 
dramatically improved RNA yields. 
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3.1.8.4 Alcian Blue perfusion 
The techniques used in alcian blue perfusion have been published 
previously.136,152 Briefly, a 23-gauge (Becton Dickinson, Oxford, UK) needle 
is inserted into the left ventricle and 5ml of modified Ringer’s solution (no 
NaHCO3 is included as this results in precipitation of alcian blue) is perfused 
systemically. Subsequently 30ml of 1% 8GX alcian blue (Sigma-Aldrich, 
Dorset, UK, A3157), 1% MgCl2 (6H2O) (Sigma-Aldrich, Dorset, UK), 2.5% 
electron microscopy grade gluteraldehyde (Agar Scientific, Stansted, UK, 
R1010) 0.1M sodium cacodylate solution (Agar Scientific, Stansted, UK, 
R1103) is infused. Throughout the perfusion a pressure of 100mmHg is 
maintained using a custom made perfusion system to ensure physiological 
pressures are maintained within the glomeruli. At the end of the perfusion 0.5 
– 1mm cubes of renal cortex and left ventricle were sent for electron 
microscopy processing by Dr Chris Neal. 
 
3.1.8.5 Mouse Syndecan 4 ELISA 
The plasma and urine concentrations of syndecan 4 ectodomain fragments 
were measured using a quantitative sandwich enzyme immunoassay 
(Cusabio, Houston, USA CSB-EL020891MO). The manufactures instructions 




3.1.8.6 Protein extraction from renal cortex 
Protein was extracted from mouse renal cortex using mechanical 
homogenisation and 300µl of ice-cold radio immunoprecipitation lysis buffer 
(RIPA Buffer, RO278 Sigma-Aldrich). Cellular debris was then centrifuged (5 
minutes, 13000rcf, 4°C) and the supernant removed to aliquots in 1.5ml 
eppendorfs tubes before being frozen on liquid nitrogen and transferred to a -
80°C freezer for subsequent use. 
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Using multiphoton imaging to investigate the 
pathogenesis of salt and aldosterone 
Whilst conceiving this project collaboration with Dr Janos Peti-Peterdi was 
established. Dr Peti-Peterdi’s group are the world leaders in glomerular 
multiphoton imaging.160,301-303 This novel technique had the potential to allow 
serial measurements of glomerular albumin permeability, and could 
potentially be adapted to allow glomerular endothelial glycocalyx depth 
measurements to be performed as well.  
 
3.1.8.7 Mouse conditions and reagents used 
All animal work conducted in Los Angeles was approved by the University of 
Southern California animal care committee and conformed to the NIH Guide 
for the Care and Use of Laboratory Animals. All mice were male and 
purchased from Jackson laboratory (Jackson laboratory, Sacramento, USA). 
C57 BL/6 mice aged 2/52 were purchased with their nursing mothers, DBA2J 
mice were purchased aged 3/52. All mice had free access to food and 
standard drinking water or 1% saline throughout the study. Mice were 
housed on a 12 hour light dark cycle. Aldosterone was purchased from 
Sigma (Sigma-Aldrich, Missouri, USA, Cat No A9477). The dose of 
aldosterone was kept at 0.6 µg of aldosterone per day and per gram of body 
weight (as used in the Bristol study). MMP 2/9 inhibitor was purchased from 
EMD Millipore (EMD Millipore, Temecula, USA Cat no 444241). The dose 
used in this study was 5mg/kg. Dr Raina Ramnath (University of Bristol) had 
used this dose previously in mice with promising provisional results in a 
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diabetic nephropathy model having based the dose on the work of Li et al.275 
MMP2/9 inhibitor was prepared in DMSO (0.05%) saline (0.9%) and 
aliquoted and stored at -20°C. 
 
3.1.9 Multiphoton Microscopy  
Multiphoton imaging is based on using two photons of relatively low energy 
to excite fluorophores in a single quantum event.304 Each individual photon 
carries approximately half the energy needed to raise the flurophore to the 
excited state, but when two photons simultaneously strike the flurophore 
excitation is achieved. As the flurophore returns to the ground state a photon 
of light (typically of a shorter wave length) is emitted (figure 3.5).304 
Figure 3-5 Multiphoton excitation 
Two-photon excitation can be achieved using long wavelength (low energy) light, 
minimising photo toxicity and increasing tissue penetration. Figure adapted from 
Schießl et al.305 
 
This phenomenon has been utilised by engineers to create systems that can 
image biological tissue at a depth that would be impossible using standard 
confocal microscopy.304 To generate an image the laser is focussed to a 
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specific depth within the tissue and pulsed. At the focal depth the density of 
photons is such that excitation events become possible. Because this only 
occurs at the depth where the laser beam becomes focussed, all light 
generated by a single laser pulse can then be directed into the photon 
multiplier tube (detection device) and correlated with the position in space 
scanned. A multiphoton image is therefore composed of thousands of 
individually imaged points that have been scanned sequentially.304 This 
process is in contrast to conventional confocal microscopy where a pinhole is 
needed to select light from the desired focal plane, and as a result not all 
generated light can be collected and used to generate an image.  
The resolution of a multiphoton system is limited by the size of the focussed 
beam from the laser and the optics of the system. The speed of the system is 
limited by the laser pulse duration and frequency, flurophore brightness 
(affecting dwell time), detection sensitivity (affecting dwell time) and the 
processing power of the system.306 Because lower energy photons are 
required for multiphoton microscopy, longer wavelength light can be used. 
This is beneficial because longer wavelength light (far red) can penetrate 
deeper into biological tissue. At points above and below the focal depth light 
toxicity is minimised due to the low photon density and low energy light (long 
wave length) used.304 
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Figure 3-6 Comparison of light micrscopy methods 
Multiphoton excitation allows the use of long wavelength laser light, improving tissue 
penetration, whilst minimising photo toxicity. A pinhole is not necessary in 
multiphoton microscopy so all the emitted light can be collected, improving 
sensitivity. Figure adapted from Ishikawa-Ankerhold et al.304 
	
3.1.9.1 Difficulties associated with renal multiphoton microscopy 
Multiphoton microscopy has been used extensively to image the brain and 
developing neural tissue.306 The brain is well suited to optical imaging for a 
number of reasons.307 The brain does not move relative to the skull, the 
transparency of brain is high (relative to other biological tissues), there is 
limited movement within the brain and capillary density is relatively low. As a 
result with modern multiphoton systems remarkable depths can be imaged 
culminating in recent work using three photon systems and 1700nM 
wavelength light where neuronal action potentials 1mm below the surface of 
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the mouse cortex were recorded.306 The biological characteristics of the 
kidney, however, make imaging significantly more difficult. The kidneys lie 
within the retroperitoneal space and move freely, typically moving with each 
breath.108 Receiving 25% of cardiac output, kidneys are highly vascular.108 
Moving cells within the circulation absorb, reflect and refract light making 
collection difficult. Glomeruli within the kidneys represent a very small 
percentage of the total kidney volume. In mice, and most rat strains, 
glomeruli do not lie within the outermost region of the renal cortex (the cortex 
corticis).307 This glomeruli-free zone also increases in depth as animals get 
older, effectively making glomeruli deeper. Historically, superficial glomeruli 
were generated by ligating the ureter causing hydronephrosis, however this 
process is associated with generalised inflammation and is unsuitable prior to 
glycocalyx depth studies or any assessment of filtration efficiency.307 For this 
reason multiphoton microscopy can only be used to study albumin sieving 
coefficients and the glycocalyx in young mice and models of disease must 
rapidly induce changes if they are to be detected using this method. 
 
3.1.10 Mouse strain selection for multiphoton microscopy 
For the reasons outlined above, DBA2J mice were the preferred strain for 
this project. However, the DBA2J strain had not been used for multiphoton 
renal imaging. I preparation for the project I liaised with Dr Ina Schießl at the 
University of Regensburg who had looked at strain differences in mice and 
their suitability for multiphoton imaging. She had looked at the very closely 
related DBA2N inbred mouse strain. In that work Dr Ina Schießl concluded 
that the average depth of the 30 most superficial glomeruli on sections at 4 
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weeks was 145.36 +/-4.3µm, a figure not statistically significantly different 
from C57 BL/6 mice (that had been frequently used in renal multiphoton 
imaging studies). Reassuringly no gender difference was detected in the 
depth of glomeruli.307 She felt that young (4 week old) male DBA2J mice 
should be suitable for multiphoton imaging. Unfortunately DBA2J mice had 
very few superficial glomeruli. A total of 24 mice were imaged and only 5 
could be included in the study (successfully imaged on day 0 and day 5). 
Only one mouse had superficial glomeruli by day 10. A potential reason for 
this difference may be subtle differences between the DBA2J and DBA2N 
mouse stains. In addition the work of Dr Schießl was conducted in Germany 
on European mouse colonies and there is potential for variability to have 
been introduced between this stock and the American stock I attempted to 
use in this study. Dr Peti-Peterdi’s research group use C57 BL/6 mice almost 
exclusively for multiphoton work. After a provisional experiment in C57 BL/6 
mice, I confirmed that this mouse strain also develop detectable albuminuria 
(detected on dip stick) in response to salt and aldosterone and so all 
subsequent work was swapped to this strain. Male C57 BL/6 mice were 
purchased with their nursing mothers aged 2 weeks allowing a period of 
acclimatisation (4-5 days) before titanium imaging windows were inserted 
when mice reached approximately 9 grams in weight. After 48 hours 
recovery mice were randomised and separated from their mother. Baseline 
imaging was then conducted before minipumps containing either aldosterone 




3.1.10.1 Minipump selection and insertion 
Due to the small size of the young mice needed in this study the minipump 
used was swapped to model 1002 (Alzet, Cupertino, USA). This model 
delivers approximately 0.25µl/hr for 14 days and can be implanted 
subcutaneously in mice weighing 10 grams. The insertion procedure was 
largely the same for these mice with the exception of the method of skin 
closure. At this age the skin was very fragile and sutures were found to close 
the wound more effectively than staples. Sutures remained in situ for 10 days 
before they were removed under light anaesthesia (at the time of imaging on 
day 10). The dose of aldosterone (as previously) was 0.6 µg of aldosterone 
per day and per gram of body weight. 
	
3.1.11 Surgical procedures 
3.1.11.1 Kidney externalisation 
Although titanium windows were planned to be used in all mice in this study 
(figure 3.8) the scarcity of superficial glomeruli in DBA2J mice made this 
method impractical. More of the kidney surface can be imaged by bringing 
the kidney through the skin via a small flank incision – a process referred to 
as externalisation. Once the kidney is ‘externalised’ multiple aspects of the 
kidney can then be sequentially imaged before the kidney is returned to the 
retroperitoneal space and the wound closed.  
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Briefly, gavage was used to administer analgesia (buprenorphine) before the 
mouse was anaesthetised using 3% isoflurane, the skin overlying the left 
kidney was then shaved and the area cleaned using 10% chlorhexidine and 
sterile saline. The area was then draped with sterile drapes (not used in the 
illustrative photos taken below to allow photos to be taken).  
Figure 3-7 Externalisation of the left kidney 
To externalise the kidney a small incision is made to the overlying skin and muscle 
layer. The kidney is then manipulated through the hole one pole at a time ensuring 
that no tension is placed on the renal vasculature. The incision should be sufficiently 
small that the kidney does not move with respiration once it is on the surface. A 
sterile plasticine ring then supports the kidney during imaging. 
 
The kidneys were easily palpable in young mice and once identified a 3-4mm 
incision was made through the skin and subcutaneous tissue at 90° to the 
long axis of the kidney (figure 3.7). The kidney was then gently manipulated 
onto the skin surface. Sterile plasticine was then cut to fit around the kidney 
to support it during imaging and it was bathed with sterile saline. The mouse 
was then transferred to the microscope stage for imaging (figure 3.9). The 
stage must be sterile to perform imaging in this way if recovery is intended. 
At the end of the imaging session the kidney was gently pushed back into the 
retroperitoneal space using a sterile cotton bud. The skin was then closed 
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with interrupted sterile 1-0 vicryl sutures (Ethicon, Irvine, USA). A second 
dose of buprenorphine was given after 24 hours to ensure animals comfort. 
 
3.1.11.2 Titanium window implantation 
Custom made ‘Titanium windows’ (a titanium disc onto which glass 
coverslips can be mounted), were the preferred method for visualising the 
kidneys because they facilitated repeated imaging and helped minimise the 
risk of infection. Windows were inserted 48 hours before imaging to allow 
mice to recover from the associated stress. Windows were inserted when all 
mice in the litter had reached 9 grams. During the 48-hour recovery period 
mice were returned to the cage with their mother to ensure their recovery 
was optimised. The mother was removed from the cage after the imaging 
session on day 0 (and the aldosterone or vehicle minipump was inserted). 
The titanium element of the window can be reused but for each mouse a new 
zero grade glass coverslip must be applied using instant glass glue (Loctite). 
Windows were prepared 24 hours before implantation to allow them to be re-
sterilised before use. To implant the window mice were prepared as 
previously but the incision was made parallel to the kidney’s long axis and is 
approximately 1cm long. Once the kidney is exposed the window was glued 
to the renal capsule using surgical glue at the peripheries. This ensures the 
kidney stays in contact with the underside of the coverslip. The window is 
then secured in place using a purse string suture (Mersilk braided suture, 
Ethicon, Irvine, USA).  
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Figure 3-8 Surgical window implantation 
Titanium windows measuring 8mm in diameter were used throughout the study. 
‘Windows’ were prepared by using glass adhesive to secure a coverslip to the 
surface of the custom-made titanium disc. A Mersilk purse-string suture holds the 
disc and attached coverslip in situ, with a small quantity of surgical adhesive 
securing the renal capsule to the window. Mice do not appear overtly stressed by 
the procedure and all mice remained well throughout the study. 
 
This suture pulls the skin and subcutaneous tissue into a recess on the 
titanium window ensuring a tight seal. This process and the results are 
illustrated in figure 3.8. 
 
3.1.12 Measuring the glomerular sieving coefficient for albumin (GSCalb) 
Intravital multiphoton microscopy was performed using a Leica TCS SP5 
multiphoton confocal fluorescence imaging system (Leica, Illinois, USA) 
powered by a Chameleon Ultra-II MP laser (Coherent Inc., Santa Clara, 


















immersion lens (refractive index 1.333). Standardised settings were used to 
gain 12-bit, 1.5µm Z-stack images of all superficial glomeruli. Imaging 
duration for glomerular permeability was limited to 30 minutes. Animals were 
anaesthetised using isoflurane before 40µl of Alexa Flour 594 BSA 
(Invitogen, USA, 1812249), prepared using Pall Nanosep 30kDa omega spin 
columns (Sigma-Aldrich, Missouri, USA) to remove free dye, was injected 
into the retro-orbital sinus (figure 3.9 A). Z-stack images were then taken of 
all superficial glomeruli found within 30 minutes. Images were selected for 
blinded analysis provided the Bowman’s space could be clearly defined and 
there was sufficient area to analyse florescence at two sites with no capillary 
loops within 4.5µm (3 frames in z-stack). Imaging the same glomeruli on 
days 0, 5 +/- 10 allowed me to measure changes in the glomerular sieving 
coefficient for albumin (GSCalb) resulting from salt and aldosterone exposure 
(a detailed explanation of the GSCalb is included in the results chapter.) 
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Figure 3-9 Multiphoton Microscopy 
A. Delivery of fluorophores was achieved by injection into the retro-orbital sinus at 
the time of imaging. This venous sinus is readily accessible and can be used 
repeatedly.308 B. Mice were maintained under light (<1% isoflurane) anaesthesia on 
a heated stage for the duration of imaging. C/D. The setup used for multiphoton 
microscopy in Los Angeles. 
 
3.1.13 Imaging glycocalyx thickness 
Fluorescein isothiocyanate (FITC) conjugated wheat germ agglutinin (WGA) 
(Sigma-Aldrich, Missouri, USA, Cat no L4895) was given as a 2µg/g (20µl) 
bolus via the retro-orbital sinus only after images used to measure the 





images were taken from 10 minutes after the bolus (to allow equilibration) up 
to 40 minutes post bolus. The FITC-WGA staining intensity was quantified 
within the glomerular capillaries and normalised to adjacent proximal tubular 
auto-fluorescence to negate the effects of tissue depth and overlying light 
absorption (detailed methodology and validation methods are included in the 
results section). In addition peak to peak analysis of the FITC-WGA labelled 
glycocalyx was use to derive a direct measure of glycocalyx depth (detailed 
methodology and validation in the results section). Having established that 
the GSCalb rapidly increased (within 5 days) in response to salt and 
aldosterone exposure the protocol was amended before testing the 
effectiveness of MMP 2/9 inhibitor. Amendments included baseline 
assessment of the glycocalyx using FITC-WGA and a shortened exposure to 
salt and aldosterone to optimize image resolution for glycocalyx depth 
calculations. 
 
3.1.14 Urine collection  
Due to the small size of mice used in this study, metabolic cages were 
avoided where possible. Mice weighing <10 grams rapidly cool when singly 
housed and become distressed. Urine was therefore collected by ‘scruffing’ 
the mice. This was best performed at the end of the dark cycle of the animal 
facility (7am). Using this method I was able to collect urine from all mice 
rapidly, avoiding having to singly house mice in metabolic cages. 
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3.1.15 Blood pressure 
To complement the work performed in Bristol, blood pressure was again 
recorded in all mice used in the USA. The blood pressure system used 
(Visitech BP-2000 series II, Visitech, Apex, USA) relied on 
photoplethysmography. In contrast to the method used in Bristol, mice were 
trained for awake blood pressure measurement. Training consisted of 5 days 
of daily handling and mock blood pressure measurement (5 inflation cycles 
repeated twice on days 1,2 and 3 before increasing to three repeats on days 
4 and 5). For the final blood pressure measurement 5 inflation cycles were 
used to acclimatise the mice, before 10 inflation cycles were used to 
determine the blood pressure for each mouse. For inclusion the computer 
had to accept 6 of the 10 readings (no systolic time out). This protocol is 
adapted from work that showed tail vain blood pressure measurement can 
closely correlate with invasive blood pressure monitoring and has been used 




Figure 3-10 Procedural flowcharts for C57 BL/6 mice used at the 
Unversity of Southern California 
Adaptations were made to the initial protocol to optimise imaging of the 
GEnC glycocalyx, allowing precise, serial measurements of the GEnC 







































































































































































































































































































































































































































































































































Investigating if spironolactone protects GEnC 
glycocalyx in diabetic nephropathy 
The protocol summarised in figure 3.11 and methods presented in this 
section are the combined work of Dr Joanne Ferguson and myself. Dr 
Ferguson worked with me as part of her academic foundation year 2 medical 
training. 
 
3.1.16 Model selection 
The rat streptozocin (STZ) induced diabetic model was selected for this 
study. Rats were chosen after considering the quantities of tissue required 
for the planned outcome measures and to allow a collaborative pilot study to 
be performed with Dr Daniela Patinha and Dr Maarten Koeners (University of 
Bristol). Male Wister rats have frequently been used in STZ induced diabetic 
studies.310-312 Dr Sarah Desideri had also used this model at the University of 
Bristol and demonstrated albuminuria in early disease, suggesting that this 
model should be ideal for this project.		
 
3.1.17 STZ induction  
Diabetes was induced in rats aged 4-6 weeks by administering a single 
50mg/kg intra-peritoneal injection of STZ (Sigma-Aldrich, Dorset, UK, Cat No 
S0130). Control rats received 100µl of 0.1M Ph4.5 sodium citrate buffer 
(Fisher Scientific, Loughbourgh, UK, BP327-500). Prior to injection rats were 
fasted for 6 hours. Fasting is believed to minimize competition for the GLUT2 
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transporter on beta cells of the pancreas and increase the effectiveness of 
STZ.312 Diabetes was then allowed to develop for 4 weeks before the 
treatment phase of the model was initiated. This period ensured we were not 
treating the direct renal toxicity of STZ with spironolactone, only the resultant 
diabetic disease.313 
 
3.1.17.1 Blood glucose monitoring 
After 4 weeks recovery from STZ, diabetes was confirmed (blood glucose 
>16mmol/l) using a hand held glucometer (Accu-check blood glucometer, 
Aviva, UK). All rats that received STZ became diabetic but 1 rat randomized 
to the vehicle group had to be culled due to excessive weight loss. Diabetic 
rats were then randomised to receive either spironolactone (n=8) or vehicle 
(n=7) for 21 days before they were culled. 
 
3.1.17.2 Spironolactone 
Eight diabetic rats received 50mg/kg of spironolactone (Sigma-Aldrich, 
Dorset, UK, Cat no S3378) daily from week 5 of the study (4 weeks after STZ 
injection) for 3 weeks. Spironolactone, dissolved in corn oil, was delivered by 
subcutaneous injection in the area between the scapulae. Dr Joanne 
Ferguson performed all injections. This dose was chosen because it had 
previously been shown not to affect blood pressure, even after chronic (20 
weeks) administration.314 In addition this dose of spironolactone had been 
shown to effectively reduce uACR levels in a rat STZ diabetic model 
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following 8 weeks treatment.310 Vehicle (corn oil) treated diabetic rats, and 
non-diabetic rats acted as controls. 
 
Figure 3-11 Procedural flow chart for STZ-rat model 
Initially rats were randomised to receive STZ / vehicle. Of the rats that received STZ 
all became diabetic over the next 4 weeks. At week 5 of the study diabetic rats were 
randomised again to receive either spironolactone (n=8) or vehicle (n=7) for a 
further 3 weeks before being culled. 
 
3.1.18 Outcome measures in diabetic rats 
Urine was collected by Dr Joanne Ferguson by placing individual rats in 
metabolic cages for up to 4 hours. Urine was collected at baseline (before 
the single STZ or vehicle injection were administered) and at week 4 (before 
daily spironolactone or vehicle injections were commenced) and finally at 
week 7 (after 21 days treatment).	Although urine was collected, aliquoted and 
rapidly frozen we failed to generate consistent data using a rat albumin 
ELISA (Nephrat ELISA kit, Exocell, Sussex, UK Cat No NR002). High levels 
of variability were seen within triplicate repeats and between aliquots of the 
same urine. As a result I lacked confidence in the quality of the data the 
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ELISA was producing and have elected not to use the data. Unfortunately we 
had insufficient urine to try an alternative albumin ELISA. Because of this I 
had to use total protein results, which were generated by Langford veterinary 
services at the time of creatinine analysis by Kay Burt (senior biochemistry 
technician) at Langford Vets, University of Bristol. However, total protein 
measurements will contain tubular proteins in addition to albumin. As a result 
total protein/ creatinine ratios are a less reliable marker of glomerular 
damage and this limitation should be noted. 
 
3.1.18.1 Blood pressure 
Under terminal anaesthesia Dr Daniela Patinha performed carotid 
cannulation. This allowed central systolic and diastolic blood pressure to be 
recorded, providing confirmation that the blood pressure had not dramatically 
altered in response to spironolactone. 
 
3.1.18.2 Alcian blue perfusion  
Alcian blue perfusion was performed on 14 rats using the same technique as 
outlined previously with the exception that 50ml of alcian blue solution was 
perfused to account for the increased circulating volume of rats. 
 
3.1.18.3 Electron Microscopy  
Dr Chris Neil processed samples of renal cortex for electron microscopy 
before images were taken using a Technai 12 (120KV BioTwin Spirit) 
transmission electron microscope (FEI, Cambridge, UK) and FEI Eagle 4k 
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x4K CCD camera (FEI, Cambridge, UK) by Dr Joanne Ferguson and myself. 
 
3.1.19 Glomerular permeability 
A novel glomerular permeability assay was used to measure how diabetes 
and spironolactone affected the GFB.152 The data generated using this assay 
was the result of a collaborative effort between Dr Joanne Ferguson, Dr 
Daniela Patinha and myself. The assay was developed at the University of 
Bristol and has now been validated in a number of species and disease 
models.152 The assay measures the apparent permeability to albumin based 
on the rate of diffusion of FITC-BSA out of ex vivo glomerular capillaries. The 
albumin permeability values generated have been modelled mathematically 
and shown to approximate to the glomerular sieving coefficient for albumin 
measured in vivo.152 This novel assay excludes the potential confounding 
effects of systemic blood pressure and local glomerular perfusion pressure, 
allowing the true filtration barrier permeability to be studied.152 
	
3.1.19.1 Glomerular RNA analysis 
Rat glomeruli were sieved by myself at the time of culling. Dr Joanne 
Ferguson (using the techniques outlined previously) performed RNA 
extraction and cDNA conversion. I subsequently used qPCR to analyse the 
glomerular RNA expression of MMP2, MMP9 and Syndecan 4.  
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3.1.20 Lectin analysis of PFA fixed kidney 
To study the glomerular glycocalyx changes associated with diabetes Dr 
Joanne Ferguson and myself developed a method utilising lectins to label the 
glycocalyx. Lectins are carbohydrate-binding proteins that have high levels of 
specificity for individual sugar moieties. Lectins were used on PFA fixed rat 
renal cortex that had been fixed for 24 hours before transferring to 70% 
ethanol. Slides were prepared from paraffin embedded tissues by Debbie 
Ford in the University of Bristol histology department. Initially the sections 
were de-waxed using histoclear (Sigma-Aldrich, Dorset, UK, Cat No H2779). 
Tissue sections were then sequentially re-hydrated in ethanol (stepwise 
100%, 90%, 70% for 2 minutes) before washing with PBS. Sections were 
then blocked with 1% BSA (Sigma-Aldrich, Dorset, UK, 1kg), 0.5% PBS – 
Tween (Thermofisher, Gloucester, UK, Cat no PI28352) for 30 minutes. After 
a further wash step endogenous biotin was blocked (15 minute incubation 
with streptavidin before a further wash and 15 minute incubation with biotin). 
Samples were then incubated with biotinylated lectins. Multiple lectins were 
screened for glycocalyx specificity (Table 3) before MOA lectin (marasmius 




Lectin Manufacturer Catalogue 
number 
Biotinylated MAL 1 Vector Laboratories, 
Peterborough, UK 
B-1315 
Biotinylated SNA Vector Laboratories, 
Peterborough, UK 
B-1305 














Biotinylated Marasmium Oreades 
Agglutinin (MOA) 
TCS Biosciences Z8-BA-9001-1	
Table 3 Lectins used on rat renal cortex	
All the above lectins were used on sectioned rat cortex and the distribution of 
labelling studied to confirm if specific GEnC glycocalyx labelling was likely. 
 
MOA lectin is Galα1, 3Gal/GalNAc specific, a target not expressed by human 
cells. However this target is expressed in lower mammals on the surface of 
their vascular endothelial cells, including GEnC, within the glycocalyx.315,316 
The protocol used to label glomeruli with MOA lectin included an overnight 
incubation of samples with 2mg/ml of biotinylated MOA, diluted 1:100 in 1% 
BSA, 0.5% PBS tween, Ph6.8, at 4°C. After washing, steptavadin-Alexa 
Flour 488 (1:500 in 1% BSA, 0.5% PBS tween, Ph6.8) was applied for 1 hour 
at room temperature (protected from light). Nuclear and membrane stains 
were subsequently applied after further washing (twice more with PBS-tween 
mix then subsequently with PBS only). DAPI nuclear stain was added 
(1:10000) to the PBS wash solution and tissue incubated for 2 minutes. R18 
(Octadecyl Rhodamine B Chloride) (Thermofisher, Gloucester, UK, O246) 
was diluted 1:1000 from the stock solution, and incubated on slides for 10 
minutes at room temperature (protected from light). Slides were finally 
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washed in PBS before vectashield (Vecta laboratories, Peterborough, UK, 
Cat No H-1000) and a coverslip were applied. This protocol reliably stains 
the glomerular glycocalyx with Alexa Flour 488 – MOA, the cell membranes 
with R18 and the nuclei with DAPI. 
 
3.1.21 Imaging MOA lectin labelled sections 
All images were taken after blinding, using a 100x oil immersion lens and a 
Leica wide field microscope or a Leica confocal microscope. On each slide 
glomeruli were selected from all 4 quadrants of the section. Glomeruli were 
imaged provided capillary loops were clearly visible within the glomeruli, with 
at least 3 capillary loops sectioned at 90° to the blood flow (i.e. capillary 
approximately round in profile). A detailed explanation of subsequent ‘peak to 
peak’ analysis is given in the results section. The results of individual 
capillary measurements were averaged to generate the average for each 
glomerulus sampled.  These data were then combined to generate average 





Statistics and data handling 
All statistics and graphs have been prepared using GraphPad Prism V7.0c 
unless stated. Choice of statistical tests applied was governed by the nature 
of the data presented and followed the published guidance from the Journal 
of Pharmaceutical Negative Results.317 To assess if data were normally 
distributed the distribution of results was assessed visually and using the 
Shapiro-Wilk normality test (Prism). For comparison between 2 unpaired 
groups Mann-Whitney tests are applied to all ratio data and all data where 
normality could not be established. Where data are normally distributed T-
Test have been applied. Where paired data are tested, Wilcoxon tests have 
are used where normality cannot be assumed and paired T-Tests used on 
normally distributed data. For comparison between multiple groups where 
data are unmatched one-way ANOVA has been used on normally distributed 
data and a Kruskall-Wallis test used where normality has not been assumed. 
For multiple comparisons on matched data a repeated measures ANOVA 
has been used on normally distributed data and a Friedman test applied to 
data where normality has not been assumed. Post hoc analysis test selection 
was governed by the comparisons being made. Where possible Tukey’s 
analysis has been used (comparison of all groups to all other groups with 
adjustment). In some instances where multiple data sets have been 
presented together comparison of all groups was not relevant e.g. the 
comparison of one group of mice’s ACR values on day 5 to another groups 
baseline values. In these instances more selective comparisons have been 
used on the selected data sets (e.g. Sidak’s comparison). Correlations were 
assessed using Pearson correlation on normally distributed data and 
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Spearman correlation on data where normality has not been assumed. For 
all results the overall ANOVA and non-parametric tests p-values are 
displayed where significant, and the post hoc test used stated. All data are 
presented as mean values +/- SEM where relevant. The significance 
displayed on graphs is relative to controls or baseline values unless 





4 Do	 salt	 and	 aldosterone	 damage	 the	 glycocalyx	 on	
CiGEnC?	
	
Are glomerular endothelial cells aldosterone-
responsive? 
My first task was to establish if GEnC were aldosterone responsive. Other 
vascular endothelial cell line had been shown to express MR and 11β HSD2, 
but limited information was available regarding their expression on highly 
specialised GEnC. 
	
4.1.1 Glomerular endothelial cells express mineralocorticoid receptors 
To confirm that GEnC expressed MRs tissue from human donor kidneys 
(unfit for transplantation) was used. Renal lysates were prepared from tissue 
taken from the renal medulla and cortex. FACS sorted GEnC were kindly 
provided by Dr Raina Ramnath. Conditionally immortalised GEnC (CiGEnC 
(passage 22) were grown in a T75 flask and thermoswitched for 6 days prior 
to protein extraction. Western blotting using an anti MR antibody (Abcam, 
Cambridge, UK, Cat No ab62532) confirmed that both primary isolated 




Figure 4-1 A western blot confirming MR expression on GEnC 
Western blotting confirmed that human GEnC express MR. A single band is seen at 
the predicted molecular weight of 90kDa. Whole kidney lysates and FACS isolated 
GEnC were obtained from human kidneys declined for transplantation and donated 
to research.  
	
4.1.2 The GEnC MR is stably expressed in culture 
To confirm the CiGEnC stably expressed MR over the range of experimental 
conditions used in this study, cell culture lysates were used in western 
blotting. Cells were grown in T75 flasks to 80% confluence before 
thermoswitching for 5 days. Cells were then exposed to 145mMol NaCl, 
0.1nM aldosterone or a combination of these conditions for 5 days. No 











Figure 4-2 The expression of MR in CiGEnC under test conditions 
A representative western blot demonstrating the stable expression of MR over the 
conditions used in this project. Human renal medulla (from a kidney declined from 
transplantation and donated to research) was used as a positive control. ✔ salt 
indicates NaCl concentration increased to 145mMol ✖ salt indicates mannitol added 
to balance osmolarity ✔ aldosterone indicates 0.1nM aldosterone added to media, 
✖ indicates vehicle alone added to media. 
	
4.1.3 Glomerular endothelial cells express 11β HSD2 in culture 
At the RNA level I was able to show that CiGEnC expressed 11β HSD2. 
Typical Ct values from qPCR ranged from 25 to 29. Levels of expression 
were, however noted to fluctuate at the RNA level during time course 
experiments (figure 4.3). This made me question the validity of the data. In 
retrospect I now believe that fluctuation was due to 11β HSD2 expression 
changing in response to the application of new cell media. Media contains 
hydrocortisone and multiple growth factors and well as 5% serum and 
inevitably results in osmotic shifts when it is changed. I have not investigated 
which element was responsible for this effect, but this area is discussed 
further in the chapter summary. 
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Figure 4-3 Representative time course of 11β HSD2 mRNA 
expression in CiGEnC 
The illustrated time course (from a single experiment) highlights the level of 
fluctuation seen (at the fold change level) of 11β HSD2 mRNA. This time course is 
from an experiment where the osmotic control mannitol (20mMol) has been added 
to media for the duration represented on the x-axis. Arrows indicate each time point 
when the media was changed. New media resulted in a rapid up regulation of 11β 
HSD2 mRNA. The fluctuation of this ‘baseline’ made studying changes in response 
to salt and aldosterone very difficult. 
 
To confirm the expression of 11β HSD2 in CiGEnC at the protein level 
proved difficult. Initially western blotting was attempted using an antibody 























Figure 4-4 Blots using the Proteintech 11β HSD2 antibody 
A. Representative blot imaged using automatic exposure. The only clear band is 
non-specific (arrow indicates the position of the expected band). B. The same blot 
imaged using a fixed exposure of 1 minute highlighting the likely non-specific bands. 
C. Actin blot from the same experiment. Renal medulla was run as the positive 
control (column 1). 
	
Despite trialling multiple blocking solutions no specific signal could be 
generated using this antibody. Subsequent work was conducted using a 
monoclonal R&D systems antibody (R&D systems, MAB8630, clone 
921215). Using this antibody a single band was evident corresponding to the 
approximate molecular weight of human 11β HSD2 (figure 4.5). In addition I 
was able to use this antibody at a concentration of 10μg/ml on frozen 
sections of human renal medulla, where characteristic 11β HSD2 staining 
was seen within the renal tubules (figure 4.6). Densitometry analysis of 
western blots suggested that short-term application of media containing 
145mMol NaCl and 0.1nM aldosterone up-regulated 11β HSD2 in the first 48 
hours after exposure (figure 4.5.B). However, it should be noted that time 
matched controls were not used in this series and these effects may have 
been due to the substitution of the culture medium. The reverse effect was 
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evident after prolonged exposure (96 hours) when compared to time 
matched controls (figure 4.5.C). 
Figure 4-5 CiGEnC express 11β HSD2 protein 
A. A representative western blot demonstrating that CiGEnC express 11β HSD2. B. 
Densitometry confirmed that the expression of 11β HSD2 varied depending on the 
duration of exposure of cells to 145mMol NaCl and aldosterone 0.1nM (ANOVA 
p<0.05, n=3). After the initial exposure there is a trend to increased levels of HSD2 
however after prolonger exposure (>96 hours) levels of 11β HSD2 fall (ANOVA 
p=0.0198 with Tukey’s correction displayed). C. Densitometry at 96 hours comparing 
time matched samples from cells maintained in standard media (with mannitol for 
osmotic control) and cells maintained in the presence of 145mMol NaCl and 
Aldosterone 0.1nM (T-test p<0.05, n=3). All error bars = SEM. *P<0.05; **P<0.01; 
***P<0.005; ****P<0.001. ✔ salt indicates NaCl concentration increased to 145mMol 
✖ salt indicates mannitol added to balance osmolarity. ✔ aldosterone indicates 0.1nM 
aldosterone added to media, ✖ indicates vehicle alone added to media. 
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Figure 4-6 11β HSD2 distribution in tubules 
The characteristic distribution of 11β HSD2 was evident on IF using the monoclonal 
antibody MAB8630, clone 921215 on human renal medulla. The 11β HSD2 signal 
generated by the Alexa Flour 488 secondary was seen within tubules with a size 




4.1.4 Glomerular endothelial cells express 11β HSD1 in culture 
At the mRNA level CiGEnC express 11β HSD1 in addition to 11β HSD2. 
However, in contrast to 11β HSD2 no changes were seen on the initial time 
course (mRNA) experiments (ANOVA p=0.23) or when densitometry was 
performed (ANOVA p=0.27, n=3). The time course data and a representative 




Figure 4-7 Western blot for MR and 11β HSD1 and mRNA time 
course for 11β HSD1 
A. A representative western blot demonstrating 11β HSD1 expression over the 
conditions tested Densitometry revealed no significant differences although 
considerable variation was noted between series (n=3). B. mRNA time course data, 
showing that the duration of salt and aldosterone exposure was not altering the 
expression of 11β HSD1 mRNA (ANOVA p=0.23) ✔ salt indicates NaCl 
concentration increased to 145mMol ✖ salt indicates mannitol added to balance 
osmolarity ✔ aldosterone indicates 0.1nM aldosterone added to media, ✖ indicates 
vehicle alone added to media. All treatments were added for 5 days. 	
	
4.1.5 Glomerular expression of 11β HSD2 and MR in vivo 
The glomerular expression of 11β HSD2 and MR were studied using 
immunofluorescence on frozen human kidney sections. The expression 
levels of 11β HSD2 seen within the glomerulus were markedly lower than 
those seen with the tubules, however specific staining was seen in a pattern 























IgG control images. Co staining was also attempted using VE-Cadherin as 
an endothelial marker, but it remained unclear which cell type (or types) 
within the glomerulus expressed 11β HSD2. 
	
Figure 4-8 Immunflorescence on human glomeruli 
A representative human glomerulus (from an adult kidney declined for 
transplantation) with 11β HSD2 (green) and mineralocorticoid receptors (MR) (red). 
A = co-stained glomeruli B = green channel only (converted to grey scale) 
highlighting the distribution of 11β HSD2. The glomerulus is surrounded by tubules, 
some of which exhibit very large quantities of 11β HSD2 but within the glomerulus 
localised areas of expression are noted. C = red channel (converted to grey scale), 
again, some of the surrounding tubules express MR, but within the glomerulus 

















Does aldosterone and salt exposure alter the 
structure of the glomerular endothelial glycocalyx? 
	
As discussed within the introduction the glycocalyx has a number of key 
components. Evaluation of the expression of these key components can give 
an indication of what may be occurring to the glycocalyx structure as a 
whole. 
4.1.6 Assessing GEnC surface HS and syndecan 4 using 
Immunofluorescence  
Immunofluorescence was selected to quantify the expression of syndecan 4 
and heparan sulphate because it allowed us to isolate changes occurring 
within the glycocalyx, from changes occurring within the cytoplasm or at the 
basement membrane. Glycocalyx components HS and the HS proteoglycan 
syndecan 4 can be detected on the surface of CiGEnC and each component 




Figure 4-9 HS and Syndecan 4 on the cell surface 
A. The cell surface expression of Syndecan 4. B. The surface expression of HS. C. 
Surface expression of HS following 3 hours incubation with 1mU/ml heparatinase III 
(taken with identical settings to image B). D. Digitally enhanced version of image C, 
demonstrating the presence of an endothelial cell with minimal cell surface staining 
confirming the anti HS antibody’s specificity. E. IgG control for syndecan 4 staining. 
F. IgG control for HS staining (Bar = 25µm). 
 
4.1.6.1 Quantifying changes in surface expression 
Cultured monolayers of CiGEnC exposed to 145mM NaCl and 0.1nM 
aldosterone for 5 days lose significant quantities of HS and syndecan 4 from 
their cell surface (figure 4.10 A and B respectively).	
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Figure 4-10	Quantification of surface expression changes 
Syndecan 4 surface expression falls following 5 days exposure to salt. In 
combination, salt and aldosterone also result in a significant reduction in cell surface 
syndecan 4, however in the presence of spironolactone this effect is prevented and 
no significant loss occurs relative to control. (ANOVA p=0.0021, Tukey’s correction 
displayed, N=3) B. Heparan sulphate surface expression falls significantly in 
response to salt and aldosterone in combination (ANOVA p=0.0120, Tukey’s 
correction displayed, N=3).✔ salt indicates NaCl concentration increased to 
145mMol ✖ salt indicates mannitol added to balance osmolarity.✔ aldosterone 
indicates 0.1nM aldosterone added to media, ✖ indicates vehicle alone added to 
media, ✔ Spiro = 1μm Spironolactone added to media. 
 
In contrast the addition of aldosterone to osmotically balanced media 
containing 125mM NaCl had no measurable effect and media containing 
145mM NaCl had only a small effect in the absence of aldosterone (figures 
4.10 A and B). The addition of spironolactone (spiro) to media for the 
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duration of the exposure prevented salt and aldosterone from having any 
significant effect (relative to control cells). 
 
4.1.6.2 Correlation between the two glycocalyx components 
Syndecan 4 is a known attachment site for heparan sulphate; it was possible 
therefore that loss of HS was primarily due to do loss of syndecan 4. To see 
if this was possible, a correlation analysis was performed, on excel (including 
the observed standard errors from each observation figure 4.11).  
	
Figure 4-11 Correlation between HS and syndecan 4 surface 
expression 
The loss of the two components correlates significantly over the conditions tested 
(n=7 per condition, Pearson r p=0.0146). The R2 value of 0.97 suggests a linear 
relationship between the expression levels of the two components.	
	
Although a significant correlation existed between the two glycocalyx 
components, it should be noted that this does not infer causality, but it is 
consistent with HS loss from the cell surface occurring as a result of 




















4.1.7 Syndecan 4 ELISA on cell lysates 
To confirm the changes seen on IF, an ELISA was performed to study 
changes in the ectodomain of syndecan 4 (figure 4.12). This is the 
component that is located within the glycocalyx. The ELISA confirmed that 
salt and aldosterone exposure (in combination) reduced syndecan 4 
ectodomain concentrations in cell lysates. Again the dose of aldosterone 
used in this study had no measurable effect in the absence of elevated salt 
and spironolactone prevented the effect of salt and aldosterone. 
	
Figure 4-12 Syndecan 4 ELISA 
Syndecan 4 ELISA on CIGEnC lysates confirmed that cells loose syndecan 4 in 
response to salt and aldosterone through an MR-mediated mechanism (blocked by 
spironolactone) (ANOVA p=0.0011, Tukey’s correction displayed, N=4). ✖ salt 
indicates mannitol added to balance osmolarity.✔ aldosterone = 0.1nM added to 
media, ✖ indicates vehicle added to media, ✔ salt indicates NaCl concentration 





4.1.8 MMP induction following salt and aldosterone  
Having established that key components of the glycocalyx are lost in 
response to salt and aldosterone exposure, I next investigated potential 
mechanisms of glycocalyx loss. Believing that loss of syndecan 4 may be the 
key pathological insult in this model I focussed on MMPs 2 and 9, both of 
which have been shown to cleave syndecan 4 from the cell surface.232 
 
4.1.8.1 Salt and aldosterone increase the mRNA expression of MMP 2 
and 9 
Time course experiments were conducted (under iso-osmotic conditions) to 
establish if MMP2 and 9 mRNA expression altered in response to salt and 
aldosterone. These provisional studies suggested that the peak elevation in 
the expression of these enzymes occurred at 10 hours. A series of 
experiments were then conducted to confirm this observation (figure 4.13 A). 
Significant increases were seen at the RNA level for both enzymes.  
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Figure 4-13 Investigating the mechansim of glycocalyx loss 
A. qPCR data highlighting the increased expression of MMP2 and 9 mRNA after 10 
hour exposure to salt and aldosterone in combination (relative to mannitol treated 
controls) (ANOVA p<0.0001, Tukey’s correction displayed, N=3). B. Again salt and 
aldosterone in combination, significantly reduced syndecan 4 surface expression. 
Batimastat (a broad spectrum MMP inhibitor) prevented the loss of Syndecan 4 
surface expression (ANOVA p=0.0015, Tukey’s correction displayed, N=3). C. Again 
salt and aldosterone in combination, significantly reduced HS surface expression. 
Batimastat prevented significant loss of HS (ANOVA p=0.0164, Tukey’s correction 
displayed), with no significant difference in Batimastat treated cells relative to control 
or spironolactone treated cells. ✔ salt indicates NaCl concentration increased to 
145mMol ✖ salt indicates mannitol added to balance osmolarity, ✔ aldosterone 
indicates 0.1nM aldosterone added to media, ✖ indicates vehicle alone added to 
media, ✔ Spiro = 1µm Spironolactone added to media, ✔ Batimastat = 5µM 
Batimastat added to media. 
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4.1.9 Inhibition of MMPs prevents loss of glycocalyx components in 
response to salt and aldosterone. 
To confirm that the activity of the MMP enzymes was responsible for the loss 
of the glycocalyx components seen following salt and aldosterone 
immunofluorescence assessment of cell surface HS and syndecan 4 was 
repeated with the inclusion of a group treated with batimastat. Batimastat is a 
broad spectrum MMP inhibitor. In the presence of batimastat no significant 
loss of HS or syndecan 4 occurred following 5 days exposure to salt and 
aldosterone (figure 4.13 B and C). There was no significant difference 
between cells treated with spironolactone or batimastat suggesting that this 
pathway is both MR and MMP dependent. 
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4.1.10 Shear stress 
As discussed within the introduction the endothelial glycocalyx has been 
shown to act as a ‘sensor’ of the shearing forces applied to the endothelial 
cell surface by flowing liquid (blood in vivo, cell media in vitro).139 I therefore 
decided to study the shear response of CiGEnC to assess the glycocalyx 
function in vitro. A model of shear stress had been established and used 
within the research group previously by Dr S Slater.318 Briefly 10cm round 
tissue culture dishes were placed on an orbital shaker for 24 hours and 
10dyn/cm2 shear stress applied.  
Figure 4-14 Validation of KLF2 upregulation as a glycocalyx 
dependant response 
A low dose enzyme cocktail238 was used to confirm that an intact glycocalyx is 
needed for optimal KLF2 up regulation in response to shear. A. Removal of 
syndecan 4 was confirmed using cell surface immunofluorescence. (T-Test 
p=0.0073, N=6 control, N=14 enzyme treated). B. Fold change in KLF2 confirmed 
that enzymatic damage to the glycocalyx was associated with a significant 
impairment in cells ability to upregulate KLF2 in response to shear stress. (Paired T-
Test, N=6, P=0.013). ✔ shear = 24 hours 10dyn/cm2 shear, ✔ glycocalyx degrading 
enzymes = 2 hours pre-treatment and on going exposure during shear stress. 
Enzymes used = hyaluronidase (2.5µg/ml), chondroitinase (1mu/ml), neuraminidase 
(1mu/ml), ✖ enzyme = vehicle only. 
	
	 180	
Specific enzymatic degradation of the glycocalyx impaired this response 
(figure 4.14), inhibiting KLF2 up-regulation in response to shear stress, whilst 
having no effect on KLF2 expression in static cells, suggesting that the 
glycocalyx may be a key mechanosensor for the KLF2 response. During 
preliminary studies, however, it was noted that this protocol, using 10cm 
round dishes resulted in very high rates of evaporation. Over 24 hours, 
dishes typically lost a mean volume of 1.2 (+/- 0.21) ml (assessed by weight) 
(n=4). For comparison, static dishes lost less than 0.2 (+/- 0.1) ml of fluid. 
The fluid loss was the result of evaporation, with large quantities of fluid 
condensing on the lids of the culture dishes. Initially I tried to limit 
evaporation by conducting experiments at weekends, believing most 
condensation would occur when the incubator door was opened, exposing 
dishes to cool air. This step, combined with insulating the dishes surface with 
polystyrene reduced the volume of evaporation to 0.8 (+/- 0.10) ml. However 
this level of evaporation would still result in an increase in sodium 
concentration from 125mM to 135mM at the end of 24 hours. Therefore to 
validate the data generated a system was devised to continually replace the 
evaporated fluid (figure 4.15). The system consisted of a syringe pump 
delivering media to dishes at twice the rate of evaporation and a suction 
system aspirating excess fluid to maintain the volume at 10mls. With the 
mixing that resulted from the orbital shaker this system effectively clamped 
the concentrations within the media. Due to the complexity of the system this 
method was only used to validate the data generated, but it confirmed that 
0.1nM aldosterone in media containing only 125mMol NaCl had no effect on 
KLF2 up-regulation (mean fold change in controls = 9.2 +/- 2.3 mean fold 
change in the presence of aldosterone 10.1 +/- 3.2, N=4, t-test NS).  
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Figure 4-15 System to prevent evaporation altering sodium 
concentrations 
System devised to limit the impact of evaporation from tissue culture dishes 
exposed to shear stress. Simultaneous delivery and aspiration of media ensured 
continual mixing of fluids and was mathematically modelled to result in minimal flux 
in sodium concentrations over 24 hours. 
	
4.1.11 Salt and aldosterone impair CIGEnC response to shear stress 
Cells exposed to salt and aldosterone for 5 days had a significant impairment 
in their ability to up-regulate KLF2 mRNA in response to shear (figure 4.16 A 
and B) relative to mannitol-treated control cells. In two separate series of 
experiments both spironolactone (figure 4.16 A) and batimastat (figure 4.16 
B) were shown to prevent the effects of salt and aldosterone. It should be 
noted that the absolute magnitude of KLF2 response varies with cell line and 
passage number and so comparison should not be made between the two 
series. Neither spironolactone nor batimastat had a significant effect on KLF2 
up-regulation in the absence of shear stress. These combined data suggest 
that salt and aldosterone exposure act via an MR-dependant pathway to 
generate MMPs which impair the cellular response to shear stress. Having 
shown that Syndecan 4 (a known shear responsive molecule) is lost from the 
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glycocalyx in response to salt and aldosterone, it seemed likely that this 
effect may be mediated through syndecan 4.		
	
Figure 4-16 Alterations in KLF2 following shear stress 
A. KLF2 mRNA up-regulates in response to shear stress. This response is 
significantly impaired following salt and aldosterone exposure, but can be restored 
with spironolactone. Spironolactone had no effect on static cells (ANOVA p= 
<0.0001 Tukey’s analysis displayed, N=4). B. In cells exposed to salt and 
aldosterone for 5 days batimastat significantly increased cells’ ability to up-regulate 
KLF2 mRNA in response to shear stress. Batimastat did not affect KLF2 expression 
under static conditions (n=3) (ANOVA p=0.0015, Tukey’s analysis displayed, N=3). 
✔ shear = 10dyn/cm2 shear stress for 24 hours, ✖ shear = static, ✔ salt + 
aldosterone = 0.1nM aldosterone + 145mMol NaCl, ✖ salt + aldosterone = vehicle + 
mannitol, ✔ spiro = 1nM spironolactone added to media, ✖ spiro = vehicle ✔ 
batimastat = 5µM batimastat added to media, ✖ batimastat = vehicle.	
To further confirm that cells’ ability to sense shear stress was impaired by 
salt and aldosterone exposure I also studied the alignment of actin fibres in 
response to shear stress. Figure 4.17 A shows representative images of cells 
grown on fibronectin-coated cover slips after exposure to 10dyn/cm2 shear 
stress for 24 hours. Under control conditions cells could be seen to orientate 
their long axis in the direction of flow. Actin phaloidin labelling also 
highlighted the cytoskeletal rearrangement that typically occurred in 
response to shear. Actin fibres re-modelled and aligned in the direction of the 
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applied shear stress. In cells exposed to salt and aldosterone no visible 
alteration occurred. Exposed cells did not align and actin fibres remained 
distributed at the cells’ periphery. In contrast, in the presence of batimastat 
cells aligned in the direction of shear stress and the actin fibres re-orientated.  
The alignment of actin fibres can be quantified (figure 4.17 B). Using Image J 
software the angles of actin fibres relative to the direction of shear stress can 
be calculated for each cell imaged. Because actin fibres do not have a 
direction, all data distribute from 0° (perfect alignment) to 90° alignment 
(perpendicular to flow). Each point on the graph represents a single cell. 
Analysis of the data confirmed that salt and aldosterone exposure impaired 
cells ability to sense and respond to shear stress, and that this effect could 




Figure 4-17 Actin alignment in reponse to shear is impaired by 
salt and aldosterone, but restored by batimastat 
A. Grey scale images of CIGEnC with nuclear staining (DAPI), and actin staining 
(Alexa Fluor 568 phaloidin) highlighting actin cytoskeleton alignment. 
Representative images illustrate actin alignment in the tested conditions (arrows 
indicate direction of flow, bar = 100µm for scale) B. Measurement of actin alignment 
relative to the direction of applied shear stress. Actin alignment did not alter after 24 
hours shear stress in CIGEnC exposed to salt and aldosterone for 5 days. In 
contrast, control cells and cells exposed to salt and aldosterone in the presence of 
batimastat demonstrated significant actin alignment in response to shear, with no 
detectable difference in the response between them (ANOVA p<0.0001, Tukey’s 
analysis displayed, N=3). ✔ shear = 10dyn/cm2 shear stress for 24 hours, ✖ shear = 
static, ✔ salt + aldosterone = 0.1nM aldosterone + 145mMol NaCl, ✖ salt + 





GEnC expressed MR, and responded to aldosterone. In vitro the combination 
of sodium chloride (145mM), and aldosterone (0.1nM) resulted in the loss of 
key glycocalyx components including HS and syndecan 4. Atomic force 
microscopy has previously demonstrated that the glycocalyx on ex vivo 
human umbilical artery endothelial cells reduced in height by 50% following 
salt and aldosterone exposure.260 This structural change may have occurred 
as a result of loss of the same components. These data together suggest 
that the endothelial glycocalyx at multiple anatomical sites may be prone to 
damage following salt and aldosterone exposure. 
Glomerular endothelial cell in culture express 11β HSD2 at the RNA and 
protein level. These results confirmed work conducted using 
immunohistochemistry and electron microscopy to study the distribution of 
11β HSD2 in human glomeruli.319 Katoka et al found that 11β HSD2 was 
localised to the cytoplasm in GEnC.319 The presence of 11β HSD2 suggests 
that in health these cells are aldosterone responsive and that the effects 
resulting from MR activation should largely be attributed to the actions of 
mineralocorticoids, not glucocorticoids. Expression of 11β HSD2 appears to 
be dynamic in cell culture at the mRNA level. Changing the cell media 
resulted in an increase in mRNA within 24 hours.  Multiple growth factors are 
contained in the EGM2-MV media used in cell culture and identifying which 
factor or factors altered expression would be very interesting. A likely 
candidate is the hydrocortisone contained within the singlequots provided 
with the media. In mature lung (BEAS-2B) cells dexamethasone was shown 
to increase the expression and activity of 11β HSD2 in a dose responsive 
mannor.320 In vivo, corticosterone injections increased renal 11β HSD2 
expression in a dose responsive manor in adrenalectomised rats.321 This 
observation may have therapeutic relevance.  Dehydroepiandrosterone has 
been shown to modulate the ratio of expression of HSD1 and 2 within the 
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renal tubules of mice and rats, shifting the balance of expression towards a 
corticosterone metabolism. These effects could explain the anti-obesity and 
anti-diabetic effects reportedly associated with this adrenal steroid 
precusor.322 Chronic salt and aldosterone exposure down regulated 11β 
HSD2 at the protein level in CiGEnC but I have not investigated the individual 
effects of elevated salt and aldosterone in isolation.  Interestingly whole body 
11β HSD2 knockout in transgenic mice was associated with endothelial 
dysfunction (impaired eNOS activity), suggesting that it may perform a vital 
role within these specialised cells.323 
Salt and aldosterone exposure in combination resulted in loss of syndecan 4 
and heparan sulphate from the cell surface. This loss could potentially be 
explained by cleavage of syndecan 4 by MMPs. Loss of syndecan 4 would 
be expected to result in loss of heparan sulphate because syndecan 4 has 
multiple HS binding sites on its ectodomain.191 However, additional 
mechanisms such as heparanase up-regulation cannot be excluded. The use 
of batimastat, a broad spectrum MMP inhibitor, however, completely 
abolished the effect, suggesting an MMP-dependant mechanism caused the 
damage in this model. 
Shear sensitivity was validated as a glycocalyx dependant mechanism using 
low doses of specific enzymes known to remove glycocalyx components.238 I 
chose to study KLF2 mRNA because this gene appears to be a major 
inducer of the shear phenotype.139 NO and eNOS are commonly studied in 
experiments using shear stress however the expression of these targets has 
been shown to be dependent on KLF2.324 In addition it has been shown that 
increasing salt concentrations above 137mM acutely suppresses NO 
production in a dose-dependant manor (range 137-157mM NaCl).102 This 
effect occurred within 15 minutes and was not dependant on shear stress.102 
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This pathway is therefore unlikely to be glycocalyx-dependant and may have 
confounded my results and so NO assays were avoided. 
Both the KLF2 response and the cells’ ability to align in response to shear 
stress were impaired following salt and aldosterone exposure for 5 days. The 
impairment of KLF2 up regulation could be reversed by MR inhibition using 
spironolactone, or MMP inhibition using batimastat. These data suggest that 
an MR-MMP dependant mechanism may explain the impairment. 
 
4.1.11.1 The potential interaction between salt and aldosterone 
Whilst studying the loss of glycocalyx components from the CiGEnC surface, 
it became apparent that the elevated salt or aldosterone (at the low dose 
used) in isolation had a very limited effect. In contrast, the combination of 
145mmol NaCl and 0.1nM aldosterone had a profound effect within 5 days. 
The discovery that CiGEnC expressed 11β HSD2 offered one potential 
explanation. Chronic salt and aldosterone exposure may result in 
suppression of 11β HSD2 (although only very provisional work has been 
conducted to date). This may explain why such low doses of aldosterone are 
having such a severe effect, because following the suppression of 11β HSD2 
glucocorticoids will increasingly activate MR in addition to aldosterone.  
Other microvascular endothelial cells also appear to express 11β HSD2 in 
culture including retinal endothelial cells.325 Knock down mouse studies have 
also given us an insight into the distribution and role of 11β HSD2 within the 
systemic vasculature of rodents. ApoE-/- 11β HSD2 -/- double knock down 
mice develop accelerated systemic atherosclerosis.326 The accelerated 
atherosclerosis in this model was despite similar plasma cholesterol levels 
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between the groups.326 Interestingly eplerenone (an MR inhibitor) reduced 
the lesion size without affecting the blood pressure of mice, suggesting that 
MR activation was directly implicated in the pathogenesis of this model, not 
via increased systemic blood pressure.326 The distribution of atherosclerotic 
plaque studied in this model was typical – affecting the aortic arch and large 
vessel branch points. These areas have been shown to have turbulent blood 
flow and are predisposed to atheroma formation.190  
Ideally I would like to study the activity of 11β HSD2 in our cultured cells and 
from FACS isolated human primary GEnC because this would provide 
information about how the overall system is working (11β HSD2 and 11β 
HSD1). Swapping the hydrocortisone (present within the media used) with an 
equivalent dose of dexamethasone (which wont bind to MR) may also help to 
prove if glucocorticoids stimulate MR following suppression of 11β HSD2. 
However this work was beyond the scope of this project where it was only 
necessary to confirm that GEnC are aldosterone responsive. 
As discussed within the introduction, other groups have explored alternative 
mechanisms linking salt and aldosterone. The level of nuclear receptor 
activation will be governed by; ligand levels, ligand type, nuclear 
translocation, histone modulation, co-activators and co-repressors and cross 
talk between intracellular signalling pathways.327 The Rho GTPase Rac1 has 
received considerable interest for its role in modulating MR activation.  Rac1 
activates MR in both a ligand dependant and ligand independent manner, 
possibly by regulating nuclear translocation of transcription factors.327 The 
relative contribution that alterations in Rac1 and 11β HSD2 made to MR 
signalling in my model were not assessed. However, the novel finding that 
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salt may alter the expression of 11β HSD2 in the presence of aldosterone in 
glomerular endothelial cells warrants further investigation as it suggests that 
salt is not acting solely through Rac1 to modulate MR activation. 
 
4.1.11.2 Loss of syndecan 4 from the glycocalyx may render 
CiGEnC unresponsive to shear stress 
Syndecan 4 has been shown to be vital in the process of cellular alignment 
and remodelling in response to laminar shear stress.190 Knockdown of this 
glycocalyx component results in dramatic increases in atheroma burden, and 
interestingly atheroma forms in resistant arterial segments (where laminar 
flow exists) and is associated with poor endothelial cell alignment. These 
findings suggest that syndecan 4 knockdown impaired cells’ ability to sense 
and react to laminar shear stress and increased the tissues’ propensity to 
form atheroma.190 The authors of the 11β HSD2 ApoE knock down study do 
not state if atheroma developed in sites less prone to disease – linear arterial 
segments with laminar flow. This may be relevant if 11β HSD2 knock out 
resulted in MR stimulation at levels equivalent to my in vitro work. If MR 
stimulation occurred to a level where MMP up-regulation occurred syndecan 
4 may be lost from the glycocalyx predisposing linear arterial segments to 
disease.190 
 
4.1.11.3 Loss of shear sensitivity as a mechanism of glomerular 
injury 
As discussed shear stress is a major regulator of eNOS and NO production. 
Within the glomerulus nitric oxide acts as a signalling molecule. NO is 
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predominantly produced by the vascular endothelial cells but it has been 
found to signal to podocytes.328 Podocytes in the absence of NO appear 
susceptible to mitochondrial injury, suggesting they may be dependant in 
vivo on their close proximity to nitric oxide producing GEnC. This 
dependence may have particular relevance when they are stressed. In 
diabetic models of renal disease eNOS knock out exacerbated diabetic 
glomerular injury, provoking mesangiolysis, glomerular capillary 
microaneurysms and sclerotic lesions.328 Loss of shear sensitivity and nitric 
oxide production by GEnC may therefore profoundly affect the GFB. 
4.1.11.4 Concluding remarks 
The identification of a novel potential pathway linking salt and aldosterone in 
combination to MR overstimulation in endothelial cells warrants further 
investigation but was beyond the scope of this project. Salt and aldosterone 
exposure resulted in loss of key glycocalyx components from the endothelial 
cell surface. This appears to be due to the induction of MMPs including 
MMP2 and MMP9. The resultant glycocalyx damage impaired endothelial 
cells ability to sense and react to shear stress and may have impaired other 
glycocalyx functions. I decided not to investigate other functions of the 
glycocalyx in vitro because the glycocalyx in vivo is known to differ 
significantly from that generated in culture and so an in vivo model was likely 
to have greater applicability. In addition in vivo models account for the 
complexity of the glomerulus, with flowing blood and close approximation of 
the cells types. Currently no in vitro work can model this complex structure 
satisfactorily. Therefore having identified a potential mechanism of glycocalyx 
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5 Does	 salt	 and	 aldosterone	 supplementation	 cause	 a	
renal	phenotype	in	vivo?	
The initial phase of investigation in Bristol concentrated on establishing the 
phenotype of the model. Salt (1% NaCl in drinking water and standard chow 
– containing 0.4% NaCl) and aldosterone (0.6µg/g/day delivered via 
subcutaneous minipump) had not been delivered to DBA2J mice previously 
and so I needed to confirm that hypertension did not result. If mice in the salt 
and aldosterone group had become significantly hypertensive this would 
have confounded the study because we were primarily interested in changes 
occurring within the endothelial glycocalyx. A contingency plan to use 
hydralazine (an antihypertensive working remotely from the RAAS) if mice 
had become hypertensive was in place, but was not needed (figure 5.1 A). 
Following 28 days of salt and aldosterone DBA2J mice did not have 
significantly elevated systolic blood pressures under 1% isoflurane 
anaesthesia.  Tail cuff plethesmography has a number of limitations, and 
these should be considered whilst interpreting the data. The diastolic blood 
pressures recorded using photo-plethesmography are derived from the 
systolic measurement (when blood flow first returns to the occluded tail 
artery) and therefore are inherently inaccurate. In addition and the blood 
pressure is only ever recorded at set times of the day in the presence of a 
human operator, whilst radio telemetry can sample the blood pressure 
continuously without disturbance.  As result, changes in the diastolic blood 
pressure, ‘remote’ blood pressure and nocturnal blood pressure cannot be 
excluded using this method.  Whilst remote telemetry would have provided a 
more complete blood pressure analysis, it would have been required a 
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separate animal group and it has also been shown to affect the RAAS.329 
Overall it was felt therefore that it could not be justified in this study. 
Mice receiving salt and aldosterone continued to gain weight at the expected 
rate (comparison to Charles River published growth charts330) and no 
significant differences in weight gain between the groups were detected 
(figure 5.1 B). Salt and aldosterone caused a progressive increase in urinary 
albumin creatinine ratio (uACR) over 28 days (Figure 5.1C). Although the 
uACR increased in all the exposed mice used in this model by day 28, 
considerable variability in baseline uACR values and the magnitude of the 
increase was noted. It was also noted that the group of mice randomised to 
receive salt and aldosterone had a higher mean baseline uACR compared to 
the control mice (before any intervention). The reason for this variability is 
unclear but random variation cannot be excluded and statistical comparison 
was not significant (ANOVA with Tukey’s correction p = 0.68). In addition to 
baseline and final urine measurements samples were collected from mice 
receiving salt and aldosterone on day 8 to confirm that salt and aldosterone 
could rapidly induce albuminuria (in a time scale suitable for multiphoton 
microscopy). Comparison of uACR values of individual mice at day 8 and day 
28 suggested that in three mice the uACR fell over this period (although 
remained significantly higher that the baseline values). However in the 
remaining 5 mice uACR values progressively increased. Comparison of 
uACR values between the groups at day 28 confirmed that salt and 
aldosterone had significantly increased urinary albumin leakage (figure 5.1 
D). 
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5.1.1 Investigating the mechanism of albuminuria 
Having established that this model results in albuminuria in the absence of 
hypertension the mechanism of albuminuria was investigated further. To 
study changes in glomerular gene expression in response to salt and 
aldosterone mRNA was extracted from glomeruli and processed using 
targeted qPCR. This focussed approach allowed us to target genes relevant 
to our hypothesis. I have displayed both individual mouse fold change values 
normalised to mean control values (figure 5.2 A-E) to illustrate the distribution 
of responses and a summary graph showing the group mean data and 
statistical significance to controls (figure 5.2 F). Salt and aldosterone 
exposure significantly increased the glomerular expression of syndecan 4 
(figure 5.2 A) and MMP2 (figure 5.2 B). Although both MMP2 and MMP9 are 
gellatinases and within the same family of MMPs I did not see significant 
increases in the expression of MMP9 (figure 5.2 E) within the glomeruli of 
mice in this model. A two-fold increase in glomerular TNFα mRNA was seen 
in mice receiving salt and aldosterone (figure 5.2 C). A significant increase in 




Figure 5-1 Salt and aldosterone cause albuminuria 
A. Systolic blood pressure measured with tail cuff plethysmography under 1% 
isoflurane did not vary with time or between groups (n=8 per group, ANOVA 
p=0.7785). B. Mice continued to gain weight at an expected rate during the study, 
with no significant differences between the groups at each time point (N=8 per 
group, T-tests p=0.8256 day 0, p=0.2616 day 28). C. The urine albumin creatinine 
ratio (ACR) of mice receiving salt and aldosterone increased during the study 
(ANOVA p=0.0491). D. By day 28 mice that received salt and aldosterone had 
significantly higher uACR levels than time matched control mice. (T-test p=0.0025)	
✔ salt + aldosterone = 1% NaCl in drinking water (ad libitum) and 0.6µg/g/day aldosterone 
delivered s.c. via minipump. ✖ salt and aldosterone = standard drinking water (ad libitum) 






Figure 5-2 Glomerular mRNA fold change data 
Figures A-E illustrate the changes in the glomerular expression of mRNA encoding 
for key genes of interest A. Syndecan 4, B. MMP2, C. TNFα, D. VCAM, E. MMP9. 
F. Summary of the same data with statistical significance illustrated, comparisons 
displayed are to control mice (mean control value normalised to 1 for each gene and 
not displayed) ✔ salt + aldosterone = 1% NaCl in drinking water (ad libitum) and 
0.6µg/g/day aldosterone delivered s.c. via minipump for 28 days.  ✖ salt and aldosterone = 




5.1.2 Glomerular gene expression changes 
Earlier work by Dr Raina Ramnath had suggested that syndecan 4 mRNA 
increased in response to shedding of the protein ectodomain from the 
glomerular endothelial cell surface.191 In my cell based models in vitro I too 
had seen a low level (1.4-fold increase) up regulation of syndecan 4 mRNA 
in response to salt and aldosterone despite reduced surface expression by IF 
and reduced cell syndecan 4 on ELISA. However a power test suggested 20 
experiments would be needed to confirm that the elevation was significant 
and this was not pursued. However in vivo it was noted MMP2 and syndecan 
4 mRNA fold changes were correlating closely (figure 5.3). This effect was 
true when the two mice groups were analysed together, but remained 
significant when just mice that had received salt and aldosterone were 
included in the analysis. This suggested that the mice expressing high levels 
of MMP2 were also expressing high levels of glomerular syndecan 4 mRNA. 
This data is consistent with the possibility that MMP2 mediated loss of the 
syndecan 4 ectodomain could result in increased syndecan 4 mRNA. 
Figure 5-3 Spearman correlation analysis 
Glomerular expression of MMP2 and Syndecan 4 mRNA correlated strongly for 
individual mice within the group receiving salt and aldosterone (R2=0.93, p=0.0022) 
and in all mice (not shown) (R2=0.92, p<0.0001).	
	 	
























Figure 5-4 Mouse plasma and urine syndecan 4 ectodomain 
levels 
A. No significant increase in plasma syndecan 4 levels was detected (T-test 
p=0.2835 N=7 (plasma not obtained from 2 mice). B. Urine syndecan 4 levels 
increased significantly relative to baseline, and time matched control mice (ANOVA 
p=0.0025, Tukey’s analysis displayed, N=8). C. After normalising urine samples for 
creatinine concentrations the effect of salt and aldosterone remained significant. 
(ANOVA p=0.0014, Tukey’s analysis displayed, N=8). ✔ salt + aldosterone = 1% NaCl 
in drinking water (ad libitum) and 0.6µg/g/day aldosterone delivered s.c. via minipump. ✖ salt 
and aldosterone = standard drinking water (ad libitum) and vehicle (ethanol (0.05%) saline 
(0.9%)) filled minipump. 
	
5.1.3 Results of syndecan 4 ectodomain ELISA 
Plasma concentrations of syndecan 4 ectodomain did not increase 
significantly relative to control mice (figure 5.4 A). In contrast urine levels of 
the syndecan 4 ectodomain did increase in mice that had received salt and 
aldosterone. This effect remained significant when adjustments were made 
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DBA2J mice developed significant albuminuria after 28 days of salt and 
aldosterone when compared to baseline values or time matched controls. 
Albuminuria was significantly increased by day 8 of salt and aldosterone 
exposure, suggesting that this model can be used in combination with 
multiphoton microscopy. After 28 days the blood pressure of the two mouse 
groups did not differ significantly from baseline values (measured before 
minipump implantation) or in comparison to each other. These findings 
confirm the work of Schreier et al,253 who used FVB/N mice, but identical 
doses of salt and aldosterone. They also found significant albuminuria 
developed in the absence of hypertension in this model. My results provide 
further evidence that salt and aldosterone in vivo act via mechanisms other 
than systemic hypertension to cause albuminuria.  
 
The blood pressure in this series of mice was measured under anaesthesia 
to make sure readings were applicable to mice during multiphoton 
microscopy. It is not possible to monitor mouse blood pressure whilst they 
are on the multiphoton microscope, but it was important to check that the 
systemic hypertension would not influence the glomerular sieving coefficient 
of albumin (measured by multiphoton microscopy see chapter 6). Because I 
also wanted to confirm that awake, trained mice did not become hypertensive 
in response to salt and aldosterone this work was done on the mice used in 
Los Angeles (see chapter 6) 
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Targeted qPCR enabled me to confirm that salt and aldosterone were 
significantly altering glomerular gene expression. This work was performed 
using RNA because a much smaller quantity of renal tissue is needed for this 
work compared to protein quantification. Measuring RNA has obvious 
limitations and so important discoveries should be validated with studies at 
the protein level and ideally activity level in the case of enzymes. The gene 
expression changes that I have studied suggest again that MMP2 may 
contribute to glomerular syndecan 4 shedding and the resultant mRNA up 
regulation. In contrast to my work using human CiGEnC, I did not find any 
evidence that glomerular MMP 9 mRNA increased in vivo in response to salt 
and aldosterone. Glomerular mRNA changes in the Ren2 overexpressing 
rats (TGR(mRen2)27), have also been shown to follow this pattern.331 This 
model has been used frequently to study hypertension, but the underlying 
renin over expression would be expected to result in high levels of 
aldosterone secretion as well. Studying 8 week old male rats suggested that 
renin over expression resulted in a 2.3 fold increase in glomerular MMP2, but 
a significant suppression of glomerular MMP9 mRNA.331 Interestingly in a 
small study looking at plasma MMP 2 and MMP 9 levels in patients with 
glomerulonephritis (GN) MMP2 plasma levels were significantly elevated. In 
contrast MMP 9 levels were reduced approximately 6-fold. These findings 
were confirmed using zymography. In contrast urinary levels of MMP 2 and 9 
were both increased. Within renal biopsy tissue patients with GN had 
significantly elevated levels of MMP 2 compared to control kidney tissue, 
suggesting that the MMP2 may form part of common glomerular sclerotic 
pathway.332  
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Plasma levels of MMP 2 and 9 also appear to have predictive value in renal 
disease. In a study conducted on non-diabetic patients referred for coronary 
angiography patients with an elevated level of plasma MMP 2 or MMP 9 
were 2.5 and 4.7 (respectively) times more likely to develop a decline in GFR 
than patients with the lowest circulating levels of these enzymes.333 Together 
these data suggest that MMPs 2 and 9 are at least associated with renal 
disease and may be contributory in some glomerular pathologies. 
 
The elevation in TNFα mRNA within the glomeruli of mice exposed to salt 
and aldosterone is an interesting finding. TNFα is an inflammatory cytokine 
produced largely by monocytes and macrophages, but it has also been 
shown to be produced by mesangial cells within the glomerulus.334 The 
effects of TNFα in renal disease include production of vaso-active 
substances, stimulation of immune cell recruitment and local ROS 
generation.334 Inhibition of TNFα has been shown to be effective in at 
reducing renal injury in the DOCA-salt model (DOCA = deoxycorticosterone 
acetate – an active mineralocorticoid). This effect was again independent of 
blood pressure modulation (measured by telemetry).335 Inhibition of TNFα 
has also been shown to be effective in double transgenic rats over 
expressing renin and Ang II, where it reduced immune cell infiltration into the 
kidney, again independently of blood pressure modulation.336 
 
TNFα and MMP 2 are known to interact. TNFα has been shown to induce 
MMP 2 expression, but it also selectively enhances the activity of MMP2 by 
promoting the activation of pro-MMP 2.337 Conversely MMP 2 and 9 inhibition 
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has been shown to be effective in preventing the conversion of pro-TNFα to 
active TNFα.337 Aldosterone and salt, in combination, have previously been 
shown to increase renal TNFα protein and M1 macrophages, however these 
effects were studied in whole kidney lysates and so the relative contribution 
of glomerular changes is hard to estimate.338 Overall it seems possible that 
MMP 2 and TNFα are interacting within glomeruli, amplifying the 
inflammation seen in this model but to test this further, analysis at the protein 
levels +/- knock out animal models would be needed. 
 
Vascular cell adhesion molecule-1 is expressed on endothelial cells after 
they have been stimulated by inflammatory cytokines. VCAM-1 mRNA 
increased in mice exposed to salt and aldosterone and, within individual 
mice, VCAM-1 and syndecan 4 mRNA expression with individual mice 
correlated significantly (Spearman r p=0.0022). VCAM-1 has previously been 
shown to increase in glomeruli in the DOCA-salt model, however in this 
model rats were significantly hypertensive.339 Interestingly in this model 
spironolactone failed to reduce glomerular endothelial VCAM-1 expression, 
in contrast to a triple therapy designed to normalise blood pressure.339 
However triple therapy also returned uACR values to control levels, whilst 
spironolactone did not. These data suggest that spironolactone (at the dose 
used) cannot reverse established hypertension in the DOCA salt model and 
that persisting hypertension may then continue to ‘drive’ glomerular 
inflammation and albumin loss.339 This hypothesis is supported by the finding 
that endothelial MR knockout failed to prevent renal cortex up regulation of 
VCAM-1 associated with DOCA-salt when mice were significantly 
hypertensive.177 
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It is possible that glomerular hypertension can directly result in inflammation, 
via damage to the filtration barrier and the filtration of inflammatory mediators 
and that hypertension needs to be corrected (or not induced as in our model) 
to isolate specific effects of MR activation. In addition data generated using 
the DOCA-salt (and uninephrectomy) model should be interpreted with 
caution. Marked hypertension develops in this model that cannot be reversed 
by MR inhibition at 4 weeks, hypertension may directly stimulate 
inflammatory pathways in the glomeruli making it very hard to investigate 
direct MR mediated effects. In this study up-regulation of VCAM-1 suggests 
that significant inflammation is occurring within the glomeruli of salt and 
aldosterone treated mice, in the absence of systemic hypertension. 
 
5.1.3.1 Concluding remarks 
Work conducted in vivo at the University of Bristol allowed me to confirm that 
salt and aldosterone rapidly induced albuminuria in male DBA2J mice in the 
absence of systemic hypertension. Analysis of RNA extracted from mouse 
glomeruli suggested that significant glomerular inflammation and possible 
glycocalyx injury had occurred by day 28.  
 
The next stage of the project was to confirm that albuminuria was the result 
of increased glomerular albumin leakage and not altered tubular protein 
handling. If I could establish that glomeruli are damaged by salt and 
aldosterone I would then investigate if the glycocalyx was damaged in this 
model and if glycocalyx preservation could prevent this damage. 
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6 Is	 albuminuria	 the	 result	 of	 increased	 glomerular	
albumin	leakage	following	glycocalyx	damage	in	this	
model?	
Validating multiphoton microscopy techniques 
The technique to measure the glomerular sieving coefficient for albumin 
GSCalb using multiphoton microscopy is well established. However 
controversy remains about the absolute levels of albumin leakage measured 
by this technique.340 Variations in the published values for the GSCalb have 
been attributed to animal condition and health, offset calibration and the 
microscope and imaging equipment used.340 I decided to measure and 
display fold change GSCalb data. This method allowed me to image multiple 
glomeruli from each mouse and then study how the GSCalb changed in 
response to salt and aldosterone using standardised settings. This method 
should be more easily reproducible using another multiphoton microscope 
because variations in the microscope settings/ equipment will be fixed, but I 
was keen to validate that if I could detect changes in GSCalb as a result of 
glycocalyx damage using this method. Simultaneous measurements of 
glomerular glycocalyx thickness and GSCalb have not been made before. To 
achieve this, new techniques to label and measure the glycocalyx within 
glomeruli had to be devised and validated. The processes used to validate 
the data generated using multiphoton microscopy are outlined below. 
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Figure 6-1 Multiphoton z-stack image of a glomerulus 
Images highlight the unique patterns generated by overlying tubules that can 








6.1.1 Multiphoton images can be used to calculate the glomerular 
albumin sieving coefficient  
Having established that detailed images could be captured of mice glomeruli 
within the renal cortex (figure 6.1) I tested the validity of using the resultant 








Figure 6-2 Using multiphoton images to calculate GSCalb 
A. Simultaneous measurement of Alexa 594 albumin florescence intensity in the 
Bowman’s space (red, BS) and within plasma filled glomerular capillary loops (CL) 
allowed calculation of the glomerular sieving coefficient for albumin (GSCalb). 
Multiphoton Images were selected for analysis provided the Bowman’s space could 
be clearly defined and two sites with no capillary loops within 4.5µm (X Y and Z 
plane) could be sampled, minimising background florescence. The same glomeruli 
were imaged on day 0, 5 +/- day 10 (series dependant) allowing calculation of the 
fold change in GSCalb in each glomerulus before calculating the mean for each 
mouse (Bar= 50µm). B. The formula applied to calculate GSCalb. C. To validate the 
technique GSCalb was measured in the same glomeruli repeatedly over time. This 
was done to confirm if the duration of imaging influenced the GSCalb. GSCalb 
remains stable for 40 minutes after the injection of Alexa 594 albumin. Imaging for 
longer than 40 minutes can result in significant increases in the measured GSCalb 
and was therefore avoided (ANOVA p=0.0451, Tukey’s adjusted p value 20 vs 50 





Figures 6.1 and 2 A illustrate typical glomerular multiphoton images. Alexa 
Flour 594 labelled BSA is seen circulating within the glomerular capillaries. 
Due to the Fåhræus-Lindquivist affect a column of fast moving erythrocytes 
forms at the centre of each glomerular capillary (often seen as a darker area 
due to relative exclusion of plasma, light absorption and light scattering from 
the moving erythrocytes). At the margins of each vessel the Alexa Flour 594 
labelled BSA concentration is maximal due to the cell-free boundary region. 
Figure 6.2 B. illustrates the formula used to calculate the GSCalb. Multiple 
regions of interest (ROI) were placed within the capillaries and Bowman’s 
space on images and then florescence intensity calculated. Areas for ROI 
placement within the Bowman’s space were selected for blinded analysis 
provided the Bowman’s space could be clearly defined and there was 
sufficient area to analyse florescence intensity at two sites with no capillary 
loops within 4.5µm (3 frames in z-stack). Areas within the plasma at the 
margin of adjacent glomerular capillaries were then selected for further ROI 
placements. The fluorescence intensity measurements at these points were 
then used to calculate the GSCalb for each level of the z-stack included 
before values were combined to generate specific GSCalb values for each 
glomerulus. The same glomerulus could then be re-imaged using identical 
microscope settings on day 5 +/- day 10 and the GSCalb recalculated. Fold 
change data could then be generated for each glomerulus before data were 
combined to calculate the final GSCalb fold change value for each mouse. 
Figure 5.2 C illustrates that GSCalb remains stable within individual glomeruli 
for the first 40 minutes on the microscope. Beyond this time point GSCalb 
increased significantly. This phenomenon has been noted previously by Dr 
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Peti-Peterdi, he has previously shown that it is not due repeated imaging 
(and resultant light toxicity) and believes it is due to induced metabolism of 
the Alexa Flour 594 labelled BSA, generating free dye which is freely filtered 
increasing the apparent GSCalb. However the effect of prolonged anaesthesia 
has not been excluded. For my study all images used for the calculation of 
the GSCalb were captured within the first 30 minutes of imaging to eliminate 
this variability. 
 
6.1.2 Multiphoton images can be used to measure changes in lectin 
labelled glycocalyx 
Wheat germ agglutinin (WGA) is a 36kDa lectin that has been used 
previously to label the endothelial glycocalyx in the systemic vasculature.203 
Unlike many lectins that cause agglutination of circulating cells, WGA can be 
used in live perfused animals to give real-time information about the 
glycocalyx and used repeatedly in recovery procedures. WGA binds to sialic 
acid residues within the glycocalyx.203 Sialic acids are, however, widely 
expressed including within the glomerular basement membrane.341 Whist the 
distribution of WGA labelling seen on images was more consistent with the 
discrete ‘loops’ seen with classical endothelial surface staining it was still vital 
to confirm that WGA bound to the endothelial cell glycocalyx in vivo.	To test 
this, endothelial confetti mice were kindly supplied by Dr Dorrine 
Desposito.301 This mouse can be induced with tamoxifen (Tamoxifen Cre-
loxP) to express one of 4 florescent dyes within endothelial cells. Cyan 
florescent protein in this model is expressed within the endothelial cells 
luminal membrane giving a reference point to compare the location of 
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adherent FITC-WGA to. Using the endothelial dyes expressed within the 
confetti mouse glomerulus following induction it was possible to demonstrate 
that FITC-WGA adhered to the luminal aspect of the GEnC following 
perfusion (figure 6.3). Having established that WGA lectin binds to the 
glomerular endothelial glycocalyx two methods were devised to quantify the 




Figure 6-3 FITC- WGA binds to the luminal surface of glomerular 
endotheilal cells 
A. A representative composite image of GEnC expressing fluorescent protein tags 
generated using the confetti system, (yellow fluorescent protein in cytoplasm, red 
florescent protein in cytoplasm and blue membrane-tethered cyan fluorescent 
protein), and FITC-WGA staining (green) and Alexa 594 albumin (red) in the plasma 
in the same glomerulus at the same level. B. Enlarged image of ROI 1 with the 
yellow line indicating the position of the line profile illustrated in figure C. (Bar = 
4µm). C. The line profile across the optically sectioned capillary demonstrates the 
FITC-WGA signal on the luminal side of the yellow fluorescent protein signal 
(expressed in the endothelial cell cytoplasm) but external to the peak Alexa 594 
albumin (plasma) signal consistent with localisation to the endothelial glycocalyx. D. 
Enlarged image of the area containing the line profile ROI2 (yellow line) illustrating 
the spatial relationship in more detail using an oblique, optical section through an 
endothelial cell expressing the membrane specific cyan florescent protein label (Bar 
= 4µm). E. The associated line profile demonstrates the binding of FITC-WGA to the 
luminal side of the endothelial cell membrane, again consistent with glycocalyx 
localisation. 
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6.1.3 Peak to Peak measurement 
Peak to peak measurements have been used previously to study the depth 
of the glycocalyx and have been found to be more accurate than other 
measurements including ‘signal width at half maximal height’.203 However 
membrane labels such as R18 do not emit a strong enough signal to be used 
in multiphoton glomerular imaging. The confetti mouse model is also not 
ideal, requiring the delivery of tamoxifen (to induce Cre recombinase activity) 
and L-NAME and to maintain superficial glomeruli (by causing tubular 
atrophy).  
Figure 6-4 A represenatative glomerular image following WGA 
and peak to peak analysis explanation 
Red = Alexa-BSA, Green= FITC-WGA. Plasma albumin concentrations are maximal 
towards the periphery of glomerular capillaries. The glycocalyx contributes to the 
GFB – excluding albumin, thus the plasma level of labelled albumin falls as it meets 
the glycocalyx. The distance between the maximal FITC-WGA signal within the 
glycocalyx and the adjacent peak plasma Alexa-594 albumin level (dotted lines in 
figure) can therefore give us vital information regarding the thickness of the 
glycocalyx. 
	
Indeed the glomerular glycocalyx in confetti mice was significantly thinner 
than in wild type mice in the provisional experiments I conducted (80% 
reduction in glycocalyx thickness). Therefore ‘confetti’ membrane labels 
could not be used as a reference point against which to measure the 


















glomerular glycocalyx in vivo.  Instead I developed a method that relied on 
the ability of the glycocalyx to exclude albumin. Because the glycocalyx is 
highly charged it naturally contributes to the reflection of albumin away from 
the vessel wall. Conversely erythrocyte flow marginates the plasma, 
concentrating it at the periphery of vessels. The concentration of Alexa Flour 
594 labelled BSA within the plasma is therefore maximal adjacent to the 
glycocalyx. The concentration of albumin begins to fall as it is repelled by the 
charged glycocalyx at the vessel margins. Measurement of the distance 
between the peak Alexa Flour 594 labelled BSA signal and the peak FITC-
WGA signals can therefore be used as a measure of approximately half the 
glycocalyx thickness (figure 6.4). Carefully selected optically sectioned 
(round in profile) capillaries or transversely sectioned capillaries at their 
maximal width (from the z-stack) were analysed to ensure true thickness of 
glycocalyx was measured (not an oblique measure). 
	
6.1.4 Peak fluorescence intensity 
The second method I used to evaluate the glycocalyx was peak florescence 
intensity. Measuring the peak florescence intensity of a line profile placed 
perpendicular to the optically sectioned glycocalyx and normalising it to 
adjacent tubular auto florescence (also in the green channel) generated 
consistent values. Normalisation was used to adjust for variations in the 
optical characteristics of the overlying tissues. Peak florescence intensity 
gives a measure of the density of WGA binding sites (sialic acid residues) 
within the glycocalyx. 
	 214	
Combining the information gathered using peak to peak measurements and 
peak florescence intensity could therefore tell us how the glycocalyx structure 
responded to an insult. 
 
6.1.4.1 Validating peak to peak and peak florescence intensity 
measures 
To validate my new techniques to study the glycocalyx in vivo I needed a 
reproducible glycocalyx insult. I selected hyaluronidase infusion for this 
purpose. Hyaluronan chains form a key part of the glycocalyx and 
hyaluronidase has been shown to have a plasma half-life of approximately 3 
minutes before being taken up in the liver by a mannose-dependant 
mechanism.342 The short plasma half-life and high molecular weight (61kDa) 
of hyaluronidase meant that the major site of action should be the glycocalyx. 
After locating superficial glomeruli a bolus of 20units of hyaluronidase was 
delivered via the retro orbital sinus and serial images captured. An example 
series is illustrated in figure 6.5 (the green channel has been isolated to 
make visualisation of changes easier). Following the delivery of 
hyaluronidase the FITC-WGA signal rapidly and visibly declined. After 1 hour 
no visible signal was seen, in contrast FITC-WGA signals in mice not given 
hyaluronidase did not significantly alter over 1hour. To study recovery of the 
glycocalyx FITC WGA was also given to mice at 70 minutes or 120 minutes. 
A second bolus of WGA at 70 minutes revealed minimal glomerular labelling, 




Figure 6-5 A representative series of images from a glomerulus 
following hyaluronidase delivery 
A. Representative images taken of a single glomerulus over the time course of the 
experiment. Twenty units of hyaluronidase delivered IV resulted in a rapid, visible 
reduction in the glomerular capillary FITC-WGA signal. The glomerular capillary 
FITC-WGA intensity was significantly reduced within 20 minutes, before 
spontaneous recovery (detected with a second WGA bolus) occurred between 70 
minutes and 120 minutes. (Bar = 25µm) B. The administration of a second WGA 
bolus at 70 minutes failed to reveal a clear glomerular WGA signal (separate 
series). 
	
6.1.5 Applying and contrasting peak to peak and peak florescence 
intensity analysis  
The data generated by the two methods of glycocalyx assessment are 
illustrated in figures 6.6 and 6.7. Whilst broadly following the same trend the 
differences between the two methods at 20 minutes are intriguing. By eye 
minimal signal remains at 20 minutes and this is confirmed by the peak 
florescence intensity measure, however peak to peak analysis suggests that 
a residual structure does remain and that the glycocalyx has only lost 43% of 
its height at this early time point.  







 WGA) B. 
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Figure 6-6 Peak to peak analysis of glycocalyx loss 
Glomerular peak to peak measurements fall significantly in response to IV 
hyaluronidase. Recovery occurs by 120 minutes. Again data suggested that removal 
of HA, a key glycocalyx component, and the resultant glycocalyx damage are 
detectable using the peak to peak method (ANOVA p<0.001, Tukey’s analysis 
displayed). N=3 C57 BL/6 mice.	Significance	relative	to	baseline.	
	
Figure 6-7 Fluorescence intesity analysis of glycocalyx loss 
Glomerular capillary wall WGA intensity falls significantly in response to IV 
hyaluronidase, partial recovery occurs by 120 minutes. Data suggest that removal of 
HA, a key glycocalyx component, and the resultant glycocalyx damage are 
detectable using the glomerular capillary WGA intensity method. (ANOVA 




























































These discrepancies may be due to how the structure of the glycocalyx 
reacts to the insult, initially becoming less dense before possibly collapsing – 
reducing the measureable thickness. From the analysis both methods are 
able to detect glycocalyx loss within glomeruli and so both methods have 
been used throughout the project to allow contrasting data between the two 
methods to be examined. 
	
6.1.5.1 Do changes in glycocalyx thickness correlate with changes in 
the GSCalb? 
To validate the GSCalb measurement in this model, and confirm that changes 
to the glycocalyx resulted in increased glomerular albumin leakage I then 
analysed changes in the GSCalb for individual glomeruli following the 
hyaluronidase bolus. The data generated suggested that GSCalb correlated 
with glycocalyx thickness measured by peak to peak analysis (figure 6.8). 
These data together suggest that the glycocalyx contributes to the GFB and 
that acute insults to the glycocalyx will result in increased glomerular albumin 
leakage. Whilst a linear analysis has been used to study the relationship 





Figure 6-8 Correlation between glycocalyx loss and GSCalb 
A. Summary data for changes in glycocalyx thickness and GSCalb following a 20unit 
bolus of hyaluronidase (N=3). Time adjusted values are displayed at 60min and 120 
minutes B. GSCalb and glycocalyx thickness measured using peak to peak analysis 
correlate significantly. Linear correlation displayed (solid line) with 95% confidence 




Using multiphoton microscopy to study the 
glomerular effects of salt and aldosterone in DBA2J 
mice. 
During the first 5 weeks in Los Angeles a total of 20 male DBA2J mice were 
imaged but only five mice had sufficiently superficial glomeruli on days 0 and 
5 (and only 1 mouse on day 10, data not shown) to be included in the study. 
The first z-stack glomerular image captured from a DBA2J mouse is 
illustrated in figure 6.1. Images 1-12 represent sequential z-stack images 
every 1.5µm illustrating the changing tissue architecture as the depth of 
imaging increases. Images 14, 18 and 22 illustrate the glomerular structure. 
Glomeruli occupy a very small proportion of the volume of the most 
superficial renal cortex and so to find glomeruli to image was often difficult. 
The pattern of the tubules surrounding each glomerulus and the configuration 
of the glomerular capillaries however, are unique to each glomerulus, 
ensuring that the same glomeruli can be found for serial images. When 
glomeruli were found their location was noted on a hand drawn map to 
facilitate re-imaging the same glomerulus 5 days later. 
 
6.1.6 Exposed young DBA2J mice develop albuminuria in the absence 
of hypertension  
Young DBA2J mice receiving 1% NaCl drinking water ad libitum and 
subcutaneous aldosterone 0.6µg/g/day via minipump gained weight at the 
expected rate for the strain330 (figure 6.9 A). Blood pressure measured in 
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awake trained mice on day 12 of salt and aldosterone was not elevated when 
compared to published data for this strain343 (although no matched control 
mice were available for comparison in this study) (figure 6.9 B). Urine 
collected and analysed for creatinine and albumin concentrations confirmed 
that young DBA2J mice rapidly developed albuminuria (figure 6.9 C). ANOVA 
of the serial measurements confirmed that the increased levels of 
albuminuria became statistically significant from day 10. In contrast to the 
uACR data, the change in the GSCalb was significant after 5 days exposure to 
salt and aldosterone (figure 6.9 D). 
Comparison of the GSCalb data and uACR data on day 5 suggested that 
glomerular albumin leakage did not directly correlate with urine albumin 
creatinine ratios at this time point. From day 0 to day 5 the group mean urine 
albumin creatinine values increased 2.4 fold. In contrast the GSCalb 
measurement suggested that mean glomerular albumin leakage had 
increased 6.5 fold. These data suggested that tubular handling of albumin 
may be influencing the final uACR value in this strain and this phenomenon 






Figure 6-9 Salt and aldosterone-treated DBA2J mice phenotype 
characterisation	
Young male DBA2J mice receiving salt (1% NaCl drinking water ad libitum) and 
aldosterone (0.6µg/g/day delivered s.c. via minipump) gain weight at an expected 
rate but developed increased glomerular albumin leakage by day 5 and increased 
uACR by day 10. DBA2J mice are not suited to glomerular multiphoton imaging. 
Significant difficulty was encountered imaging DBA2J mice due to the depth of 
glomeruli within the renal cortex. For this reason all DBA2J mice with superficial 
glomeruli (N=5) received salt and aldosterone. The mouse strain used for the 
remainder of the project was changed to C57 BL/6. A. Mouse weights increased as 
expected for the strain. B Systolic BP in awake trained mice was also within the 
published range for the strain.343 C. DBA2J mice developed significantly increased 
levels of albuminuria after 10 days exposure salt and aldosterone (ANOVA 
p=0.0176, Tukey’s analysis displayed, N=5). D The GSCalb was significantly 
elevated by day 5 of salt and aldosterone (Mann-Whitney p= 0.0079). Displayed 




6.1.7 DBA2J mice summary 
Young male DBA2J mice become albuminuric after 10 days exposure to salt 
and aldosterone in the absence of significant detectable hypertension. 
Despite the difficulty associated with using DBA2J mice for multiphoton 
glomerular imaging I was able to confirm that the GSCalb had increased to a 
greater extent than the uACR over the same time period. These data 
suggested that tubular handling of albumin might have influenced the uACR 
in this model. However the scarcity of superficial glomeruli in this mouse 
strain meant future work had to be conducted in C57 BL/6 mice. 
 
Assessing the C57 BL/6 mouse phenotype 
As stated previously C57 BL/6 were selected, after DBA2J mice were found 
to be unsuitable for multiphoton imaging, because of their availability and 
because Dr Peti-Peterdi believed their glomeruli should remain more 
superficial at day 5 and 10 of the protocol. The change of mouse strain 
however meant that the phenotype resulting from salt and aldosterone 
exposure had to be re-assessed. Again young male C57 BL/6 mice did not 
develop significant hypertension (measured in awake trained mice on day 
12) in response to salt and aldosterone (figure 6.10 A). Mice exposed to salt 
and aldosterone continued to gain weight at the expected rate with no 
significant differences developing between the groups (figure 6.10 B). Mice 
receiving salt and aldosterone again became significantly albuminuric by day 
10 (figure 6.10 C). 
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Figure 6-10 C57 BL/6 mouse phenotype following salt and 
aldosterone 
Young male C57 BL/6 mice receiving salt and aldosterone developed significant 
albuminuria in the absence of detectable hypertension or altered growth. A. Male 
C57 BL/6 mice receiving salt and aldosterone do not develop significant systolic 
hypertension by day 12 (measured via tail cuff plethysmography in awake trained 
mice) T-test p=0.9694. B. Mice in both groups gain weight at an expected rate with 
no significant difference between the groups developing. C There was no significant 
variation in the uACR values for control mice during the study (ANOVA p=0.1170). 
In mice receiving salt and aldosterone the uACR increased significantly by day 10 
(ANOVA P=0.0191). Comparison between the groups at each time point confirmed 
that salt and aldosterone had increased the uACR significantly by day 10 (ANOVA 
p=0.0191, Sidak’s Comparison for each time matched group displayed). ✔ salt + 
aldosterone = 1% NaCl in drinking water (ad libitum) and 0.6µg/g/day aldosterone delivered 
s.c. via minipump. ✖ salt and aldosterone = standard drinking water (ad libitum) and vehicle 
(ethanol saline) filled minipump. Significance relative to day 0 unless indicated.  
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6.1.8 Using multiphoton microscopy to study the glomerular effects of 
salt and aldosterone on C57 BL/6 mice 
In C57 BL/6 mice titanium windows were inserted to facilitate renal imaging, 
the protocol was otherwise unaltered. Mice were imaged at baseline, day 5 
and day 10. FITC-WGA was used to image the glycocalyx on day 10 only. 
 
6.1.8.1 Studying the GSCalb of C57 BL/6 mice 
The GSCalb was significantly increased in C57 BL/6 mice following 5 days of 
salt and aldosterone compared to control mice (figure 6.10 C). The level of 
increase in C57 BL/6 GSCalb was not statistically different from DBA2J mice 
(DBA2J = 6.5 +/- 1.5 fold increase, C57 BL/6 mice = 5.1 +/- 0.99 fold 
increase, T-Test NS) suggesting both strains reacted similarly to salt and 
aldosterone. Data for individual mice are shown in figure 6.11 A. These data 
highlight the consistency of the model in increasing GSCalb although the 
magnitude of the increase does vary widely. More superficial glomeruli were 
present in C57 BL/6 mice compared to DBA2J mice. In contrast to DBA2J 
mice, glomeruli were still superficial enough to image on day 10 of the study. 
The GSCalb remained significantly elevated after 10 days of salt and 
aldosterone (Figure 6.11 B). No significant variation was detected in the 
GSCalb of control mice during the study although there was a trend towards a 
reduction in glomerular albumin leakage (figure 6.11 A). This reduction may 
be a normal aging phenomenon or it may represent on-going recovery from 




Figure 6-11 GSCalb C57 BL/6 Mice 
The GSCalb increased significantly in male C57 BL/6 mice receiving salt and 
aldosterone A. Changes in GSCalb over time in individual mice are displayed. The 
GSCalb in control mice did not alter significantly (non parametric Friedman test of 
paired data with repeated measures p=0.0864) although there was a trend for 
GSCalb to fall between day 0 and day 5. The GSCalb values for mice receiving salt 
and aldosterone, in contrast, increased significantly (non parametric Friedman test 
of paired data of repeated measures p=0.0085). B. Time matched comparisons 
between control mice and those receiving salt and aldosterone. Dotted line 
represents the GSCalb day 0 measurement for all mice (normalised to 1) Mann-
Whitney comparisons displayed. ✔ salt + aldosterone = 1% NaCl in drinking water 
(ad libitum) and 0.6µg/g/day aldosterone delivered s.c. via minipump ✖ salt and 





6.1.9 The relationship between GSCalb and uACR 
The results generated using the DBA2J mouse strain suggested that the 
uACR values were influenced by variable tubular albumin handling. Studying 
the data generated using C57 BL/6 mice showed a similar pattern. However 
the additional ability to study the GSCalb at day 10 has yielded further insight 
into tubular albumin handling in this model of disease. Whilst day 5 uACR 
values held no predictive value for day 10 uACR values, day 5 GSCalb 
measurements correlated significantly with day 10 uACR values (as did day 
10 GSCalb measurements). This suggested that in the early phase of this 
albuminuric model the tubules variably influenced the level of albuminuria 
seen (and available for measurement by ELISA). However, by day 10 of the 
model this system may have become damaged or saturated ensuring the 
glomerular leakage became proportional to urine albumin levels. Again linear 
correlations have been studied in figure 6.12 A, however with further data the 
relationship may not be linear. 
Figure 6-12 GSCalb day 5 predicts day 10 uACR 
Fold change GSCalb on day 5 predicts uACR values on day 10 more strongly than 
uACR values on day 5. A. Day 5 GSCalb fold change values correlate significantly 
with day 10 uACR values (R
2 
= 0.9301, Spearman test p=0.0167). B. In contrast the 
uACR values on day 5 did not correlate with the uACR values on day 10 
(R
2
=0.001577, Spearman test p=0.9500).  
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It seems likely that if the mechanisms of tubular albumin metabolism and 
reabsorption can be saturated then the initial relationship may not be linear. 
However, once saturation of, or damage to, this mechanism has occurred a 
linear relationship between GSCalb and uACR would be expected. These 
findings warrant further investigation to allow comparison of this effect in 
different mice strains and in different mouse disease models. These data 
could be very useful in wider renal research because tubular effects may 
help explain some of the strain variability seen in mice models of disease. 
	
6.1.10 Studying Changes to the glomerular glycocalyx 
Following 10 days of salt and aldosterone exposure, the glomerular 
glycocalyx thickness and florescence intensity had both fallen significantly 
compared to time matched control mice. These data suggested that the 
number of sialic acid residues within the glycocalyx had been significantly 
depleted in response to salt and aldosterone (figure 6.13 A) and that the 




Figure 6-13 Peak to Peak and florescence intensity measures of 
glomerular glucocalyx on day 10 
After 10 days exposure to salt and aldosterone the glomerular endothelial 
glycocalyx bound significantly less FITC-WGA and was significantly thinner. A. The 
normalised peak FITC-WGA signal intensity across glomerular capillary wall was 
significantly lower in mice exposed to salt and aldosterone suggesting a reduced 
number / density of FITC-WGA binding sites (Mann-Whitney p=0.0079). B. Peak to 
peak analysis confirmed that the glomerular endothelial glycocalyx was significantly 
thinner following 10 days exposure to salt and aldosterone (T-test p=0.0013 ) ✔ salt 
+ aldosterone = 1% NaCl in drinking water (ad libitum) and 0.6µg/g/day aldosterone 
delivered s.c. via minipump ✖ salt and aldosterone = standard drinking water (ad 
libitum) and vehicle (ethanol saline) filled minipump.  
	
6.1.11 C57 BL/6 mice summary 
Young male C57 BL/6 mice proved to be much better suited to glomerular 
multiphoton microscopy. The use of titanium windows in this mouse strain 
was possible due to the increased frequency of superficial glomeruli. The use 
of titanium windows made re-finding the same glomeruli much easier on day 
5 and day 10 because it provided a fixed field of view and a reference point 
from which to map the location of the glomeruli. 
Young male C57 BL/6 mice given salt and aldosterone continued to gain 















































developed significant albuminuria after 5 days of salt and aldosterone 
compared to time match controls, and this effect remained significant at day 
10. Again the GSCalb markedly increased from day 0 to day 5. Interestingly 
the level of glomerular albumin leakage on day 5 (illustrated by the day 5 
GSCalb measurement) predicted the day 10 uACR values of individual mice. 
In contrast day 5 uACR values held no predictive value for day 10 uACR 
values. Again these data support a variable level of tubular albumin handling 
early on in this model. And this effect warrants further investigation. 
Measurement of the glycocalyx thickness peak florescence intensity on day 
10 confirmed that exposure to salt and aldosterone resulted in glomerular 
endothelial glycocalyx damage. Both measures of the glycocalyx were 
significantly reduced in mice exposed to salt and aldosterone compared to 
time matched controls. Having established that salt and aldosterone caused 
albuminuria in C57 BL/6 mice and glycocalyx damage, the next series of 
experiments were designed to study the protective value of MMP2 and 
MMP9 inhibition in this model.  
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Can MMP 2 and 9 inhibition protect the glomerular 
endothelial glycocalyx in vivo? 
Having established that C57 BL/6 mice developed albuminuria and increased 
GSCalb values by day 5 the imaging protocol was adapted to optimise the 
measurement of glycocalyx thickness. To achieve this FITC-WGA imaging of 
the glomerular endothelial glycocalyx was performed on days 0 and 5 only. 
Previously FITC-WGA was only used on day 10, however a number of 
images (5 glomeruli) had to be excluded from analysis at this stage because 
the glomerular depth was too great to generate clear florescence peaks. The 
use of FITC-WGA on day 0 enabled me to measure how the glycocalyx 
changed in response to salt and aldosterone in the same glomeruli. Due to 
the increased duration of each imaging session using FITC-WGA, mice were 
only imaged twice. Blood pressure was still measured on day 12 following 5 
days training as previously.  
All mice in this series received 1% NaCl drinking water and 0.6µg/g/day 
aldosterone with a daily intraperitoneal (IP) injection of MMP2/9 inhibitor 
(5mg/kg) or vehicle (DMSO (0.05%) saline (0.9%)). 
	
6.1.11.1 MMP2/9 inhibitor did not alter blood pressure 
In mice receiving salt and aldosterone, 12 days of daily MMP2/9 inhibitor did 




Figure 6-14 MMP2/9 inhibitor did not alter blood pressure but did 
significantly reduce albuminuria and GSCalb 
A. The systolic blood pressure of mice exposed to salt and aldosterone for 12 days 
was unaltered by MMP2/9 inhibitor (T-test p=0.4385). B. Mice in both groups gained 
significant weight, however mice receiving MMP2/9 inhibitor were significantly 
heavier by day 10 (ANOVA p=<0.0001, Tukey’s analysis at day 10 p=0.0006). C. 
uACR values increased significantly in mice receiving salt, aldosterone and vehicle 
by day 5. No significant change was detected in mice receiving salt, aldosterone 
and MMP2/9 inhibitor. Baseline comparison was not significant, but comparison on 
day 5 confirmed that mice receiving salt, aldosterone and MMP2/9 inhibitor had 
significantly lower uACR levels (ANOVA p=0.0010, Tukey’s analysis displayed). D. 
Mice receiving salt, aldosterone and MMP2/9 inhibitor had significantly lower GSCalb 
fold change values by day 5 compared to mice receiving salt, aldosterone and 
vehicle. (Mann-Whitney p=0.0079) ✔ salt + aldosterone = 1% NaCl in drinking water (ad 
libitum) and 0.6µg/g/day aldosterone delivered S.C. via minipump ✖ salt and aldosterone = 
standard drinking water (ad libitum) and vehicle (ethanol saline) filled minipump. ✔ MMP2/9i 
= 5mg/kg I.P. daily, ✖ MMP2/9i = daily vehicle (DMSO saline).  
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6.1.11.2 Weight changes following MMP2/9 inhibitor 
The mice that received MMP2/9 inhibitor were significantly heavier by day 10 
than matched controls (figure 6.14 B). Interestingly the mice treated with 
MMP2/9 inhibitor were also heavier than the control mice from the previous 
series (although these mice did not receive a daily IP injection and so this 
information should be interpreted with caution). Kidney weights were also 
heavier in the mice treated with MMP2/9 inhibitor, but this effect was not 
significant when kidney weight was adjusted for mouse body weight. 
	
6.1.12 MMP2/9 inhibitor prevented the development of albuminuria 
Mice receiving MMP2/9 inhibitor did not develop albuminuria (no significant 
increase in uACR from baseline values) by day 5 (figure 6.14 C). 
Comparison between the groups on day 5 confirmed that MMP2/9 inhibitor 
had significantly reduced the urinary albumin creatinine ratio. 
	
6.1.12.1 The GSCalb did not increase in mice treated with MMP2/9 
inhibitor 
After 5 days of salt and aldosterone the GSCalb had not changed significantly 
from the baseline value in mice receiving MMP 2/9 inhibitor (figure 6.14 D). 
These data suggested that the prevention of albuminuria was due to reduced 
glomerular albumin leakage and not increased tubular uptake or metabolism. 
The mice given salt, aldosterone and vehicle in this series did have a 
significant increase in GSCalb (figure 6.14 D). In addition comparison of the 
two groups on day 5 confirmed MMP2/9 reduced glomerular albumin leakage 
in this model (figure 6.14 D).  
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The vehicle treated mice in this series had a smaller increase in GSCalb than 
expected. In the previous series the GSCalb had increased 5.1 fold +/- 0.99 
after 5 days of salt and aldosterone. In contrast in this series the fold change 
was only 2.6 fold +/- 0.35. Statistical comparison of the two groups however 
was not significant (Mann-Whitney p=0.056). This variation could therefore 
be attributed to chance and the relatively small sample sizes necessitated by 
the complexity of the protocols used. However the daily IP injection of vehicle 
or the use of FITC-WGA during the imaging protocol on day 0 may have had 
an effect. For this reason in a limited series of glomeruli (day 5 salt, 
aldosterone and vehicle) I also re-measured GSCalb on images taken after 
the bolus of FITC-WGA to see if there was a direct, measurable effect from 
WGA. However, within this time frame WGA did not alter the GSCalb (N=6 
glomeruli, fold change following WGA = 1.03 Wilcoxon-matched pairs NS) 
making a significant influence from WGA unlikely in this series. It would be 
interesting to repeat this series to see if the daily saline and DMSO (0.05% 
vehicle) injection was having an effect or if this variability was due to random 
variation and the small sample size. 
	
6.1.13 MMP2/9 inhibitor preserved the glomerular endothelial 
glycocalyx 
Whilst imaging the glomeruli of mice on day 5 of the protocol it became clear 
that MMP 2/9 inhibitor had preserved the glomerular endothelial glycocalyx. 
A weak FITC-WGA signal was still visible in select glomeruli in MMP2/9 
inhibitor treated mice from 5 days previously. I had not seen this 
phenomenon during any of my validation experiments and no signal was 
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visible in mice that had not received MMP2/9 inhibitor. Following the bolus of 
FITC-WGA on day 5 the glomerular FITC-WGA signal in mice given MMP2/9 
inhibitor was very bright, with no visible difference in the signal strength from 
that seen on day 0. Representative images are shown in figure 6.15 
highlighting the glycocalyx destruction seen following salt and aldosterone 
and the preserved glycocalyx of mice treated with MMP2/9 inhibitor. 
 
Figure 6-15 Representative images of the same glomeruli on day 
0 and 5 of salt and aldosterone +/- MMP2/9i 
Representative images of the same glomeruli at day 0 and day 5 with FITC-WGA 
labelled glomerular glycocalyx (green) and circulating Alexa Flour 594 albumin 
labelled plasma (red). All mice were given 1% NaCl (drinking water) and 
0.6µg/g/day aldosterone (via subcutaneous mini-pump). Half the mice received an 
additional daily intra-peritoneal injection of MMP 2/9 inhibitor (5mg/kg) and half the 
mice received an equivalent daily vehicle injection (DMSO saline). All images were 





Figure 6-16 MMP2/9 inhibitor increased glycocalyx fluorescence 
intensity and maintained glycocalyx thickness 
A. Quantitative analysis of FITC-WGA fluorescence intensity confirmed MMP2/9 
inhibition preserved the endothelial glycocalyx (Mann-Whitney p=0.0079). B. Peak 
to peak measurement of glomerular endothelial glycocalyx depth demonstrated a 
significant thinning of glycocalyx during the first 5 days exposure to salt and 
aldosterone. In the presence of MMP2/9 inhibitor no trend was observed (ANOVA of 
paired data p=0.0033, Sidak's multiple comparison test displayed). Time matched 
comparison between the groups on day 0 confirmed no difference in baseline 
values, comparison on day 5 confirmed MMP2/9 inhibitor significantly increased 
glycocalyx depth in mice exposed to salt and aldosterone. (ANOVA of unpaired data 
p<0.0001, Sidak’s multiple comparison test displayed) ✔ salt + aldosterone = 1% 
NaCl in drinking water (ad libitum) and 0.6µg/g/day aldosterone delivered S.C. via 
minipump ✖ salt and aldosterone = standard drinking water (ad libitum) and vehicle 
(ethanol saline) filled minipump. ✔ MMP2/9i = 5mg/kg I.P. injection once daily, ✖ 
MMP2/9i = daily vehicle (DMSO saline).  
	
6.1.13.1 Quantifying glycocalyx preservation 
Analysis of the glycocalyx using florescence intensity measurements and 
peak to peak analysis confirmed that salt and aldosterone damaged the 
glycocalyx relative to baseline analysis (figure 6.16). Fluorescence intensity 
fell in the same glomeruli (0.6 fold change) between day 0 and day 5 in the 
absence of MMP2/9i (Mann-Whitney P=0.0079). However in the presence of 
MMP2/9 inhibitor the glycocalyx florescence intensity actually increased (1.8 
fold change) over the 5 days (Mann-Whitney P=0.0079) despite salt and 
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aldosterone exposure. Comparison of between the groups on day 5 
confirmed that MMP2/9 inhibitor significantly increased glomerular glycocalyx 
florescence intensity (figure 6.16 A). 
 
Peak to peak analysis suggested that the glycocalyx became significantly 
thinner over the 5 days in the absence of MMP2/9 inhibitor, however no 
detectable change in the glycocalyx thickness occurred in the presence of 
MMP2/9 inhibitor (figure 6.16 B). Comparison between the groups on day 5 
confirmed that mice that had received MMP2/9 had a significantly thicker 
glycocalyx after 5 days exposure to salt and aldosterone (figure 5.16 B). 
	
6.1.14  Changes in glomerular endothelial glycocalyx thickness predict 
changes in the GSCalb  
The use of FITC-WGA during the imaging protocol on day 0 and day 5 
allowed a fold change value to be calculated for the peak to peak glycocalyx 
thickness. In a total of 6 mice GSCalb and peak to peak analysis could be 
performed in at least one glomeruli on day 0 and day 5 (the same glomerulus 
was found and imaged twice within the time cut-offs of the protocol (before 
and after FITC-WGA) on day 0 and day 5).  
 
When this data was compared to the GSCalb fold change data, a strong 
correlation was evident (figure 6.17). Comparison of this data with the data 
generated during the validation experiments using hyaluronidase to remove 
the glycocalyx suggests a very similar relationship (hyaluronidase series 




Figure 6-17 Correlation between GSCalb and peak to peak 
glycocalyx thickness 
At least 1 glomerulus was imaged from 6 mice on day 0 and day 5 for both GSCalb 
(within 30 minutes of anaesthesia) and following FITC-WGA, allowing a fold change 
GSCalb and a fold change peak to peak glycocalyx thickness to be calculated. Fold 
change GSCalb and fold change glycocalyx thickness (within individual glomeruli) 
correlate significantly (R
2
=0.8185, Spearman R p=0.0028). Interestingly the 
correlation between these data sets is very similar to the correlation seen in the 
series of experiments where hyaluronidase was infused acutely into C57 BL/6 mice 
to specifically remove the glycocalyx (illustrated by the red line, data previously 
presented in figure 6.8). 
	
	 	






















Data form hyaluronidase experiments
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Discussion  
Young male mice from the DBA2J and C57 BL/6 strains developed 
albuminuria in response to salt and aldosterone. In DBA2J and C57 BL/6 
mice after 10 days of salt and aldosterone uACR values had significantly 
increased from baseline values. The increase in urinary albumin was not 
associated with, or the result of, a detectable increase in systolic blood 
pressure.  
Multiphoton images allowed me to monitor how the GSCalb altered in both 
mouse strains. This measure enabled me to isolate changes occurring within 
the glomerulus from alterations in tubular albumin handling (which would 
affect uACR values). In DBA2J mice the mean fold change in GSCalb was 6.5 
+/- 0.99 by day 5. In C57 BL/6 mice the mean fold changes were 5.1 +/- 0.98 
by day 5 and 7.7 +/- 2.1 by day 10. Comparison between the two mouse 
strains was not statistically significant suggesting both mouse strains 
responded similarly in this model. The use of hyaluronidase to validate the 
glycocalyx measurements and the GSCalb has also provided further 
convincing evidence that the glycocalyx directly contributes to the filtration 
barrier. 
The GSCalb markedly increased between day 0 and 5 in mice receiving salt 
and aldosterone. However uACR values over the same period in the same 
mice did not increase at the same rate. These data suggest that tubular 
albumin handling may influence the final uACR at this early time point. The 
GSCalb values on day 5 strongly predicted day 10 uACR but did not correlate 
with day 5 uACR values. Day 10 GSCalb and uACR data also correlated 
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strongly. Together these data suggest that early on in the model the renal 
tubules can partially compensate for the increased rate of glomerular albumin 
leakage. However by day 10 this mechanism / mechanisms have become 
damaged or saturated resulting in a close correlation between glomerular 
albumin leakage and the final uACR. Other groups have examined the ability 
of the proximal tubules to influence albumin excretion. Dr Bruce Molitoris has 
worked extensively in this field and published multiple reviews on the 
subject.141,344 Their work suggests that the albumin overload model of 
albuminuria is dependent on alterations in tubular uptake of albumin – with 
no detectable increase in GSCalb seen in this model.344 In addition they have 
shown in a podocyte specific diphtheria toxin model that tubular albumin 
uptake increases in response to increased glomerular leakage.344 Whilst the 
absolute GSCalb figures given for control rats are surprisingly high in their 
work, my method using fold changes in GSCalb and serial imaging of 
individual glomeruli also suggested that tubular albumin uptake can 
dramatically alter the final uACR value in rodents. Evidence for damage to 
these uptake and clearance systems has also been published. Studying 
diabetic OVE26 mice 3 days after the injection of fluorescently labelled 
albumin demonstrated retention of the injected albumin in diabetic mice 
tubules – a phenomenon that was not seen in control mice.165 They also 
found that albumin retention was linked with tubular cell damage and death, 
suggesting that chronic albumin leakage will result in tubular injury unless 
adaptations occur.165  
Overall I think these data indicate that normal uACR values in mice and rats 
should be interpreted with caution, especially in short protocol disease 
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models. Whether tubular albumin handling is having such a significant impact 
in human disease has not been investigated. However if human tubular 
albumin uptake is significant, these data suggest that we as clinicians may 
miss early glomerular disease if we rely solely on urine albumin testing. 
The depth of glomeruli by day 10 prevented glycocalyx assessment in 
DBA2J mice. From the first series of experiments in C57 BL/6 mice it was 
however clear that the glomerular endothelial glycocalyx was significantly 
damaged by day 10 of salt and aldosterone compared to controls. In the final 
series of experiments (using the MMP2/9 inhibitor) baseline glycocalyx 
assessment allowed me to study changes with time / salt and aldosterone in 
the same glomeruli. These data confirmed that salt and aldosterone caused 
glycocalyx damage by day 5. Of the two glycocalyx measures, normalised 
florescence intensity changed more than the peak to peak measurement. 
Following 5 days of salt and aldosterone, the normalised fluorescence 
intensity fell to 0.56. In contrast the normalised florescence intensity 
increased 1.8 fold in exposed mice where MMP2/9 inhibitor was given. The 
peak to peak measurement fell 0.69 fold and increased 1.2 fold in the same 
mice. These data may indicate that the density of FITC-WGA binding sites 
may change more dynamically than the thickness of the structure. I found 
that the peak to peak measurements correlated more strongly with GSCalb 
than the florescence intensity measurements in the same glomeruli. These 
data suggested that the GSCalb might be more dependant on the depth of the 
glycocalyx than the number or density of sialic acid residues available to bind 
FITC-WGA within the structure. 
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Preservation of the glycocalyx using MMP2/9 inhibitor was associated with 
the prevention of the development of significant albuminuria or an increase in 
GSCalb by day 5. To my knowledge only one study using MMP inhibition in 
renal disease has been published. This is surprising given the number of 
clinical observational studies suggesting that MMP levels can predict the 
progression or development of renal disease.345 However, MMP inhibition 
with low dose doxycycline was effective in a rat ischaemia reperfusion model 
of renal disease preventing reactive polyuria and kidney injury from 
developing.346  
 
As discussed previously the GSCalb measurement on day 5 in the mice 
receiving salt, aldosterone and vehicle in the MMPi series appeared to be 
lower than the level measured in the earlier work. It seemed unlikely that the 
daily IP injection of DMSO saline would reduce the GSCalb and so this 
variation may have been due to random variation of the mice sampled (which 
was not excluded by the statistical comparison). An alternative possible 
explanation was that the FITC-WGA given on day 0 reduced the GSCalb 
measurement on day 5 in controls. WGA has been shown to reduce albumin 
leakage from micro vessels and glomeruli following a pathological insult, 
however the doses used in that study were much higher than those used in 
this study.160 In my study there was no evidence of persistent FITC-WGA 
within the glycocalyx on day 5 in mice that had not received MMP2/9 inhibitor 
(no detectable peak for florescence intensity measurement or peak to peak), 
so minimal WGA remained attached to the glycocalyx at the time of imaging 
for GSCalb. In addition no acute change in the GSCalb was detectable 
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following WGA administration. These data suggest that the use of WGA on 
day 0 was not responsible for the trend towards a lower GSCalb in this series, 
however a delayed effect cannot be excluded. 
In summary multiphoton microscopy confirmed that the albuminuria seen in 
this model was due to increased glomerular albumin leakage, but the level of 
albuminuria was modulated by the tubules initially. The systolic blood 
pressure of mice did not change in this model. Although localised glomerular 
hypertension cannot be excluded it seems likely that the increased albumin 
leakage was due to damage to the GFB. The glycocalyx on the surface of the 
GEnC is damaged in this model and the degree of damage correlates 
strongly with glomerular albumin loss suggesting the two are linked. Although 
causality cannot be proven directly in this model, targeted glycocalyx removal 
using hyaluronidase had a comparable effect. Inhibition of the gellatinases 
MMP2 and 9 prevented glycocalyx damage and albuminuria suggesting that 




7 Investigating	 MR-mediated	 glycocalyx	 damage	 in	
diabetic	nephropathy	
In vitro I have shown that spironolactone prevented the loss of glycocalyx 
components associated with MR activation. To expand this work we decided 
to study if the effectiveness of MR blockade in diabetic nephropathy was due 
to its ability to protect the glomerular endothelial glycocalyx. The data 
presented below are from provisional work conducted to investigate this 
possibility. As discussed in the methods section a rat model of type-1 
diabetes (STZ model) was chosen for this work. As stated previously Dr 
Joanne Ferguson (an academic F2 doctor) under the supervision of Dr 
Simon Satchell and myself performed much of the work presented in this 
chapter. 
  
Investigating the phenotype of the STZ-rat model 
Diabetic rats did not develop hypertension during the duration of this study. In 
addition, spironolactone did not reduce the blood pressure of diabetic rats 
(figure 7.1 A). Rats rendered diabetic by STZ gained weight more slowly than 
vehicle injected control rats, but spironolactone did not affect the rate of 




Figure 7-1 The rat phenotype following STZ +/- spironolactone 
therapy 
A. Central systolic blood pressure, measured under anaesthesia from the right 
carotid artery, did not vary across the groups (ANOVA, n=3 p=0.8253). B. The rate 
of increase in body weight was reduced in diabetic rats. C. The uPCR in control rats 
(non diabetic rats) increased significantly from week 0 to week 4 of the study but no 
further rise was detected. (ANOVA p=<0.0001, Tukey’s analysis displayed). D. The 
uPCR increased significantly in diabetic rats and did not alter significantly following 
3 weeks of daily vehicle injection (ANOVA p=0.0065, Tukeys analysis displayed). E. 
Again the uPCR increased significantly in diabetic rats before treatment with 
spironolactone started (week 4). Following 3 weeks of daily spironolactone uPCR 
levels fell significantly. (ANOVA p=<.0001, Tukey’s analysis displayed). F. uPCR 
values in individual diabetic rats treated with spironolactone, illustrating the reversal 
of proteinuria in the subgroup with nephropathy. ✔ Diabetes = 50mg/kg STZ I.P. 
administered week 4 and diabetes confirmed (blood glucose level >16mmol/l) ✖ 
Diabetes = vehicle injection I.P. week 4. ✔ Spironolactone = 50mg/kg S.C once 
daily from week 4-7, ✖ Spironolactone = daily S.C. vehicle injection (corn oil)). 







In all rats the urine protein creatinine ratio (uPCR) increased from week 0 to 
week 4 (figure 7.1 C-E). However, in diabetic rats the uPCR increase was 
approximately 2 fold higher. In control rat’s uPCR values stabilised after 
week 4 with no further rise seen (figure 7.1 C). In untreated rats the mean 
uPCR value continued to increase from week 4 (42 mg/mMol) to week 7 
(47mg/mMol) although the increase was not statistically significant. In 
contrast following the initiation of spironolactone at week 4 the uPCR values 
of treated rats fell significantly from week 4 (44 mg/mMol) to week 7 (21 
mg/mMol) (figure 7.1 D). Studying the variations in uPCR seen in individual 
rats in this group gave me an additional insight into how rats responded to 
spironolactone treatment. The three rats in this group that had developed 
significant proteinuria were those that benefitted most from the 
spironolactone therapy. Spironolactone also prevented any new rats from 
developing significant proteinuria (figure 7.1 F).  
 
The high degree of heterogeneity in uPCR levels is well recognised in STZ 
models of diabetic disease.169 In this series the heterogeneity occurred 
despite all rats becoming diabetic. The high level of variation seen in this 
group suggested that larger group sizes were needed to generate statistically 
significant data with the current protocol. In the future increasing the duration 
of the study may also help to generate more congruous data, but to allow 
more prolonged administration of spironolactone an alternative delivery 




7.1.1 Rat glomerular RNA analysis 
Glomeruli were sieved from the renal cortex at the time of culling and mRNA 
extracted using the column method. Again gene targets were selected based 
on our hypothesis that MR inhibition may be effective in diabetic nephropathy 
because it preserved the glycocalyx (Figure 7.2). 
	
Figure 7-2 Rat glomerular mRNA analysis 
Analysis of rat glomerular mRNA suggested a trend towards increased syndecan 4 
and MMP2 expression. Again there was a significant correlation between the 
expression of these molecules. A. qPCR analysis of RNA extracted from rat 
glomeruli suggests a trend (ANOVA not significant) towards increased expression of 
syndecan 4 (p=0.2970 ) and MMP 2 (p=0.3936 ) in diabetic animals, with reversal of 
this trend in the presence of spironolactone. Power calculations suggest however 
that a further 4 rats (syndecan 4) 8 (MMP2) rats would be needed in each group to 
reach significance. B. The expression of glomerular syndecan 4 and MMP2 
correlate significantly R
2
=0.8031, Pearson test p=<0.0001. ✔ Diabetes = 50mg/kg 
STZ I.P. administered week 4 and diabetes confirmed (blood glucose level 
>16mmol/l) ✖ Diabetes = vehicle injection I.P. week 4. ✔ Spironolactone = 50mg/kg 





No significant trend was seen in changes in MMP 9 and so work focussed on 
MMP 2 and syndecan 4 (figure 7.2). The high level of variability seen 
between rats in this model left the analysis underpowered. Trends appeared 
to be developing however, that suggested that; glomerular syndecan 4 
mRNA was increasing in response to diabetes, and that this effect was 
prevented by spironolactone. In addition MMP2 mRNA appeared to be 
increasing in diabetic rats and again seemed to be suppressed by 
spironolactone. Despite the lack of significant data when analysed 
individually, MMP2 and syndecan 4 expression within individual rats 
correlated significantly suggesting they may interact or be co-regulated. 
Following power calculations further rat work has been planned. At this stage 
tissue will be collected for MMP activity analysis and plasma and urine 
collected for syndecan 4 ectodomain ELISAs to help study this pathway in 





Figure 7-3 Glomerular albumin permeability increases in 
diabetes, but not in the presence of spironolactone 
Untreated diabetic rat glomeruli have an increased permeability to albumin A. The 
distribution of recorded albumin permeability from individual glomeruli sieved from 
the kidneys of control, diabetic and spironolactone treated diabetic rats. B. Analysis 
of data averaged for each rat. Diabetic rats had significantly increased glomerular 
albumin permeability. Diabetic rats treated with spironolactone had no increase in 
glomerular albumin permeability relative to controls and had a significantly lower 
permeability compared to untreated diabetic rats (ANOVA p=0.0008, Tukey’s 
analysis displayed.) ✔ Diabetes = 50mg/kg STZ I.P. administered week 4 and 
diabetes confirmed (blood glucose level >16mmol/l) ✖ Diabetes = vehicle injection 
I.P. week 4. ✔ Spironolactone = 50mg/kg S.C once daily from week 4-7, ✖ 
Spironolactone = daily S.C. vehicle injection (corn oil)).  
	
7.1.2 Diabetes increased rat glomerular albumin permeability 
To confirm that the alterations in uPCR were due to changes in glomerular 
albumin permeability an ex-vivo glomerular albumin permeability assay was 
used.152 The permeability to albumin of sieved individual glomeruli from each 
group are displayed in figure 7.3 A. No statistics have been applied to the 
data gathered from individual glomeruli but figure 7.3 A illustrates the 
distribution of permeability values. When these data are combined to 
generate mean values for each rat statistics can be applied (figure 7.2 B). 
Diabetes resulted in a dramatic increase in glomerular albumin permeability, 
which was prevented by spironolactone. No difference could be detected 
between the albumin permeability of glomeruli from control rats and diabetic 
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rats treated with spironolactone. These data suggested that the recovery of 
uPCR values seen in the spironolactone treated rats were due to reduced 
glomerular albumin leakage rather than altered tubular protein handling. 
	
Developing an ex vivo method to assess the 
glomerular endothelial glycocalyx 
At the time of culling, rats that were not used for the glomerular albumin 
permeability assay were infused with alcian blue to fix and label the 
glomerular glycocalyx for electron microscopy. Dr Joanne Ferguson and 
myself have subsequently taken a limited number of EM images and 









Figure 7-4 Electron microscopy of the rat filtration barrier 
A. A representative image of the GFB from an untreated diabetic rat. Minimal 
glycocalyx cover is seen on the endothelial cells surface B. A representative image 
of the GFB from a spironolactone treated diabetic rat. Glycocalyx is seen within the 
fenestrations and over the endothelial cell surface. 
 
In figure 7.4 the vessel lumen lies on the right hand side of the filtration 











by the presence of podocyte glycocalyx labelling. The glycocalyx is the ‘fluffy’ 
staining over the top of the endothelial cells and filling the fenestrations of the 
spironolactone treated rat (figure 7.4 B). The diabetic glycocalyx appears 
less uniform and does not fill the fenestrations (figure 7.4 A). These findings 
warranted further investigation however electron microscopy has several 
drawbacks. The glycocalyx offers little resistance to the passage of electrons 
and so a secondary label has to be used. Alcian blue has been commonly 
used for this purpose however considerable batch variation exists making 
comparisons difficult. Alcian blue solution is also prone to precipitating in the 
microcirculation preventing the perfusion of the glomerular microvasculature. 
These factors and the considerable delays and costs associated with EM 
imaging made me seek an alternative method to quantify endothelial 
glycocalyx on ex-vivo specimens. 
 
7.1.3 Rat glomerulus lectin panel  
As discussed previously lectins have the ability to bind to specific substrates 
contained within the glycocalyx. To find a lectin that selectively bound to the 
glomerular endothelial glycocalyx in rats a panel of lectins were trialled by Dr 
Joanne Ferguson and myself. 
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Figure 7-5 Lectin Panel 
Multiple lectins were trialled in an attempt to find a lectin that adhered to the 
glomerular endothelial glycocalyx in PFA fixed rat renal cortex. The MOA lectin 
staining pattern appeared to be specific, labelling endothelial cells surface with no 
apparent basement membrane staining in initial screens.  
	
Initial screens were performed on a selection of lectins (representative 
images are shown in figure 6.5). Glomerular capillary endothelial cell staining 
produces complete circular labelling around each vessel. In contrast, GBM 
staining produces continual lines of lectin labelling. MOA lectin was selected 
for further staining after images were shown to have very specific endothelial 
labelling on the luminal aspect of endothelial cells (luminal to DAPI stained 
endothelial nuclei). This position, and the known MOA lectin binding site 
(Galα1, 3Gal/GalNAc)347 were consistent with glycocalyx staining.  
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7.1.4 Total glomerular MOA florescence intensity was confounded in 
diabetic nephropathy 
The first method used in an attempt to quantify the MOA lectin staining was 
whole glomerulus florescence intensity. This method has the advantage of 
being relatively simple to perform using image J analysis software and so it 
was included in a medical student project that I supervised. In this project 
Anna Ogier used a free-hand ROI tool to outline the glomeruli on images and 
then normalised the recorded florescence intensity to the background value 
(measured within the Bowman’s space). Blinded analysis using this method 










Figure 7-6 Glomerular fluorescence intensity 
A. Grey scale image of a glomerulus labelled with FITC-MOA. Each glomerulus was 
outlined manually before the florescence intensity was measured and normalised to 
the background (within the Bowman’s capsule) B. Total glomerular fluorescence 
intensity did not vary significantly in the three groups tested (ANOVA p=0.0605) C. A 
high magnification colour image of glomerular capillaries labelled with FITC-MOA 
(green), R18 (red membrane label) and DAPI (nuclei label). Scale bar = 10µm. D. A 
grey scale image of the FITC-MOA signal in isolation from the same capillary loops. 
Images C and D illustrate the confounding effect that erythrocytes within the 
capillaries had on total floursecence calculations. Empirically diabetic glomeruli had 
increased numbers of adherent erthrocytes, which were likely to have confounded 
this form of analysis.  
B	
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The images presented in figure 7.6 highlight the confounding effect that 
adherent erythrocytes had on this form of analysis. The erythrocytes of non-
primates also express	Galα1, 3Gal/GalNAc on their surface.347 This can be 
clearly seen in the images in figure 7.6. At the time of culling the rats kidneys 
were removed without flushing the circulation of blood cells. Unexpectedly 
diabetic glomeruli appeared to contain more erythrocytes than control rat 
kidneys. The reasons for this are unclear, however the additional 
erythrocytes confounded this form of analysis rendering it inappropriate for 
on-going use. In addition it was noted that the diabetic rats, with polyuria, had 
an expanded Bowman’s capsule. This resulted in the background 
florescence intensity measurements being significantly lower in diabetic 
animals, again confounding the data generated.	
	
7.1.5 Peak to peak analysis of ex-vivo glomeruli 
Having used peak to peak analysis on my multiphoton images I believed this 
was the most reliable way to assess glycocalyx depth on images. Dr Joanne 
Ferguson and myself therefore worked on a labelling protocol to allow us to 
use the membrane label octadecyl rhodamine B chloride (R18), the nuclear 
label 4’,6-diamidino-2-phenylindole (DAPI) and MOA-lectin on PFA fixed, 
wax embedded tissue. The protocol we developed is outlined in the methods 
section. Using this method we were able to reliably label the glomerular 
glycocalyx and the endothelial cell membrane enabling us to measure the 
glycocalyx thickness in sections. A typical glomerular image is illustrated in 
figure 7.7 A. The MOA lectin is shown in green, R18 membrane label is red 
and nuclear staining with DAPI is shown in blue. The colour channels can be  
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Figure 7-7 Peak to peak analysis on PFA fixed glomerular 
sections 
A. A representative image of a PFA fixed  (spironolactone treated) rat glomerulus 
labelled with R18, FITC-MOA and DAPI. (line = 7.5µm). To ensure glycocalyx depth 
was only measured at 90° to the cell membrane only round capillary loops were 
included in analysis B. Isolated FITC-MOA signal from the same glomerulus, 
illustrating the endothelial pattern of FITC-MOA labelling. C R18 signal localised to 
cell membranes. D. A magnified image of a sectioned glomerular capillary 
(ROI=8.4µm long). E The resulting ROI intensity profiles for MOA and R18, left hand 
peaks separated by 0.42µm, right hand peak separated by 0.49µm. 
 
separated to highlight the staining patterns of the individual components 
(figure 7.7 B and C), this also facilitates operator blinding when placing linear 
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ROIs perpendicular to the endothelial membrane. ROIs were placed using 
only the red channel to locate suitable vessels without knowing the state of 
the lectin staining at that site. Line profiles were then generated for both 
channels. Data were included for analysis provided clear peaks were visible 
in both channels. The line profiles produced confirmed that MOA lectin binds 
to the luminal aspect of the endothelial cell membrane (figure 7.7 D and E). 
Using this method I performed blinded analysis of sections from all available 
rats. In total 431 capillary loops were measured from 82 different glomeruli 
(figure 7.8 A). When these data were analysed as mean values for each 
individual rat (figure 7.8 B) significant differences in the glomerular glycocalyx 
depth were evident between the groups. Untreated diabetic rats had a 
significantly thinner glycocalyx than time matched control animals.  
	
Figure 7-8 Peak to Peak analysis of glomeruli and individual rats 
A. The distribution of glycocalyx peak to peak measurements in individual glomeruli. 
B. Peak to peak data aggregated into averages for each rat. Diabetic rats had 
significantly thinner glycocalyx coverage on glomerular endothelial cells relative to 
controls and spironolactone treated rats. There was no detectable difference in the 
glycocalyx thickness between controls and diabetic rats treated with spironolactone. 
(ANOVA P<0.0001, Tukey’s analysis displayed) . ✔ Diabetes = 50mg/kg STZ I.P. 
administered week 4 and diabetes confirmed (blood glucose level >16mmol/l) ✖ 
Diabetes = vehicle injection I.P. week 4. ✔ Spironolactone = 50mg/kg S.C once 
daily from week 4-7, ✖ Spironolactone = daily S.C. vehicle injection (corn oil).  
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In contrast spironolactone treated rats trended towards having a glycocalyx 
that was thicker than control rats and was significantly thicker than untreated 
diabetic rats.	
These data suggest that MR inhibition can preserve the glomerular 
endothelial glycocalyx in diabetic models of disease suggesting that 
glycocalyx preservation may be one mechanism through which MR blockade 





Overall the increased heterogeneity seen in the rat STZ model of diabetes 
tended to leave the study under powered. However it has generated useful 
provisional data that will be used whilst we plan and conduct a larger study. 
Whilst a number of authors have published that rats become significantly 
albuminuric within 7 weeks of STZ injection (with similar group sizes) we did 
not find this in our series. A number of factors may have contributed to this. 
The poor reproducibility of the albumin ELISA we had selected rendered the 
data unusable. As a result we had to use total urinary protein as our measure 
of glomerular protein leakage. This measure will be influenced by tubular 
protein secretion, which may have introduced additional variability to our 
results. STZ toxicity is dependant on the peak serum concentration and so 
individual variations in absorption of the IP injection of STZ may have 
resulted in variable pancreatic toxicity. Direct renal toxicity is unlikely to 
explain the variability seen however, because pancreatic islet transplantation 
has been shown to prevent albuminuria in this model suggesting that 
hyperglycaemia, or low insulin levels are the key pathological steps rather 
than STZ toxicity to the kidneys.313 However it is possible that alterations in 
the peak levels of STZ may have resulted in variable pancreatic injury 
potentially resulting in variable blood glucose levels. 
When this work is repeated an alternative rat albumin ELISA will be sourced 
ensuring that consistent data can be generated before it is used in the study. 
As mentioned previously, increasing the number of rats used and increasing 
the duration of treatment will may also help to generate more significant data. 
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Despite the limitations of this study we have been able to confirm that 
diabetes increased glomerular albumin permeability and that spironolactone 
prevented or reversed these changes without altering the rats systemic blood 
pressure. In agreement with our data a number of other groups have shown 
that STZ and spironolactone at the doses used in this study do not affect the 
blood pressure169 or the blood glucose levels of rats.169,348,349 Using lectin 
staining we have confirmed that the glomerular endothelial glycocalyx 
thickness is reduced in diabetic rats. These data are in agreement with a 
number of studies that have looked at the glycocalyx thickness in 
diabetes.241,350 In diabetic rats treated with spironolactone the glycocalyx 
thickness remained un-altered from control levels. Analysis of the RNA 
extracted from glomeruli suggested that syndecan 4 shedding in response to 
MMP 2 up-regulation may have played a role in the pathogenesis of this 
model. This interesting possibility should be studied further using an MMP2 
activity assay and a syndecan 4 ectodomain ELISA. 
Since this project was completed I have optimised the perfusion system used 
at the time of culling animals. Using abdominal aorta cannulation, animals 
can now be perfused systemically with a Ringer solution (+/- R18 for 
glomerular permeability assay or future IF) before the left kidney is removed. 
Subsequently alcian blue or a second perfusion fluid can be perfused into the 
remaining right kidney and systemic vasculature. This modified technique 
allows us to collect renal tissue from all the animals used in the study rather 
than having to choose between alcian blue perfusion or tissue collection, and 




Achievement of objectives and discussion of the 
hypothesis 
Having completed this project I believe I have proven my hypothesis: 
Simulation of mineralocorticoid receptors does result in the loss of key 
glycocalyx components and causes albuminuria. 
	
Summary 
Studying the effects of salt and aldosterone on conditionally immortalised 
endothelial cells allowed me to confirm that key components of the 
glomerular endothelial glycocalyx are lost following MR stimulation. 
Interestingly the presence of aldosterone (at the dose used in this study) 
alone was insufficient to cause significant glycocalyx damage. In contrast salt 
and aldosterone in combination resulted in loss of heparan sulphate and 
syndecan 4 from the cells surface. This damage had a functional impact, 
impairing cells ability to sense and respond to shear stress. Treating cells 
with spironolactone prevented the structural and functional changes to the 
glycocalyx from occurring confirming that stimulation of the MR is a key step 
in this model. 
Salt and aldosterone increased the mRNA expression of MMPs 2 and 9 in 
GEnC. Inhibition of these enzymes prevented the loss of glycocalyx 
components and restored shear sensitivity suggesting that MMP related 
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damage is a key step in this model. In two mouse strains salt and 
aldosterone delivery caused albuminuria in the absence of detectable 
hypertension. Studying the gene changes within extracted glomeruli again 
suggested that MMPs were up regulated in this model. From these data it 
was not possible to deduce the cell type within the glomerulus responsible for 
these changes, however it seems likely that endothelial cells reacted similarly 
in vivo and contributed to these changes. The up-regulation of MMP 2 or 9 
seems likely to have contributed to the significant increase in syndecan 4 
ectodomain concentrations in the urine. 
Multiphoton microscopy confirmed that the GFB of DBA2J and C57 BL/6 
mice was damaged in response to salt and aldosterone exposure. This 
damage occurred rapidly, within 5 days. However, I have shown that 
glomerular albumin leakage did not correlate with urinary albumin levels at 
day 5. The most likely explanation for this finding is that the renal tubules 
were significantly altering the final level of albumin within the urine. By day 
10, however this mechanism appeared to have become saturated or 
damaged and a significant correlation between the level of glomerular 
albumin leakage and the albumin level in urine occurred.  
Other groups have examined the ability of the proximal tubules to influence 
albumin excretion. Dr Bruce Molitoris et al have worked extensively in this 
field and published multiple reviews on the subject.141,344 My work using fold 
changes in GSCalb and serial imaging also suggested that tubular albumin 
uptake could dramatically alter the final uACR value in rodents. Evidence for 
damage to these uptake and clearance systems also exists. Studying 
diabetic OVE26 mice 3 days after the injection of fluorescently labelled 
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albumin demonstrated retention of the injected albumin in diabetic mice 
tubules – a phenomenon that was not seen in control mice.165 This replicates 
my observation that in salt and aldosterone treated mice Alexa Flour 594 
albumin was still visible within proximal tubule cells on day 10, 5 days after 
the previous injection, a phenomenon not seen in control mice. They found 
that albumin retention was linked with tubular cell damage and death, 
suggesting that chronic albumin leakage will result in tubular injury unless 
adaptations occur.165  
Overall I think these data indicate that normal uACR values in mice and rats 
should be interpreted with caution, especially in short protocol disease 
models. Whether tubular albumin handling is having such a significant impact 
in human disease has not been investigated. However if human tubular 
albumin uptake is significant it does suggest that we as clinicians may miss 
early glomerular disease if we rely solely on urine albumin testing. 
 
Direct damage to the glomerular endothelial glycocalyx with hyaluronidase 
increased glomerular albumin leakage. The increase in albumin leakage and 
the associated level of measureable glycocalyx damage correlated strongly. 
Given the short half-life and large size of hyaluronidase intravascular effects 
should predominate in this model, suggesting that glycocalyx damage may 
have caused the increased albumin leakage. It is also worth noting that the 
recovery rate for the GEnC glycocalyx in vivo was considerably faster than 
published data generated in vivo (on mouse cremaster venules) and in 
vitro.351 This may be the result of the different vascular beds studied. 
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The development and validation of new techniques to study the glomerular 
endothelial glycocalyx formed a major part of this project from the outset. The 
development of a lectin based glomerular endothelial glycocalyx 
measurement method in vivo allowed serial data to be gathered from the 
same glomeruli at multiple time points during the study. This technique 
allowed me to prove that salt and aldosterone caused glomerular endothelial 
glycocalyx thinning in vivo. This effect could be prevented by a daily injection 
of MMP2/9 inhibitor. This inhibitor preserved the glycocalyx on GEnC and 
prevented increases in glomerular albumin leakage or urinary albumin from 
occurring. 
Overall my data suggested that salt and aldosterone, via a MR dependant 
mechanism, up-regulated the gellatinases MMPs 2 and 9 resulting in 
glomerular endothelial glycocalyx damage causing albuminuria. 
 
To expand this work I tested a second hypothesis; mineralocorticoid receptor 
inhibition in diabetes preserves the glomerular endothelial glycocalyx to 
reduce albuminuria.  With the preliminary data I have gathered I have shown 
that spironolactone reduced proteinuria to normal levels in diabetic rats, 
however I was unable to gain reliable data on the level of albuminuria in 
these rats. I was able to show however that this effect was not the result of a 
change in systemic blood pressure.  
The data from the ex-vivo glomerular albumin permeability assay is 
consistent with this data. This novel assay suggested that the GFB of 
diabetic rats had an increased permeability to albumin when compared to 
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control rats. In addition when diabetic rats were treated with spironolactone 
their glomerular permeability was restored to a normal level. Analysis of the 
glomerular endothelial glycocalyx using a newly developed lectin based peak 
to peak method confirmed that the glycocalyx is damaged by diabetes and 
that spironolactone prevented glycocalyx damage. 
 
Implications of this work 
8.1.1.1 Direct clinical implications of this work 
My work in vitro suggests that MR activation, in the presence of sodium 
chloride in the high physiological range, causes endothelial glycocalyx 
damage through an MMP dependant mechanism. As discussed in the 
introduction to this thesis, high levels of aldosterone are found in a number of 
clinical conditions, including primary hyperaldosteronism,6 and secondary 
hyperaldosteronism, which occurs in a number of common conditions 
including idiopathic hypertension,61 obesity,62,63 advanced renal failure,64 
obstructive sleep apnoea61 and sleep disorder including shift work.61 Not all 
these patients will have high serum sodium chloride levels, however the 
consumption of a salty meal can transiently increase serum sodium even in 
healthy subjects by 1.5mMol/l.352 Loss of the endothelial glycocalyx could 
dramatically increase these elevations if the glycocalyx acts as a sodium 
buffer, as suggested by Oberleithner et al, exposing a large number of 
patients to potentially damaging serum sodium levels.353 Loss of the 
glycocalyx from the surface of endothelial cells has been suggested to be an 
early step in the pathogenesis of vascular disease. My work may help explain 
	 264	
why high levels of aldosterone are a risk factor for cardiac, vascular and 
renal disease progression in patients consuming a western diet high is salt. 
In addition my provisional work using spironolactone in the diabetic rat model 
has highlighted a new potential mechanism through which this drug is 
working. Preservation of the glycocalyx could help to explain many of the 
clinical benefits associated with MR blockade and this exciting finding 
warrants further investigation. 
	
8.1.2 The development of new techniques 
Studying the glomerular endothelial glycocalyx is in vivo is difficult. The 
glycocalyx structure is complex and it is shed in response to hypoxia or 
compromised perfusion.224 In contrast studying the glycocalyx in vitro is 
relatively simple, however the glycocalyx structure that develops in vitro is 
markedly thinner than the structure in vivo and the composition may 
therefore not be the same.112 
These limitations have lead to an underestimate of the importance of the 
glycocalyx within the GFB. As discussed within the introduction, selective 
knock out studies where heparan sulphate has been deleted do not result in 
albuminuria. This has led some groups to conclude that the glycocalyx plays 
a minimal role in albumin restriction across the GFB. However my work has 
shown that removal of the glycocalyx results in a rapid increase in albumin 
permeability measured by multiphoton microscopy in vivo. Simultaneously 
studying the GSCalb and uACR data for individual mice gives a unique insight 
in glomerular and tubular albumin handling. My data suggest that the renal 
tubules of mice are capable of compensating for increased glomerular 
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albumin leakage, at least in the short-term. For this reason models of disease 
that result in an isolated glomerular pathology (without inhibiting tubular 
albumin handling) may need to increase glomerular albumin leakage above a 
threshold level of tubular absorption before increases in uACR are detected. 
Specific knock out of heparan sulphate from the endothelial glycocalyx may 
not increase albumin leakage above this threshold. Work is on-going in 
Bristol using the ex vivo glomerular albumin permeability assay152 to assess 
if endothelial EXT1 knock out mice (a heparan sulphate knock out model) do 
in fact have increased glomerular albumin leakage in the absence of 
albuminuria. 
The development of a technique that allows real-time assessments of GSCalb 
and glycocalyx depth in the same glomeruli should also provide a powerful 
tool for other researchers. After extensive validation this technique has been 
shown to produce consistent accurate data and it offers great promise for the 
assessment of glycocalyx specific therapeutic options in the future. 
The development of an ex vivo method to assess the glycocalyx thickness 
within glomeruli on PFA fixed specimens also represents a valuable step 
forward. WGA lectin labels the glycocalyx when given as an infusion, 
however when used on sections considerable basement membrane labelling 
is seen. In contrast MOA lectin produces very little basement membrane 
staining and when combined with an R18 membrane label peak to peak 
measurements offer an effective way to study the glycocalyx. Since the 
development and optimisation of the protocol for this thesis a number of 
other members of our research team have started to use lectin staining. Dr 
Colin Down is using a version of this protocol on human placentas with 
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excellent results and should be able to validate the data generated against 
alcian blue gluteraldehyde fixed electron microscopy measurement from the 
same placentae. Lectin staining represents a much more user-friendly 
technique than electron microscopy and could easily be adapted to clinical 
use if an application is identified.   
 
8.1.3 Glomerular endothelial cells are aldosterone responsive 
Plasma aldosterone levels in healthy humans range between 0.05 and 
0.5nM.354 A large quantity of in vitro research has been conducted using 
much higher aldosterone concentrations; however even at a concentration of 
0.1nM I have been able to demonstrate multiple effects of aldosterone on 
conditionally immortalised GEnC. The activation of MRs by these very low 
doses of aldosterone occurs despite the presence of glucocorticoids at much 
higher doses, suggesting that GEnC may have the ability to limit 
glucocorticoid mediated MR activation. Detecting 11β HSD2 at the mRNA 
and protein level in conditionally immortalised GEnC explains this finding. 
The presence of this enzyme in GEnC has been demonstrated previously 
using immunoelectron microscopy.319 To date 11β HSD2 has also been 
demonstrated in coronary artery, aorta, umbilical vein and saphenous vein 
endothelial cells, suggesting that despite specialisation most endothelial 
subtypes may express this enzyme.355,356 In human umbilical vein endothelial 
cells knock down of 11β HSD2 was shown to exacerbate nitric oxide 
suppression in response to glucocorticoids. This effect was independent of 
the MR (spironolactone had no effect and dexamethasone had an effect 
comparable to cortisol.)38 In addition inhibition of 11β HSD2 using 
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glycyrrhetic acid in human aortic endothelial cells enhanced cortisol mediated 
activation of a mineralocorticoid response element.355 These data suggest 
that 11β HSD2 is not only present, but also active within endothelial cells and 
that its effect can potentially modulate both the glucocorticoid and 
mineralocorticoid signalling pathways.  
The co-expression of 11β HSD1 in our GEnC suggests an additional layer of 
complexity. This enzyme has also been reported to be present in other 
endothelial cell lines.357 This bidirectional enzyme can increase or decrease 
the activity of glucocorticoids, again modulating the activation of both MR and 
GR receptors. The complex interplay between these enzymes and their 
effects on MR and GR related activity warrants further investigation but were 
beyond the scope of this project. 
 
8.1.4 The importance of the endothelial MR receptor 
When examined in isolation GEnC responded to salt and aldosterone via an 
MR dependant pathway, up-regulating MMPs and shedding key components 
of the glycocalyx. The protection afforded the glomerular glycocalyx in vivo 
by MMP 2/9 inhibitor suggests that an MMP dependent pathway may also 
cause glycocalyx damage in vivo and prevention of this damage prevented 
albuminuria from developing. However endothelial specific MR knockdown 
mice were not protected from the renal damage inflicted by the DOCA salt 
model or angiotensin II infusion.177,358  
There are a number of potential explanations for this finding. FACS isolation 
of endothelial cells was performed of whole kidney lysates in the first study. 
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Whilst 80% knock down of MR was achieved within this endothelial cell 
population it is not possible to know whether the same level of knock down 
was achieved within the glomerular subpopulation of endothelial cells. With 
such high levels of DOCA being delivered in this study we do not know if the 
residual population of MR were sufficient to initiate the inflammatory 
responses seen.  
An alternative explanation to these findings is that DOCA acted via MR on 
alternative cell types. In both studies the authors have not studied changes in 
the plasma levels of MMPs. Following stimulation, cells of the immune 
system produce MMPs 2 and 9.359 Plasma levels of MMPs in diabetic 
ketoacidosis are believed to be the result of neutrophil activation.360 Both 
mononuclear and polymorphonuclear cells of the immune system express 
functional MR receptors and the presence of 11β HSD2 has been confirmed 
in neutrophils.361 To date however I am not aware of any work studying the 
effect of MR activation in neutrophils where MMP induction has been 
included as an outcome. Podocytes also express MR and 11β HSD2 and 
their close proximity to the GEnC offer another possible explanation.319 
Podocytes exposed to 100nM aldosterone up regulate heparanase mRNA 
approximately 3 fold with a 2-3 fold increase in heparanase protein at 18 
hours.176 Stimulation of this mechanism on podocytes could therefore have 
negated the glycocalyx protection afforded by endothelial MR knockdown. 
Thus damage to the glycocalyx may still have occurred as a result of 
circulating MMPs derived from the immune system and podocyte derived 
local heparanase. (The interaction between heparanase and MMPs will be 
discussed in a separate section.) 
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The last potential explanation for the findings in the endothelial MR knockout 
papers is hypertension. Endothelial MRs do not contribute significantly to the 
generation of systemic hypertension.358 As a result endothelial knockout mice 
still become hypertensive in response to angiotensin II or DOCA 
delivery.177,358 Glomerular hypertension results in a distinct inflammatory 
cascade, up regulating VECAM-1 within the glomerulus as discussed in 
chapter 4. As a result the effectiveness of MR blockade may be negated 
unless hypertension is corrected or disease models are carefully chosen to 
avoid the induction of hypertension. We have planned future work to study 
the effects of other RAAS components on the glomerulus in the absence of 
hypertension and this work will help to answer these questions. 
 
8.1.5 The interaction between heparanase and MMPs 
Heparanase is the only known enzyme capable of cleaving the heparan 
sulphate side chains; however heparanase knock out mice, unexpectedly, 
develop normally.362 This finding may be explained by the associated 
increase in MMP2 (2-3.5 fold) and MMP14 (4-7 fold) at the mRNA level. 
These data were subsequently confirmed at the protein and activity level 
where heparanase KO mouse plasma was shown to have 3 times the MMP 2 
activity compared to controls.362 Conversely cells transfected with active 
heparanase exhibited a marked suppression of MMP-2 (5.8 fold), MMP9 (6.5 
fold) and MMP14 (3 fold).362 The authors concluded that this complex 
relationship afforded a level of redundancy to these enzymes despite their 
individual and specific substrates.362 
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In addition to this direct interaction at the transcription level heparanase and 
MMPs work collaboratively in removing syndecan ectodomains.  Syndecan 1 
is similar in structure to syndecan 4, with an ectodomain that carries heparan 
sulphate side chains. The presence of these heparan sulphate side chains 
actually stabilises the ectodomain, reducing shedding.233 This effect was 
found to be due to the presence of heparan side chains inhibiting the action 
of MMPs. It is tempting to hypothesise that the presence of the highly 
charged heparan sulphate side chains inhibits the MMPs access to the 
syndecan core protein, preventing its cleavage, but this has not been 
confirmed. In summary MMPs and heparanase can alter each other’s 
expression and activity in multiple cells types and species. For this reason 
heparanase activity should be considered alongside metaloproteases activity 
when studying alterations to the glycocalyx. 
 
8.1.6 The interaction between salt and aldosterone 
As discussed previously aldosterone appears to be capable of inducing 
glomerular injury. High dose aldosterone may induce glomerular damage 
following the induction of hypertension. However my work suggests that even 
in the absence of hypertension aldosterone is still capable of inducing 
glomerular damage. Clinical studies have also shown that aldosterone 
excess conveys an increased risk of cardiovascular events and proteinuria 
even when compared to matched hypertensive controls.58,59,60 Together 
these data suggest additional mechanisms of endothelial damage are 
activated by aldosterone. The dose dependence of these hypertension-
independent pathological pathways has however not been studied. 
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I found in vitro that no measurable glycocalyx damage occurred when 
ambient sodium concentrations were maintained at 125mMol. Within other 
fields extensive work has been attempted to try to explain the interaction 
between salt and aldosterone. To date multiple pathways have been 
suggested including induction of ENaC, Rac-1 and ROS generation.97,363-365 
The discovery that GEnC express both 11β HSD1 and 2 offers an additional 
explanation. Chronic exposure (5 days) was needed in my model of salt and 
aldosterone excess to see changes in glycocalyx components. At this time 
point 11β HSD2 expression appeared to be reduced relative to time matched 
controls, whilst 11β HSD1 remained unaffected. If the reduced expression of 
11β HSD2 translated to reduced activity in this enzyme it may have left the 
MR open to activation by glucocorticoids. Additional studies are planned to 
look at the regulation of 11β HSD2 in conditionally immortalised GEnC to try 
and establish if salt exposure is reducing 11β HSD2 expression. If I can 
confirm this effect I would like to investigate if this pathway could explain why 
high sodium concentrations appear to amplify the inflammatory signals of 
autonomous aldosterone in endothelial cells. 
Although the mechanism of the interaction between salt and aldosterone has 
not been fully investigated it may have clinical relevance. The identification of 
leptin as a regulator of aldosterone production suggests that stimuli, 
independent of the renin angiotensin system may increase serum 
aldosterone levels. Leptin will not be subject to the same negative feedback 
control as RAAS stimuli. It seems likely therefore that circulating volume 
expansion and high serum sodium levels will not prevent leptin from 
increasing aldosterone production. In patients with high leptin levels the 
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scenario of high salt and high aldosterone seems more likely to occur. 
Circulating leptin levels correlate significantly with waist circumference, 
increasing with obesity.366 In these patients the presence of poorly 
vascularised fat tissue could result in very high leptin levels.367 In patients 
leptin levels have also been shown to associate with insulin resistance and 
vascular inflammation,366 whether MR inhibition would prove particularly 
beneficial in this sub group has not been studied.	
 
Future work 
8.1.7 Investigating water permeability 
Damage to the glomerular endothelial glycocalyx has been shown to 
increase water permeability.136 If water permeability increases following 
glycocalyx damage in this model then the GSCalb will always underestimate 
the quantity of albumin leakage. Applying the mathematical models of N 
Punyaratabandhu et al116 to the data I have generated using multiphoton 
microscopy allows additional information to be derived regarding water 
permeability across the GFB in this model. From my provisional calculations 
a reduction in peak to peak glycocalyx thickness of 400nM (as seen on day 5 
of salt and aldosterone) could result in a 2 fold increase in water flow. Not 
only will the increased level of water permeability lead to an underestimation 
of GSCalb (by approximately 20% for this level of glycocalyx damage), but 
also increased water flow itself may be capable of damaging the filtration 
barrier.128,129 To put this data in context, acute uninephrectomy results in a 
1.9 fold increase in water flow at 20 days and following 6 weeks recovery this 
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falls to 1.4 fold.368 These levels of flow have been suggested to contribute to 
podocyte loss.369 In the future I would like to test the calculations of N 
Punyaratabandhu et al116 further to confirm my provisional findings and 
investigate whether glycocalyx damage can directly result in podocyte loss 
as a result of increased flow. 
 
8.1.8 MMP inhibition as a therapeutic option 
I do not believe that long-term use of an MMP inhibitor is a realistic 
therapeutic option in patients with chronic kidney disease at this stage. The 
complex inter-regulation with heparanase and between the MMPs suggests 
that very broad-spectrum inhibition may be needed in the long term to 
prevent glycocalyx damage unless local endothelial targets can be identified. 
MMP inhibition has been trialled clinically already, mostly in oncology 
research. In this field MMP activity has been linked to cancer aggression, 
stage and patient prognosis.370 The MMPs 2,9 and 14 have received much of 
the attention in this field, but nearly all the MMPs have been shown to 
become deregulated in human cancers.370 Batimastat, the broad spectrum 
MMP inhibitor used in vitro in the early phase of this thesis, was the first 
MMP inhibitor tested clinically. Batimastat was found to be effective in 
malignant ascites and malignant pleural effusion, however the trial were 
stopped in phase III (clinical outcome compared to control arm) to pursue 
marimastat – a chemically similar analogue with increased oral 
bioavailabilty.370 However this trial was unsuccessful due to significant 
musculoskeletal pain and inflammation limiting the dose that could be 
used.370 Subsequently a number of alternative compounds have been trialled 
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but almost all the studies have been halted during phase II trials (drug 
activity, safety and feasibility evaluation). Doxycycline may be the exception, 
this broad spectrum MMP inhibitor is currently under evaluation for ovarian 
cancer.370 
Drug companies have continued to fund research in this field and more 
specific monoclonal therapies have been created. DX 2400 has been 
designed to target MMP14 on the cell surface.370,371 Mouse trials have been 
promising for this agent but I have not found any successful clinical trails for 
this compound.371 I have not investigated the role of endothelial MMP 14 in 
this model but I feel future work should be focussed on this target because it 
has much greater therapeutic potential due to its localised distribution 
compared to that of MMP 2 and MMP 9.  
 
8.1.9 Glycocalyx protection as a therapeutic option 
In contrast to broad-spectrum MMP inhibition, I do believe that targeted 
glycocalyx restoration offers therapeutic potential. Loss of the glomerular 
endothelial glycocalyx is likely to occur in a number of clinical scenarios 
including diabetic nephropathy and acute sepsis. However in order to 
develop therapies that effectively protect glomerular function a more detailed 
understanding of how glycocalyx loss causes disease is needed. 
My work supports the hypothesis that the glomerular endothelial glycocalyx 
contributes to the GFB directly, helping to exclude albumin and limiting the 
flow of water into the primary filtrate. In addition the glycocalyx is a key 
mechanosensor, optimising the endothelial cells ability to align with flow and 
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produce nitric oxide, and it modulates immune cells ability to migrate from the 
blood stream.  Any or all of these functions could dramatically influence the 
progression of kidney disease.129,140,223,368 Working out which elements of 
glycocalyx function are affected in individual pathologies and at what stage 
will be vital if targeted glycocalyx therapy is to be effective. Current 
glycocalyx therapy is based on the assumption that more = better this is 
unlikely to always be the case. For example a systemic therapy that reduces 
micro-vessel water and albumin permeability may be tolerated, however a 
systemic therapy that prevents immune cell transit is likely to have severe 
side effects. To generate clinically acceptable therapies we first need to 
understand what happens to the glycocalyx structure in pathological states in 
more detail. If we can study which components of the glycocalyx structure 
alter in pathology then more precise therapies can be developed. 
 
8.1.10 Testing the role of MR in diabetic and Ang II mediated 
nephropathy 
As discussed previously, the provisional data presented in chapter 6 has 
been used to refine plans for future research investigating the role of MR in 
diabetic nephropathy and Angiotensin II (blood pressure independent) 
nephropathy. Investigating why MR inhibition is effective in diabetic 
nephropathy when aldosterone levels are not elevated could give us unique 
insights into the pathogenesis of this disease. In the long term I hope this 
work could lead to specific glycocalyx restorative therapy, which would not be 




As we learn how to effectively study the endothelial glycocalyx we have 
come to increasingly appreciate its importance. Further work is however 
needed to understand how the glycocalyx is damaged in pathological states. 
As we develop a more detailed level of understanding of glycocalyx function I 
hope that therapeutic targets will be identified with the potential for minimal 
side effects. At this point I hope the techniques I have helped to develop for 
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